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ABSTRACT 
 
Structure-Based Drug Mechanism Study and Inhibitor Design Targeting Tuberculosis. 
(August 2007) 
Feng Wang, B.S., University of Science and Technology of China; 
M.S., Northwestern University 
Chair of Advisory Committee: Dr. James C. Sacchettini 
 
The increase of multi-drug resistant and extensively drug resistant tuberculosis 
(TB) cases makes it urgent to develop a new generation of TB drugs to counter 
resistance and shorten treatment. Structural biology, which allows us to “visualize” 
macromolecules, is now playing a key role in drug discovery. In this work, a structure-
based approach was applied to the study of the mode of action of current TB 
chemotherapies, the identification of potential therapeutic targets, and the design of new 
inhibitors against TB.  
Knowledge of the precise mechanisms of action of current TB chemotherapies 
will provide insights into designing new drugs that can overcome drug-resistant TB 
cases. Structural biology combined with biochemical and genetic approaches was used 
to elucidate the mechanisms of actions of isoniazid, ethionamide and prothionamide. The 
active forms of these anti-TB prodrugs were identified by protein crystallography and 
the target-inhibitor interactions were revealed by the complex structures. Although these 
drugs are activated through two completely different routes, they all inhibit InhA, an 
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essential enzyme in mycolic acid biosynthesis, by modification of the enzyme cofactor 
NAD, which unveils a novel paradigm of drug action.  
Isoniazid, ethionamide and prothionamide all target InhA, which validates the 
enzyme as a superb drug target. A structure-based approach was adopted to design new 
inhibitors targeting InhA, using triclosan as the scaffold. Guided by the InhA-inhibitor 
complex structures, two groups of triclosan analogs were identified with dramatically 
increased inhibitory activity against InhA.  
Structural biology has also provided fundamental knowledge of two potential 
therapeutic targets, Mtb β-lactamase (BlaC) and fatty-acyl-CoA thioesterase (FcoT). Mtb 
β-lactamase has been proposed to be the most significant reason for mycobacterial 
resistance to β-lactam antibiotics. The determination of Mtb BlaC structure not only 
demonstrates the mechanism of drug resistance but also provides a solid base for the 
design of new β-lactamase inhibitors that could be used with β-lactam antibiotics as a 
new regimen to treat tuberculosis. The crystal structure of FcoT provided crucial 
information in identification of the function of this previously hypothetical protein. The 
characterization of FcoT revealed an important pathway that is critical for Mtb’s survival 
in host macrophages.  
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CHAPTER I 
   INTRODUCTION 
TUBERCULOSIS 
Tuberculosis (TB) is a disease with a long history. Tubercular decay was found 
in Egyptian mummies, which indicates TB infections in humans since 5000 years ago 
(1). Into the 21st century, tuberculosis remains a serious threat to the world’s public 
health. According to WHO, nearly two billion people have tuberculosis, which causes 
more than 2 million deaths annually. It is projected that in the next 15 years, nearly one 
billion more people will be infected if no action is taken. TB is generally defined as a 
developing country disease. However, it has become an urgent health problem in the 
United States as well, due in part to HIV co-infection (2-4).  
TB is caused by the pathogen Mycobacterium tuberculosis (Mtb), which is 
spread through the air from one person to another (5). Not everyone infected becomes 
sick. Only 10% of immunocompetent people infected with Mtb develop active disease in 
their lifetime (6). The other 90% do not become ill and cannot transmit Mtb; instead they 
remain in a stage called latent infection (6). However, in the immunodeficient, the rate of 
who develop active TB disease is much higher (5).  
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           Mtb is a slow-growing Gram-positive mycobacterium that divides every 16-20 
hours. It is a small rod-like bacillus which can survive in a dry state for weeks and can 
withstand weak disinfectants but can only actively grow within its host (7).  Mtb cells 
can be stained after the treatment of acidic solution because of its thick waxy cell wall 
(7). Although Mtb most likely grows in tissues and organs with high oxygen content, 
such as the lungs, it can attack any part of the body such as the kidney, spine, and brain. 
Less than ten bacilli are enough to initiate an infection (8). Tubercle formation begins 
after the inhaled bacilli are engulfed by macrophages (8). Within the tubercles, the host 
immune system responds to the infection by cell-mediated immunity to the tubercular 
proteins (9). However, Mtb has the ability to modulate the host immune system, which 
allows it to survive inside the host cells. A dynamic balance between bacterial virulence 
and host immune system usually reaches within two to six weeks (9). The tubercle 
bacilli are under control but still persist (10). In many cases, the fibrosis and calcification 
causes slow death of the pathogens eventually. Otherwise, the bacilli remain viable for 
long periods and are a potential source of reactivation when the host immune system 
collapses (10-12). 
 
DEVELOPMENT OF TB CHEMOTHERAPY  
Current TB Drugs 
The current TB chemotherapy was developed based on animal tests and clinical 
trials mainly between the 1950s and 1970s. Currently, WHO recommended DOTS 
(directly observed treatment, short-course) as the frontline TB chemotherapy (2). It is a 
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cocktail of drugs (normally four) with both bactericidal activity and inhibition of 
resistance. Drugs such as isoniazid, rifampin and streptomycin are top choices in 
bactericidal activity, and ethambutol, pyrazinamide and rifampin have been shown to 
inhibit the development of resistance. Using a combination of isoniazid, pyrazinamide, 
ethambutol and rifampin, most patients see improvement within the first month of 
treatment, and the total treatment time is between 6-12 months (2). Current drugs are 
mainly targeting cell wall biosynthesis, nucleic acid synthesis, and protein synthesis 
(Figure 1 and Table 1).  
Isoniazid (INH) is a prodrug activated by Mtb by KatG, a catalase-peroxidase, to 
generate its active form INH-NAD, which inhibits enoyl acyl ACP reductase (InhA), an 
essential enzyme in fatty acid synthesis II (FASII) pathway, thus blocking the mycolic 
acid biosynthesis. This mechanism has been established by genetic, structural and 
biochemical studies (13-15). Mutations in katG and inhA were found in the Mtb clinical 
isolates resistant to INH (15-17). NADH/NAD ratio variation caused by mutations in 
NADH Dehydrogenase II has also been shown to confer resistance to INH (18).  
Ethionamide (ETH) is a second line drug against TB. It is structurally similar to 
isoniazid (Figure 1). ETH is also a prodrug that has to be activated by EthA, a 
monooxygenase, to exert anti-tubercular activity (19). Its active form was proposed to 
inhibit InhA, the same target as INH (13,14,20). The mode of action of ETH was 
demonstrated in a cell-based activation system (21). Its active form, the ETH-NAD 
adduct, was characterized using protein crystallographic and mass spectroscopic 
approaches (21).  
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Figure 1    Chemical Structures of Frontline and Second-line TB Drugs 
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Cycloserine is believed to inhibit two enzymes D-alanine racemase (AlrA) and 
D-alanine:D-alanine ligase (DdlA), which are essential in the cell wall peptidoglycan 
(PG) synthesis pathway. Inactivation of alrA or ddlA gene in M. smegmatis caused 
increased sensitivity to cycloserine and overexpression of alrA and ddlA conferred 8-20 
fold resistance to cycloserine (22,23). Although the genetic observations support that 
alrA and ddlA are possible targets of cycloserine, further biochemical studies are 
required to get a clear mechanism of drug action of cycloserine against Mtb.  
Streptomycin is an aminoglycoside antibiotic, used as the first antituberlar 
chemotherapy. The mechanism of its drug action is to block protein synthesis by 
inhibiting mRNA translation by ribosomes (24). Its primary targets are protein S12 
(rpsL) and 16S rRNA (rrs) in the small 30S subunit of the ribosome. 
Rifampin is a series of broad-spectrum antibiotics that disrupt RNA synthesis by 
binding to the subunit B of bacterial DNA-dependent RNA polymerase (RpoB) (25). 
The crystal structure of RNA polymerase bound with rifampin, combined with 
biochemical studies, has demonstrated that rifampin blocked the transcription after three 
nucleotides (26). Rifampin is special in TB chemotherapies because it is active against 
both actively growing and nongrowing bacilli. Targeting the slowing or nongrowing 
bacilli is believed to be the key to shorten treatment length (27). Mutations in three 
regions of the rpoB are found in about 96% of rifampin -resistant Mtb isolates (28).  
Fluoroquinolone is a class of compounds that are now used to treat multiple drug 
resistant (MDR) TB as second-line drugs. They are known to inhibit DNA synthesis by 
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targeting the type II DNA topoisomerase (GyrA and GyrB) (29). Strains that contain 
mutations in gyrA or gyrB were found to be resistant to fluoroquinolon (30). 
It is worth noting that those chemotherapies that target protein synthesis and 
nucleic acid synthesis pathways are all broad-spectrum antibiotics due to these pathways 
being essential for bacteria. In contrast, the chemotherapies that target cell wall 
biosynthesis are more specific to Mtb, which is probably because of the uniqueness of 
Mtb cell wall.   
 
 
Table 1   The Frontline and Second-line Drugs and Their Targets 
Drug Category Target 
Isoniazid Front line InhA 
Rifampin Front line RpoB 
Pyrazinamide Front line unknown 
Ethionamide Second line InhA 
Ethambutol Second line EmbCAB 
Streptomycin Second line RpsL 
Fluoroquinolones Second line GyrA, GyrB 
Cycloserine Second line DdlA, AlrA 
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Problems of Current TB Drugs 
Although DOTS can cure TB in most of the cases, some serious problems still 
remain. Among those, the TB persistence and drug resistance are most challenging (31). 
Compared to the treatment of other infectious diseases, the treatment time for TB is long 
(usually 6-9 months), which makes patient compliance very difficult. The main reason 
for this lengthy treatment is to prevent relapse of TB. Antibiotics are usually active 
against growing bacteria but are less effective against nongrowing bacteria. Nongrowing 
bacteria includes the stationary phase bacteria, persisters not killed by antibiotic, and 
dormant bacteria (32). Current TB drugs such as isoniazid are mainly active against 
growing bacteria and are not effective against the persisters and dormant bacteria (33). 
The incapability of host immune system to eliminate tubercle bacilli in the lesions could 
be another factor that leads to the persistence of TB (33).  
The first TB chemotherapy, streptomycin, came into use to treat TB in 1943 (24). 
And shortly after that, streptomycin resistant strains of Mtb were found. The following 
20 years showed tremendous promise in TB chemotherapy, each time to be let down by 
the occurrence of Mtb’s resistant strains (31). Mutations have been found for almost 
every current antitubercular drugs (Table 1). Mtb has extraordinary ability to survive for 
long periods of time of treatment. This together with the problem of low patient 
compliance has led to the emergence of multiple drug resistant strains (31). The increase 
of multidrug-resistant strains resistant to these widely available and affordable anti-
tubercular drugs is a growing clinical problem. The standard TB therapy is ineffective in 
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controlling TB in high MDR-TB incidence areas (34,35). Fifty million people have 
already been infected with drug-resistant TB (2). 
  
Promising Drug Candidates 
Facing the challenge of multiple drug resistant (MDR) and even extensively drug 
resistant (XDR) TB cases, it is urgent to search for new TB chemotherapies. Several new 
compounds that hold promise for treatment of resistant TB have been discovered by 
whole cell screen or optimization of previous drugs (Figure 2). 
PA824, a derivative of 5-nitroimidazoles, is highly active against both Mtb and 
MDR Mtb with MIC as low as 0.015–0.250 µg/ml (36). PA824 is a prodrug that requires 
activation by a F420 dependent nitroreductase, encoded by Rv3547 to generate an active 
form that could inhibit bacterial mycolic acid and protein synthesis (36). However, the 
activated form of PA824 and its final target remain unknown. In animal models, PA824 
was active against nongrowing bacilli and its bactericidal activity is comparable to INH 
and Rifampin (37). 
Diarylquinoline is a compound discovered by Johnson & Johnson that is highly 
active against mycobacteria in an in vitro drug screen using M. smegmatis. After lead 
optimization, one of the diarylquinolines R207910 showed a minimum inhibitory 
concentration (MIC) of 0.003 µg/ml for M. smegmatis and 0.030 µg/ml Mtb (38). 
R207910 is highly specific for mycobacteria and is much less active against other 
bacterial species, such as E. coli and S. aureus (MIC >32 µg/ml). Mutant screens and 
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analysis have helped to identify the drug target - proton ATP synthase, which is a key 
enzyme for ATP synthesis (38). 
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Figure 2    Chemical Structures of Some Promising TB Drug Candidates 
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The new moxifloxacin (MXF) and gatifloxacin (GATI) are designed based on 
known drugs ofloxacin and ciprofloxacin. But they are more stable and more active 
against Mtb (39). MXF has been shown to kill persisted tubercle bacilli not killed by 
rifampin. MXF in combination with rifampin and PZA showed higher bactericidal 
activity against tubercle bacilli in mice than the standard combination of INH, rifampin, 
and PZA and the treatment can be shortened to four months with no relapse (40). Thus, 
MXF has the potential to replace the standard INH, rifampin, and PZA regimen to 
shorten TB therapy in humans. 
 
Potential Therapeutic Targets 
Transposon mutagenesis and signature-tagged mutagenesis have recently been 
used to identify genes essential for Mtb growth in vitro and survival in vivo (41,42). The 
identification of these essential genes provided a solid base for the search of new drug 
targets. Many of these essential Mtb genes are potentially good targets for TB drug 
development. However, two potential problems exist. First, the gene essentiality 
determined from this approach is not 100% correct. Therefore, it has to be used very 
carefully and most of time requires target knockout studies to verify. Secondly, the 
functions of a significant number of essential genes are still unknown. Further detailed 
biochemical characterization of target genes is necessary.  
A lot of research activities are also focused on understanding the persistence 
mechanism of TB and developing new drugs that target the persister bacteria (43). Some 
genes involved in Mtb persistence, such as isocitrate lyase (ICL), PcaA (methyl 
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transferase involved in the modification of mycolic acid) and DosR (a regulator under 
hypoxic conditions), have been identified and could be potential targets for the 
development of drugs that target persistent bacilli (43-45). 
 
Mtb CELL ENVELOPE BIOSYNTHESIS 
Overview 
The cell envelope of Mtb consists of three structural components: the inner 
membrane, the cell wall, and a polysaccharide-rich capsule. Mtb’s inner membrane, 
which is similar to those of other bacteria, does not have major contribution to the 
pathological properties. Its cell wall and outer capsule, however, are unique and are 
tightly associated with its pathogenicity (46). Outside the membrane, Mtb’s 
peptidoglycan (PG) layer is covalently linked to arabinogalactan (AG), which is in turn 
attached to the mycolic acids. This mycolate-arabinogalactan-peptidoglycan (mAGP) 
complex, a very hydrophobic barrier with very poor permeability, is critical to the 
survival of Mtb in macrophages and contributes significantly to the resistance against 
many chemotherapies (47).  
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Mtb Mycolic Acid Biosynthesis Pathway 
Mycolic acids are the major building blocks of the protective layer in the Mtb 
cell envelope. The cyclopropane ring structures of mycolic acid contribute to the 
structural integrity of the cell wall complex (48) and protect the bacillus from oxidative 
stress inside macrophages (49). 
Mycolic acids are β-hydroxy fatty acids with a long α-alkyl side chain (50). Mtb 
mycolic acids are formed by a saturated short fatty acyl chain of 20-26 carbon atoms and 
a long meromycolic acid chain of 50-60 carbon atoms. There are five forms of mycolic 
acids in Mtb, α-mycolic acid, cis and trans methoxy-mycolic acid, cis and trans keto-
mycolic acid (Figure 3). Among them, the α-mycolic acid is the dominant species, 
accounting for more than 70%, whereas other forms are less than 30%. The structure and 
component of mycolic acids are critical to the virulence of Mtb. Deletion of the proximal 
cyclopropane ring of α-mycolic acid or of methoxy- and keto-mycolates in Mtb was 
found to lead to a significant attenuation in growth of the two Mtb mutants in the 
infection studies on the mouse model (45,51), while deletion of the keto-mycolates 
caused restricted growth of this mutant in macrophages (52).  
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Figure 3    Chemical Structures of Mycolic Acid. 
A. α-mycolic acid, B. cis methoxy mycolic acid, C. trans methoxy-mycolic acid, D. cis 
keto-mycolic acid, E. trans keto-mycolic Acid 
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1. Biosynthesis of precursor of mycolic acid—long chain fatty acid of Mtb 
The precursor of mycolic acid is long chain fatty acid. Mtb has both FAS-I and 
FAS-II systems. Its FAS-I, a multienzyme complex is in charge of synthesis of short 
chain fatty acids, and type II fatty acid synthetase (FAS-II), a discrete synthetase system 
continues to elongate the short chain fatty acids to long chain fatty acids.  
a) FAS-I 
By sequence alignment of the Mtb FAS gene with other known FASs, seven 
functional catalytic domains have been identified in the following order: acyltransferase, 
enoyl reductase, dehydratase, transferase, acyl carrier protein, β-ketoacyl reductase, and 
β-ketoacyl synthase (53). The mycobacterial FAS-I system elongates acetyl group by 
two-carbon building blocks, starting with acetyl-CoA and malonyl-CoA as substrates to 
yield butyryl-enzyme intermediate after reaction steps of acetyltransacylation catalyzed 
by acyltransferase, malonyl transacylation by malonyl transferase, condensation by β-
ketoacyl synthase, β-ketoacyl reduction by β-ketoacyl reductase, dehydration by 
dehydratase and enoyl reduction by enoyl reductase. After several cycles of elongation, 
C16- and C18- CoA products are generated and are used for the cell membrane synthesis 
(54). C16 and C18 products can be further elongated by Mtb FAS-I to generate C20 and 
C26 products, again as CoA derivatives. These C20 and C26 CoA products become the  
substrate of FAS-II systems and are further elongated to very long chain fatty acids (46). 
b) Transition steps from FAS-I to FAS-II 
Malonyl-CoA has to be converted to malonyl-ACP by MtbFabD (malonyl-
CoA:ACP transacylase) as the two-carbon building block for further elongation in FAS-
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II system (55). MtbFabH (β-ketoacyl-ACP synthase-III), working as the link between the 
FAS-I and FAS-II systems, initiates chain elongation of C20-CoA released from FAS-I 
as the substrate to generate a β-ketoacyl-ACP product (Figure 4) (56). 
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Figure 4    FASII Biosynthesis Pathway 
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c) FAS-II 
FAS-II of Mtb, a discrete synthetase system contains enzymes KasA and KasB 
(β-ketoacyl-ACP synthases), MabA (β-ketoacyl-ACP reductase), β-Hydroxyacyl-ACP 
dehydrase, 2-trans-Enoyl-ACP isomerase and InhA (2-trans-enoyl-ACP reductase) (46). 
KasA and KasB start fatty acyl elongation by catalyzing the condensation reactions (57). 
Although KasA and KasB share 69% sequence homology and both enzymes catalyze the 
condensation reaction, it is believed that they have different substrate profiles, most 
likely different chain length (58). MabA carries out the NADPH specific reduction of β-
ketoacyl-ACP to β-hydroxyacyl-ACP. β-Hydroxyacyl-ACP dehydrase in Mtb has not 
been identified yet. It is supposed to dehyrate the β-hydroxyacyl-ACP. In E. Coli, two 
different β-Hydroxyacyl-ACP dehydrases fabA and fabZ have been found (59). InhA, an 
NADH-dependent 2-trans-enoyl-ACP reductase, catalyzes the final step of the cycle of 
elongation by generating saturated fatty acyl ACP. Other than dehydrase, 2-trans-enoyl-
ACP isomerase has not been identified in Mtb either (Figure 4).   
In FAS-II, KasA, KasB, MabA, dehydrase, and InhA form a cycle to catalyze the 
elongation of the fatty acyl chain by two carbons. 2-trans-Enoyl-ACP isomerase replaces 
InhA in some of the cycles as the last step enzyme to introduce cis double bond into the 
fatty acyl chain. Thus, instead of saturated fatty acid, FAS-II system generates long 
chain fatty acyl products with double bonds at certain positions (60). Those unsaturated 
long chain fatty acids will be modified into different types of meroacid in the latter 
modification steps. 
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2. Modification of long chain fatty acids 
The functions of modification of long chain fatty acyl ACP derivatives are 
carried out by a group of enzymes called cyclopropane synthases and methyltransferases 
. Eight genes with high sequence homology camA1, cmaA2, mmaA1-mmaA4, umaA1 
and pcaA in this group have been identified. Among the enzymes, encoded by these 
genes, MmaA2 and PcaA convert the distal and the proximal double bonds into 
cyclopropane rings, respectively (Figure 3) (45). MmaA4 oxidizes the distal cis double 
bonds to a secondary alcohol with an adjacent methyl branch. MmaA1 converts the 
proximal cis double bonds to an allylic methyl branch with trans double bonds. SAM is 
the cofactor used in these methyltransferase reactions. Other modifications include the 
generation of cis-methoxy-meroacyl ACP and trans-methoxy-meroacyl ACP (61). 
3. Claisen condensation to form mycolic acid 
The final step in the synthesis of mycolic acid in Mtb is believed to be a Claisen-
type condensation catalyzed by a polyketide synthase Pks13 (62). α-meroacyl-AMP, 
produced by FadD32 and 2-carboxyl-C26-CoA derived from FAS-I are the substrates for 
the condensation reaction catalyzed by Pks13. Reaction starts with loading the two 
substrates by Pks13 and the transfer of a meroacyl group from PPB domain to the 
condensing domain, followed by the condensation step and reduction of the 3-carbonyl 
group to the secondary alcohol by a reductase to yield the mature α –mycolate (63,64). 
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 Mtb Arabinogalactan-Peptidoglycan Complex Biosynthesis Pathway 
 The arabinogalactan-peptidoglycan complex biosynthesis includes the 
biosynthesis of peptidoglycan and arabinogalactan. Peptidoglycan, formed by 
polymerized β-1,4-linked N-acetylglucosaminyl and N-acetylmuramic acid, is the key 
component of a eubacterial cell wall (Figure 5) (65). The D-lactyl groups of the muramic 
acid are amidated with L-alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine stem 
tetrapeptides and L-alanyl-D-isoglutaminyl-meso-diaminopimelyl tripeptides. The stem 
peptides of adjacent glycan strands are covalently linked to form the polymeric 
peptidoglycan. Compared to peptidoglycan of other bacteria, Mycobacterial 
peptidoglycan have two distinct features; first, the muramic acid residues are N-
glycolylated instead of N-acetylated as in other bacteria, and secondly, a proportion of 
the crosslinks in the peptidoglycan layer includes those between the diaminopimelic acid 
residues (so called 3-3 linkage) as well as between diaminopimelic acid and D-alanine 
(so called 4-3 linkage). It is thought that the N-glycolylation makes the peptidoglycan 
layer more rigid. Mycobacterial peptidoglycan is also highly resistant to lysozyme (47). 
Although, until recently, little is known about the biosynthesis of the peptidoglycan of 
M. tuberculosis, it is generally assumed that Mtb peptidoglycan biosynthesis is similar to 
that of E. coli, which has four sequential reaction steps (Figure 6). The initial step 
involves the synthesis of UDP-N-acetyl muramic acid (UDP-MurNAc) from UDP-
GlcNAc by two reactions. First, enolpyruvate is added to the GlcNAc residue of the 
UDP-GlcNAc and subsequently the enoylpyruvate moiety is reduced to form UDP-
MurNAc, catalyzed by MurA and MurB, respectively. The sequential addition of L-
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alanine, D-glutamate, DAP and a D-alanyl-D-alanine dipeptide to UDP-MurNAc 
generates UDP-MurNAc-pentapeptide. It is then linked with undecaprenyl phosphate to 
form Lipid I. A GlcNAc residue is subsequently added to Lipid I to produce Lipid II. 
MurX and MurG are believed to catalyze the formation of Lipid I and Lipid II. The 
Lipid II is translocated from the cytoplasm to periplasm, where it is used to assemble the 
peptidoglycan. The glycan chains are cross-linked by peptide bridges, catalyzed by 
transpeptidase. It was reported that two-thirds of the peptide bridges found in Mtb 
peptidoglycan are D, D bond between the carboxyl group of a terminal D-alanine and the 
amino group at the D-center of DAP (65). The rest of one third of the linkages are L, D 
link between the carboxyl group at the L-center of terminal DAP of one chain and the 
amino group at the D-center of the DAP of another peptide side chain. This suggests that 
there are both D, D and L, D transpeptidases in Mtb, however only D, D transpeptidase 
has been identified in Mtb (47).  The synthesis of arabinogalactan initiated from the 
transfer of a GlcNAc-1-phosphate from UDP-ClcNAc to prenyl phosphate form 
GlcNAc-P-P-C50, which is then linked with a rhamnose (Rha). The Galf moiety is 
subsequently transferred to Rha-GlcNAc-P-P-C50 to form (Galf)30Rha-GlcNAc-P-P-C50. 
Finally the Araf moiety is added to produce the (Araf)70(Galf)30Rha-GlcNAc-P-P-C50, 
which is used to covalently link with peptidoglycan and mycolic acid. Several genes 
involved in dTDP-Rha biosynthesis, such as rmlA, rmlB, rmlC and rmlD, have been 
identified (47).  
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Figure 5    Structure of Peptidoglycan of Mtb 
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Figure 6    Biosynthesis Pathway of MAP Complex of Mtb 
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STRUCTURE-BASED DRUG DISCOVERY 
Overview 
The idea to use structural biology in drug discovery first came out in the 1970s. 
However, this concept became practical only after the crystal structures of real drug 
targets were defined. Using this method, two AIDS drugs Agenerase and Viracept were 
designed targeting HIV protease (66). New technical developments in protein 
crystallization, data collection and processing have led to a dramatic increase in the 
number of protein structures. There are now more than 40,000 of 3D structures in the 
Protein Data Bank, many of which are potential therapeutic targets (www.rcsb.org). This 
provides a solid fundament of structure based drug discovery. 
Before structure based drug lead search became a practical method, high-
throughput screening (HTS) is the conventional approach to search for novel leads. 
Despite the development of HTS technology, HTS remains very costly and usually can 
only be afforded by big pharmaceutical companies (67). In contrast, structure based 
approach to lead discovery is more cost efficient and less time consuming. The structural 
guided lead search can either be carried out based on computational method (virtual 
screen) or experiment approaches (fragment based screen). 
 
Virtual Screen    
Virtual screening  (VS) utilizes computer programs to screen large “virtual” 
compound databases and selected out a small number of molecules (‘hits’) based on 
certain defined criteria (67). In contrast to the requirement of large real compound 
  
 23
 
libraries in the HTS, VS only needs three-dimensional coordinates of chemicals and 
computing power (Figure 7). Virtual screen highly relies on the development of 
algorithms on the calculation of receptor-ligand interactions. Many docking algorithms 
as well as different scoring functions have been developed (68-72). Rapidly growing 
computing power together with more complicated and realistic protein-ligand docking 
programs greatly facilitated the VS process (73,74).  
A properly and accurately defined docking site of the molecular target is critical 
for a successful virtual screen. Once the 3D structure of the therapeutic target is 
available, the coordinates of the docking site (molecular receptor) have to be defined. 
Since most of the protein structures do not define hydrogen coordinates, the hydrogen 
atoms have to be added by software. After the addition of hydrogen atoms, the correct 
protonation and tautomeric states also need to be assigned (75). In order to remove any 
steric clashes introduced by the hydrogen atoms, a few cycles of energy minimization 
are recommended. Water molecules in the crystal structure are generally deleted, unless 
they have important roles in protein structures and ligand binding. 
Chemical databases, such as ZINC and Chembridge chemical databases, offer 
atom coordinates of thousands or even millions of compounds (76). Other physical and 
chemical properties of the compounds provided in the database are useful to “filter” the 
database. The “rule of five” is the most widely used principle in compound selection 
(77). “Rule of five” is based on the sampling of known drugs, which claims that a drug-
like molecule should have molecular weight less than 500, logP value less than 5, 
hydrogen donor less than 5 and hydrogen acceptor less than 10 (77). This rule provides 
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good prediction regarding the solubility and cell permeability of the drug. Filters are 
useful to exclude compounds with some functional groups that are related to poor 
chemical stability or known toxicity. 
 
 
 
 
 
Figure 7    Virtual Screen Procedure 
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           Due to the limitation of prediction accuracy of docking algorithms and computing 
power, it is impossible to put all protein and ligand conformations into consideration. 
Therefore, most docking programs only explore the conformation flexibility of the 
ligand (78). GOLD uses a genetic algorithm to generate conformers of a ligand. This 
algorithm is time consuming and requires a powerful grid computing system to screen 
large databases. FlexX uses an alternative approach called the incremental growth 
method, which is relatively fast and able to produce good predictions of protein-ligand 
complex structures. It divides the ligand into small fragments. Then an initial base 
fragment is selected and docked into the active site, followed by the addition of the rest 
of the fragments to the base fragment (79).  
           The virtual screen results are evaluated by scoring functions that could be 
generally classified as physical based, empirical or knowledge based. Physical based 
functions, which are used by Dock and AutoDock, calculate the free energy of binding 
by force fields. Empirical based functions use an additive approximation instead of a full 
force field to calculate energy (69). They are used in FlexX and Ludi. Empirical based 
score functions are faster than the physical based functions, but biased, because they are 
derived from binding affinity data from a small set of protein-ligand complexes. 
Knowledge based functions are derived from structures of protein-ligand complexes. 
They are fast, moreover, because they do not rely on binding affinity data and are 
derived from a much larger data pool, they are less biased (80). Due to the limitation of 
the current scoring functions, the docking result may not predict the real binding affinity 
accurately. Consensus score is used in order to minimize the false positive in evaluation, 
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in which several scoring functions are used to evaluate the docked ligands (81). Only 
compounds that have high scores from each scoring functions are selected out for further 
testing. 
    
Fragment-based Screen 
In recent years, a novel approach in structure based drug design has evolved. 
This new approach is based on small fragment, namely fragment screening (66). Unlike 
typical inhibitors, fragments are typically small organic molecules (< 250 Da) and have 
low binding affinities (~100 µM to 10 mM) against target proteins. Therefore, they are 
normally not used in HTS. The determination of interactions between these small 
fragments and target proteins relies on high-throughput protein crystallographic 
technique. Hundreds or even thousands of small molecules will be screened in order to 
identify fragments that bind to protein targets and then the protein-ligand complex 
structures will be precisely defined. Soaking method is used to quickly get suitable 
crystals. As long as the binding site is not blocked by the crystal packing, small 
molecules are usually able to diffuse into the crystals and interact as if they were in 
solution (82). If a fragment binds to the target, it can be identified in an electron density 
map. The ‘hit’ fragments will be selected out as the basis for further optimization. A 
synthetic chemical library will be built to explore different functional groups on the basis 
of the “hit” fragment. Those second generation inhibitors will then be evaluated by 
enzyme kinetic studies and the best inhibitor will enter into the next round of chemical 
modification as the new lead compound. After several cycles, a low binding affinity 
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initial fragment can be eventually optimized into a highly potent inhibitor. This method 
has been proven to be successful in the kinase drug discovery (82,83).   
 
PRINCIPLE OF PROTEIN CRYSTALLOGRAPHY 
Overview 
X-ray crystallography is one of the major techniques developed in structural 
biology. Since the first crystal structure was determined in 1950s, more than 39,000 
protein crystal structures have been deposited into the Protein Data Bank 
(www.rcsb.org). In the past decade, the pace of protein structure determination 
accelerated dramatically facilitated by new techniques such as high throughput 
crystallization, the MAD phasing and synchrotron radiation source. Despite all the 
improvement in protein crystallography, the major rate limiting steps of solving protein 
crystal structure remains to be the growth of diffracting quality crystals and obtaining the 
phase. 
   
Protein Crystallization 
           Solving a protein crystal structure depends on the obtaining a protein crystal 
suitable for x-ray diffraction and data collection. Crystals are defined as solids whose 
components are arranged in a long-range three-dimensional order (Figure 8). In order to 
crystallize a protein, the purified protein undergoes slow precipitation from an aqueous 
solution. Individual protein molecules align themselves in a repeating series of "unit 
cells" periodically. The production of crystals of x-ray diffraction quality is dependent 
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on several factors, such as protein purity, concentration, buffer condition, temperature, 
and precipitants (84).  
Vapor diffusion methods including hanging drop and sitting drop are often used 
to achieve super saturation of proteins (85). Both hanging drop and sitting drop methods 
use a droplet containing purified protein and crystallization solution to equilibrate with a 
large volume of the same crystallization solution in higher concentrations, the so called 
mother liquid. Initially, the droplet of protein solution contains an insufficient 
concentration of precipitant for crystallization, but as equilibrium is reached, the 
precipitant concentration increases to a level high enough for protein crystallization.  
 Protein crystallization usually starts from screening for initial crystallization 
conditions (‘hits’) by using random or sparse matrix screen methods. Once a hit is found, 
the hit will be optimized to obtain crystals with better diffraction quality and larger size. 
The optimization approaches usually includes varying precipitant concentration, pH, 
additive agents, temperature and seeding, etc. 
 
 
 
 
Figure 8    The Picture of an InhA Single Crystal 
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Protein Crystal Diffraction and Data Collection  
           X-rays are electromagnetic radiations with wavelengths ranging from 0.1 to 1000 
Å. An X-ray could be described as wave with three properties – wavelength, amplitude 
and phase. When incoming X-rays pass through matter, the atoms scatter the X-rays, 
which radiate out at the same wave as the incoming X-rays. The electrons are much 
more effective at scattering X-rays than protons, the total scattering from atoms is almost 
completely due to the electrons. In a system with multiple electrons, each electron will 
scatter X-rays and all these scattered X-ray waves should be summated according the 
vector algebra. Because crystal elements repeat periodically, only the scattered 
reflections that fulfill the Laue conditions are detectable in a diffraction pattern. The 
maxima of a diffraction pattern occur at certain positions as determined by Bragg’s law.  
Once suitable protein crystals become available, X-ray diffraction data are 
collected. The radiation source for most single crystal diffraction data collection is 
monochromatic X-rays from either a sealed tube generator, a rotating anode generator or 
from a synchrotron source. The crystal then is mounted in a loop or capillary and 
accurately positioned in the X-ray beam. Nowadays, data collection is typically carried 
out cryogenically. A cold nitrogen gas stream keeps the crystal at 100 K throughout the 
experiment. The incoming X-rays strike the crystal to produce a diffraction pattern, 
which is recorded on the X-ray detector, such as image plates or CCD area detector. 
During data collection three important properties: resolution, completeness, accuracy 
have to be optimized by adjusting the x-ray beam intensity, wavelength, detector 
distance, exposure time and number of images (Figure 9). Upon completing data 
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collection, the images with the diffraction pattern have to be processed to generate a 
complete reflection data file using computer program such as HKL2000, Crystal-Clear 
and Molsflm (86). The first step of data processing is to determine the unit cell 
parameters of the crystal by analyzing the diffraction pattern. Based on the unit cell 
parameters, the symmetry and laue group of the crystal can be obtained. All images 
collected can then be integrated and scaled up to produce the final scalepack data file, 
which contains intensity information of the diffraction in the reciprocal space.  
    
 
 
 
 
Figure 9    An Image of X-ray Diffraction of a Single Protein Crystal 
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Phasing 
Structure factor is a complex number, including magnitude that is proportional to 
the intensity measured experimentally in the X-ray diffraction experiment, and the phase 
angle, which cannot be obtained directly from diffraction data. Three methods, 
molecular replacement (MR), multiple isomorphous replacement (MIR), and multiple 
anomalous dispersion (MAD) are generally used to acquire the phase.  
1. Molecular replacement 
The atomic coordinates can be obtained from a known protein structure (search 
model) similar to the target protein. The structure factor from experimental data file can 
be used to calculate a Patterson map. The comparison and matching of the observed and 
the calculated Patterson maps is used as strategy of MR phasing. The search model is 
usually first rotated, then based on each rotation operation, a series of translations are 
performed. For each orientation, the Patterson function is calculated and compared to 
that from the experiment data. If a significant overlap is observed, one can assume the 
correct orientation of the model has been found. Once the orientation of the search model 
is locked, the positional parameters are determined to place the search model at the 
correct position in the unit cell. The correlation coefficient is used to quantify the overlap 
between calculated and observed Patterson maps. Molerep, Amore, EPMR and Phaser 
are commonly used computer programs for molecular replacement.  
2. Multiple anomalous dispersion (MAD) 
MAD method is based on one of the physical properties of elements, which is 
called anomalous scattering. The scattered photon has a normal component and an 
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imaginary component, whose phase angel is 90º delayed. Usually the anomalous 
scattering of the atom is very weak and can be ignored. However, anomalous scattering 
becomes significant when the incident X-ray wavelength approaches the absorption edge 
of the element. When anomalous scattering happens, the Friedel’s law is broken, 
meaning the structure factor F(h, k, l) is no longer equal to its opposite phase angle 
structure factor F(-h, -k, -l). MAD technique utilizes the additional information from the 
anomalous scattering effect to acquire an experimental phase. Because Se-Met can be 
easily incorporated into protein and selenium absorption edge is about 0.9 Å which is 
easily available by common synchrotron sources, it is often used in the MAD 
experiment. Diffraction data from one single crystal under three wavelengths peak, 
inflection, and high remote are collected and used to determine the heavy metal sites 
(Figure 10). Several computer programs are currently used to determine and refine the 
heavy metal site, such as SOLVE, SHELXD and RANTAN (87). Once the heavy atom 
sites are defined, the phase of the whole protein molecule can be calculated. 
3. Multiple isomorphous replacement (MIR) 
Isomorphous replacement is the first phasing technique practical for 
macromolecular crystallographers. Heavy atoms such as transition metals, lanthanides, 
uranuim, can be introduced into specific site in crystals of the native protein by soaking 
method. If the derivative crystal is isomorphous to the native crystal, the structure factor 
amplitude differences between the derivative and the native dataset can be used to locate 
the heavy atom sites. Similar to MAD, once the heavy atom sites are defined, the phase 
of the protein molecule can be deduced. 
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Figure 10   The Fluorescence Scan Result of Se-Met  
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Phase Improvement 
After the phase is determined, there are errors in it. Density modification is often 
applied to improve the phase. Solvent flattening, solvent flipping and molecular 
averaging are the most commonly used methods. Solvent flattening and flipping are 
based on the fact that in the electron density map the protein region has higher density 
and the solvent region is flat. Computational methods are able to define the protein-
solvent boundary and flatten the density in the solvent region, which improves the 
density map and phase. Molecular averaging method averages the density corresponding 
to the symmetric molecules in one asymmetric unit to improve the phase.  
 Shake ‘n’ wARP is a computer program used to minimize the phase bias from 
the model in MR method by the combination of several different approaches, such as 
‘shaking’ the model, omitting part of the structure, maximum likelihood refinement, real 
space placing and averaging. Shake ‘n’ wARP is especially useful in determination and 
verification of additional electron density in 2Fo-Fc map (88). 
 
Model Building and Refinement 
           The model building is accomplished by manually fitting molecules into the 
electron density with the help of computer graphic programs, such as XtalView, COOT, 
and O (89,90) (Figure 11). Some model-auto-building computer programs, such as 
ArpWarp (usually for data of resolution higher than 2.2 Å) (91) and TEXTAL (92) have 
also been developed and utilized in initial model building. The model is refined and 
  
 35
 
compared with the experiment diffraction data and monitored by the R factor defined as 
the following: 
R=  Σ ||Fobs|-|Fcal|| / Σ |Fobs|     (Eq. 1) 
About 5-10% data are randomly selected as the free set before the first round of 
refinement, which is never used in the refinement, to monitor the effect of each 
refinement step and avoid over-refinement. The R factor calculated from free set data is 
defined as Rfree, while the R factor from working data set is called Rfactor. Only the 
decrease of both Rfactor and Rfree indicates a model improvement in refinement. The 
divergence of these two R factors is usually a sign of over-refinement (93). 
 
 
 
 
Figure 11   Model-Building Based on the Clear Electron Density 
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CHAPTER II 
MECHANISM OF ACTION OF ISONIAZID AGAINST 
MYCOBACTERIA 
 
BACKGROUND 
Isoniazid (INH) was discovered to have bactericidal activity against 
Mycobacterium tuberculosis (Mtb) in 1952 (94). Since then, it has been used as a potent 
front-line drug against tuberculosis (TB) (95). The mechanism of action of INH has been 
studied for more than 50 years. INH was found to inhibit mycolic acid biosynthesis in 
Mtb (96). In addition, the INH-induced inhibition of mycolic acid biosynthesis was 
demonstrated to correlate with the bactericidal activity of INH (97). Further analysis of 
the lipids of INH-treated Mtb indicated the elongation of the fatty acid beyond C26 was 
inhibited, which suggested that the target of INH is an enzyme in fatty acid elongation 
(98). Isolated INH resistant mutants were analyzed to search for the enzymes that are 
related to the drug action of INH.  The majority of INH-resistant strains isolated in the 
earlier studies were found to have lost catalase/peroxidase activity (99). In 1992, Mtb 
katG, which encodes a catalase/peroxidase, was shown to restore the INH susceptibility 
to INH resistant M. smegmatis mc2155 mutant strain (15). In the same study, deletion of 
katG from the chromosome was found in two INH-resistant Mtb clinical isolates. These 
studies suggested that katG encodes the activator of INH. Since then, 45% to 90% of the 
Mtb clinical isolates resistant to INH were found to contain mutations in the katG gene 
in different studies (16,17,100-102).  
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The mode of INH action remained unclear until an INH-NAD adduct was 
identified as the bound inhibitor in the active site of InhA, the enoyl acyl ACP reductase 
involved in long-chain fatty acid biosynthesis, by protein crystallography. The crystal 
structure of InhA bound with the adduct indicated that an isonictinoyl moiety was 
covalently attached to the 4 position of the nicotinamide ring of NAD cofactor in a S 
configuration. The chemical structure of the INH-NAD adduct was consistent with the 
molecular weight obtained by the mass analysis (13). Later studies demonstrated that 
INH was activated by a KatG-catalyzed oxidation (103,104). One of the reaction 
intermediates, the isonicotinoyl free radical then attacks the nicotinamide ring of NAD to 
form the INH-NAD adduct, which strongly inhibits InhA (Ki = 5 nM) to block mycolic 
acid biosynthesis (13,14,105).  
Mutations within inhA gene or its promoter region were found in the clinical 
isolates resistant to INH (16,17). A S94A mutation in the inhA structure gene, which was 
originally identified in an INH-resistant M. smegmatis strain, was later found in three 
Mtb clinical isolates that conferred resistance to both INH and ETH (106,107). Recently, 
the S94A mutation allele of inhA has been transferred into Mtb by a specialized linkage 
transduction, which was sufficient to confer five-fold resistance to INH (14). Moreover, 
overexpression of inhA in Mtb was found to confer more than 10 fold resistance to INH 
(108). These genetic observations support that InhA is the primary target of INH. 
Although the activation of INH by KatG has been studied by biochemical and 
structural methods (109-113), the detailed mechanism of adduct formation remains 
under investigation. The inhibition of InhA by INH-NAD has also been demonstrated 
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(105,114); however, the molecular basis of the high potency of the INH-NAD adduct has 
not yet been conclusively determined. Furthermore, some studies suggested that the 
nitric oxide released from INH oxidation is responsible for its anti-tubercular activity 
(115). INH, as a single probe, is not sufficient to help us fully understand and validate 
the mechanism of its drug action. There are many hydrazides related to INH whose 
antitubercular activities were studied soon after INH was discovered (94). Several of 
them, such as picolinic hydrazide (PNH) and benzoic hydrazide (BZH), were found to 
inhibit the growth of Mycobacterium bovis BCG strain. However, their antitubercular 
activity is 7.5 and 30 fold lower than that of INH, respectively, based on the MIC values 
(Figure 12) (94). Since those hydrazides have chemical structures similar to INH, it is 
very likely they share the same target and mechanism of drug action. If so, why is INH 
the most potent molecule to treat TB among all the hydrazides? Is there any difference in 
the activation step catalyzed by KatG or in the inhibitory potency to the final target, 
InhA?  
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Figure 12   MIC of INH, PNH and BZH against M. bovis BCG Strain 
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METHODS 
Cloning, Expression and Purification 
M. tuberculosis inhA has already been cloned  into E. coli BL21 (DE3) (116). It 
was cultured in Terrific Broth media containing 50 µg/ml carbenicillin at 37 °C until 
OD600 reached 0.8. Expression of the inhA gene was induced for 20 h at 16 °C by 
addition of 1 mM isopropyl β-D-thiogalactopyranoside (IPTG).  Cells that were 
harvested by centrifugation were re-suspended in 50 mM PIPES (PH 6.8) and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and lysed with a French press. After treatment 
with DnaseI, the insoluble material was removed by centrifugation and the supernatant 
containing soluble protein was applied to HiTrap Blue Sepharose column (AP Biotech) 
pre-equilibrated with the same buffer, using a fast protein liquid chromatography system 
and eluted through a NaCl gradient (0-2 M). InhA eluted out at a NaCl concentration of 
0.9 M. Fractions that contain InhA were pooled and applied to an octyl-sepharose 
column (AP Biotech) pre-equilibrated with 1 M NaCl and eluted out through a NaCl 
gradient (1-0 M). InhA fractions were pooled and a further step of gel filtration in a 
Superdex 200 column was performed to separate the monomeric protein from aggregated 
material. InhA was obtained at 40 mg/L of E. coli culture and appeared homogeneous by 
SDS-PAGE and Coomassie Blue staining. 
The M. tuberculosis KatG was expressed and purified as previously described 
(110).  
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Synthesis of the INH-NAD, PNH-NAD and BZH-NAD Adducts 
Adduct of INH and NAD was synthesized using similar methods described by 
Meunier B. et al. (114) with some modifications. InhA (2 µM) was incubated with INH 
(500 µM), NAD (500 µM), and Mn(III) (500 µM) in 2 ml sodium phosphate (100 mM, 
pH 7.5) buffer for 1 hour. After InhA was inhibited according to the activity assay 
below, the enzyme solution was concentrated and applied to a Superdex 200 column pre-
equilibrated with 50 mM Phosphate buffer (PH 7.5). The InhA in complex with INH-
NAD was then concentrated and heated for 60 seconds under 100°C. After the heat 
treatment, INH-NAD was separated from denatured enzyme by filtration, using a 
centricon (cutoff 30 KDa). The concentration of INH-NAD was determined by its 
absorbance at 260 nm or 326 nm (ε260 = 27 mM-1cm-1, ε326 = 7.0 mM-1cm-1).  BZH-NAD 
and PNH-NAD were synthesized and purified using the same method.  
 
InhA Activity Assay 
All assays were carried out using a Cary 100 Bio Spectrophotometer at 25 °C by 
monitoring oxidation of NADH at 340 nm. Reactions were initiated by adding substrate, 
dodecenoyl-CoA (50 µM), to assay mixtures containing InhA (1 nM), NADH (100 µM) 
and hydrazide adduct inhibitors (3 - 2000 nM). 
The IC50 was determined from dose-response plot of enzyme fractional activity 
as a function of inhibitor concentration. Ki was obtained by dividing the IC50 value by 1 
+ [S1]/Km1 + [S2]/Km2, where  [S1] and [S2] are the concentration of dodecenoyl-CoA and 
NADH and Km1 and Km2 are their Michaelis constants.  
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S94A was assayed under the same condition and evaluated using the same 
method. 
 
Adduct Formation by KatG Catalysis 
The biomimetic approach for adduct formation was carried out according to Zhao 
et al. (113).  Briefly, INH or hydrazide analogs (50 µM), NAD (50µM), M. tuberculosis 
KatG (0.5µM) and H2O2 (2 µM/min, supplied by glucose/glucose oxidase system) were 
incubated in phosphate buffer (pH 7.2) at 25 °C. Adduct formation was monitored by 
increase in absorbance at 326 nm (14DS UV-VIS spectrophotometer, AVIV 
Biomedical).  To eliminate background absorbance, the reference cuvette contained all 
reagents except NAD.  The solutions were collected after 30 min incubation and were 
centrifuged to remove enzymes using a Centricon filter (30 kD cut-off). InhA-inhibitory 
activity of the product was also subsequently measured as above described. (Note: The 
experiment was performed by Xiangbo Zhao in Richard Magliozzo’s group as a 
collaboration.) 
 
Reduction of KatG Compound I by INH and Its Analogs 
Double mixing experiments were carried out using a stopped-flow 
spectrophotometer (HiTech Scientific Model SF-61DX2) according to Yu et al. (117).  
Briefly, resting ferric KatG was mixed with peroxyacetic acid to produce Compound I 
intermediate, followed by the addition of INH or its analogs after a 2 sec delay.  The 
reduction of Compound I was monitored by the change of absorbance at 407 nm, which 
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returns to the value of the resting enzyme during this process. (Note: The experiment 
was performed by Xiangbo Zhao in Richard Magliozzo’s group as a collaboration.) 
  
Crystallization of InhA in Complex with Hydrazides-NAD 
Due to low yields of the adducts using the protocol with KatG, inhibitors used for 
co-crystallization were produced by chemical activation using manganese as described 
above. Crystallization was accomplished by the hanging drop vapor diffusion method 
(85). InhA in complex with inhibitors was co-crystallized in hanging droplets containing 
2 µl of protein solution at 10 mg/ml and 2 µl of buffer (12% MDP, 4% DMSO, 0.1M 
Hepes, 0.025M Sodium Citrate) at 16 °C in Linbro plates against 1 ml of the same 
buffer. Diamond shaped protein crystals formed ~4 days later. 
 
Crystallization of InhA S94A:INH-NAD 
Mutant S94A InhA proteins were co-crystallized with INH-NAD using the same 
method as wild type InhA. 
 
Data Collection and Processing 
Data were collected at 121 K using cryo-protection solution containing reservoir 
solution with additional 30% MPD. Crystal of InhA:INH-NAD diffracted X-rays to 1.9 
Å at beam line 14BMC at the Advanced Photon Source (APS), Argonne National 
Laboratory. Crystals of InhA:BZH-NAD and InhA:PNH-NAD diffracted X-rays to 2.6 
Å and 2.2 Å respectively, using a MacScience DIP2030 image plate detector coupled to 
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a Rigaku X-ray generator utilizing a copper rotating anode (CuKα, λ = 1.54 Å). Crystals 
of InhA(S94A):INH-NAD diffracted to 1.9 Å at beam line 19ID at the Advanced Photon 
Source (APS) in Argonne National Laboratory. Diffraction data were collected from a 
single crystal with one-degree oscillation widths for a range of 180°. The data were 
integrated and reduced using HKL2000 (86)  (Table 2). 
 
Structure Determination and Model Refinement 
Crystals produced from InhA in complex with INH-NAD, PNH-NAD and PNH-
NAD were isomorphous with those of the native enzyme. Initial phases were obtained 
by molecular replacement using the apo-InhA structure (1ENY) and refined with CNS 
(118) (Table 2). Fo – Fc and 2Fo – Fc electron density maps were calculated and 
additional density resembling the inhibitor was found. The ligand was fit into the 
additional density and the whole model was rebuilt using XtalView (89). During the 
final cycles of the refinement, water molecules were added into peaks above 3-s of the 
Fo − Fc electron density maps that were within hydrogen-bonding distances from 
appropriate protein atoms.  
For the model of InhA(S94A):INH-NAD, the apo S94A structure (1ENZ) was 
used as the initial model.  All other procedures of model building and refinement were 
the same as for InhA:INH-NAD.  The final model of InhA(S94A):INH-NAD was 
refined to Rfactor 20.1%, Rfree, 22.8%. 
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Table 2   Data Statistics of InhA in Complex with Hydrazide-NAD Adducts 
 
Data collection         
  InhA:INH-NAD InhA:BNH-NAD InhA:PNH-NAD S94A:INH-NAD
Maximum resolution (Å) 1.9 2.6 2.2 1.7 
Space group P6(2)22 P6(2)22 P6(2)22 P6(2)22 
a (Å) 98.2 97.7 97.4 98.3 
b (Å) 98.2 97.7 97.4 98.3 
c (Å) 139.6 139.6 139.8 139.2 
α (°) 90.0 90.0 90.0 90 
β (°) 90.0 90.0 90.0 90 
γ (°) 120.0 120.0 120.0 120 
Unique refections 31950.0 18441.0 32900.0 34383 
Rsym (%) 11.4 16.0 7.6 10.1 
Completeness (%) 99.8 97.7 98.0 90.5 
Redundancy 13.2 11.0 7.8 14.3 
I/σ 22.4 12.5 23.8 23.7 
     
Refinement statistics         
Resolution range (Å) 40.8-1.9 42.3-2.6 40.0-2.2 33.7-1.9 
Number of reflections 25437.0 11543.0 19558.0 28957 
Number of atoms / subunit     
Protein 1994.0 1994.0 1994.0 1993 
Ligand (s) 52.0 52.0 52.0 52 
Rcryst (%) 20.8 21.6 22.0 20.1 
Rfree (%) 26.0 26.0 26.8 22.8 
Average B-factors (Å2) 31.5 35.3 37.0 31.8 
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Minimum Inhibitory Concentration (MIC) Determination 
The M. tuberculosis H37Rv strains were obtained from laboratory stocks and 
grown in Middlebrook 7H9 medium (Difco) supplemented with 10% (v/v) OADC 
enrichment (Difco), 0.2% (v/v) glycerol, and 0.05% (v/v) Tween 80 to an OD600nm ≈ 1.0.  
The cultures were diluted 4 logs, and 0.1 ml of the diluted cultures were inoculated into 
2 ml of Middlebrook 7H9 media containing the following drug concentration: 0, 0.1, 0.5, 
1, 5, 10, 50, 75, 100, 200 and 500 µg/ml.  The cultures were incubated while shaking at 
37°C for 4 weeks.  The MIC was determined as the concentration of drug that prevented 
mycobacterial growth. (Note: The experiment was performed by Catherine Vilcheze in 
William Jacobs’s group as a collaboration.) 
 
RESULTS 
InhA(S94A) Protein Is More Resistant to INH-NAD Than the Wild Type InhA 
In order to study the molecular basis for the resistance of the inhA (S94A) mutant 
strain, the recombinant InhA (S94A) protein was expressed and purified. To determine if 
the InhA (S94A) enzyme is resistant to inhibition by the INH-NAD adduct, inactivation 
of purified InhA and S94A by this adduct was measured in a dose-dependent fashion.  
The InhA(S94A) enzyme was 17 times more resistant to inhibition by the INH-NAD 
adduct based on IC50 values, and showed a 30-fold increase in the Ki value for the INH-
NAD adduct (Table 3).  To determine the structural basis for the reduced binding of the 
INH-NAD adduct to the InhA(S94A) enzyme, the InhA(S94A) protein was co-
crystallized in complex with the INH-NAD adduct (Figure 13a) and compared to the 
  
 47
 
wild-type protein.  Although the position and orientation of the INH-NAD adduct was 
nearly identical in the active sites of the wild-type (Figure 13b) and InhA(S94A) proteins 
(Figure 13c), the loss of the hydroxyl group of serine residue resulted in the disruption of 
a water molecule and a perturbation in the hydrogen bonding network, which likely 
decreases the binding of the adduct to the InhA(S94A) protein. The biochemical and 
structural results clearly indicated that a single amino acid modification dramatically 
changed the binding of the INH-NAD adduct to InhA. This is consistent with the genetic 
observation that this single point mutation conferred resistance to isoniazid. Altogether, 
it establishes the precise molecular mechanism by which INH inhibits InhA, and 
supports the premise that inhA encodes the primary target of INH. 
 
 
 
 
 
Table 3   Inhibition of InhA and S94A by INH-NAD 
 
  IC50 (nM) KmDD-CoA (µM) KmNADH (µM) Ki  (nM) 
InhA 19 ± 10 46 66 5 ± 3 
S94A 324 ± 41 104 250 172 ± 22 
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Figure 13   Crystal Structure of S94A Bound with the INH-NAD Adduct. 
(a) Ribbon diagram of the S94A mutant protein with the INH-NAD adduct. (b) In the 
InhA:INH-NAD structure, the O9 of the phosphate of the INH-NAD adduct forms one 
hydrogen bond with the main-chain nitrogen atom of Ile21 and one hydrogen bond with 
a well-ordered water molecule. (c) In the S94A:INH-NAD structure, this hydrogen-
bonding network is disrupted by the loss of the hydroxyl group in the S94A substitution 
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Antibacterial Activity of INH Analogs against Mtb Strains 
BZH, PNH, and INH were tested against three Mtb strains: H37Rv, a wild-type 
Mtb; H37Rv inhA (S94A), a Mtb strain containing a single point mutation in inhA and 
H37Rv katG (del g371), a Mtb strain containing a single base pair deletion in katG (Table 
4).  Mutations that prevent the activation of INH as in H37Rv katG (del g371) result in 
INH resistance while the S94A mutation in inhA prevents the binding drug-NAD adduct 
to its target, InhA, leading to INH resistance.  The analogs tested are structurally similar 
to INH (BZH has no nitrogen in the aromatic ring while in PNH, the hydrazide group is 
located at the ortho position instead of the para position in INH). Each analog contains a 
hydrazide group that could be activated by the catalase/peroxidase KatG to form a 
hypothetical acyl radical. As shown in Table 4, PNH had an MIC 40 times higher in the 
H37Rv inhA (S94A) strain and 100 times higher in the H37Rv katG (del g371) strain 
suggesting that this compound is also activated by KatG and targets InhA. BZH was 
poorly active against wild-type Mtb and the inhA mutant strain, and slightly less active 
against the katG mutant strain suggesting that this compound might also be activated by 
KatG in mycobacterial cultures. 
 
  
 50
 
Table 4   The MICs of Hydrazides against Mtb Wild Type and Mutant Strains 
Strains INH (mg/ml) PNH (mg/ml) BZH (mg/ml) 
H37Rv  0.075 5 500 
H37Rv inhA(S94A)  0.5 200 500 
H37Rv katG(del g371)  >25  500 >500  
 
 
The INH-, BZH- and PNH-NAD Adducts Are Potent Inhibitors of InhA 
Previous studies have shown that INH is a pro-drug that requires activation by 
KatG to form an INH-NAD adduct that inhibits InhA. We hypothesized that BZH and 
PNH have the same mechanism of action, due to their structural similarity to INH. To 
test this hypothesis, the INH-NAD, BZH-NAD and PNH-NAD adducts were 
synthesized using Mn(III) as catalyst (Figure 14). Like INH-NAD, both BZH-NAD and 
PNH-NAD are very potent inhibitors of InhA. The inhibition constant of INH-NAD has 
been determined by several groups. In this report, the inhibition constants of INH-NAD, 
BZH-NAD and PNH-NAD were quantified, respectively, using the same assay 
conditions and analytical method (Table 5). The difference in inhibition constant for 
these three species was about two-fold, which is not significant compared to the 
experimental error. InhA:BZH-NAD and InhA:PNH-NAD complexes were isolated by 
size exclusion or ion exchange column chromatography as was done for the InhA: INH-
NAD complex. The isolated enzyme remained inactive, suggesting that all three acyl-
NAD adducts are tight binding inhibitors of InhA. 
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Figure 14   Synthesis of INH-NAD, BZH-NAD, and PNH-NAD 
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Table 5   Inhibition of InhA by Hydrazide-NAD Adducts 
 
 Inhibitors IC50 (nM) KmDD-CoA (µM) KmNADH (µM) Ki  (nM) 
INH-NAD 19 ± 10 46 66 5 ± 3 
BZH-NAD 42 ± 30  46 66 11 ± 8 
PNH-NAD 34± 19 46 66 9 ± 5 
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Structures of InhA Complexes Revealed Similar Binding Modes in the Active Site 
In order to find out the structural basis of the inhibition of INH-NAD, BZH-NAD 
and PNH-NAD against InhA, crystal structures of InhA in complex with these adducts 
were solved. Each structure includes 269 protein residues and one ligand.  
A 2.8 Å InhA:INH-NAD structure has previously been published (13). Due to 
the resolution limitation, there was ambiguity of the real form of INH-NAD adduct. The 
1.9 Å electron density map of the newly solved InhA:INH-NAD structure clearly 
showed that the open-form adduct with 4S configuration at carbon 4 of nicotinamide 
ring is the inhibitor bound in the enzyme active site. The INH-NAD inhibitor binding 
site includes the same nucleotide binding site observed in the structure of InhA:NADH, 
and an extended small pocket which contains the isonicotinic acyl group of the inhibitor. 
The small pocket, that is below and partially overlapped with the fatty acyl substrate-
binding site, is composed of residues Tyr158, Phe149, Met199, Trp222, Leu218, Met199, 
Met155, Met161, and Pro193. Among them, Tyr158, Pro193 and Gly192 are conserved in other 
ENR homologues. The isonicotinic acyl group of the adduct points toward the entrance 
of the small portal. The pyridyl group of the adduct forms a aromatic stacking interaction 
with the flipped phenyl ring of residue Phe149 and the pyridyl nitrogen atom forms a 
hydrogen bond with a buried water (TIP18s). The structures of the InhA:BZH-NAD and 
InhA:PNH-NAD complexes appear to have binding modes similar to InhA:INH-NAD 
based on structural alignment. The phenyl ring of BZH and the picoline ring of PNH all 
stack with the flipped phenyl ring of the sidechain of Phe149 at a distance of 3.6 Å. Most 
of the interactions between ligand and protein are conserved in all three complex 
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structures with a few exceptions (Figure 15). For instance, in the structure of InhA:INH-
NAD, the pyridyl nitrogen atom forms a hydrogen bond with a conserved water, which 
does not exist in InhA:BZH-NAD and InhA:PNH-NAD structures. PNH-NAD forms 
one unique hydrogen-bonding interaction between its pyridine nitrogen and the hydroxyl 
group of Tyr158. Nevertheless, the minor structural difference does not affect the potency 
of the inhibitors (Table 5). 
 
KatG Mediated InhA Inhibition Assay of INH, BZH and PNH 
Even though hydrazide-NAD adducts could be conveniently synthesized using 
inorganic catalysts, the yield of adduct generated from this approach could not truly 
reflect an enzyme mediated process. To better mimic the in vivo activation of INH and 
its analogs, biomimetic studies were carried out to examine the KatG catalyzed adduct 
formation. As shown in Figure 16, the rate of INH-NAD formation is the highest and 
remains steady during the time period monitored, while the formation rate of PNH-NAD 
decreases with time and the formation of BZH-NAD is not detectable using this method. 
BZH was found to be activated by KatG at a rate below 2% of INH in a separate study, 
which is consistent with the present results (119). The reaction mixtures from the 
aforementioned activation were also collected, removed from KatG, and examined for 
their InhA-inhibitory activity.  InhA was most effectively inhibited by the products 
derived from INH, slightly inhibited by those of PNH, and almost not affected by BZH. 
These observations suggest that the difference in anti-tubercular activity among INH, 
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PNH, and BZH results from their varied abilities to form hydrazide-NAD adduct, 
catalyzed by KatG. 
 
 
 
 
 
Figure 15   Surface Diagram of InhA in Complex with Hydrazide-NAD Adducts 
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Figure 16   Formation of Hydrazide-NAD Adduct Catalyzed by KatG. 
INH (50 µM), NAD+ (50 µM), KatG (0.5 µM) and H2O2 (2 µM/min, supplied by 
Glucose/Gox) were incubated in Phosphate buffer pH 7.2 at 25 oC. Absorbance at 326 
nm was monitored  
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The Difference of Adduct Production Rates Is Not due to Different Oxidation Rates 
of the Hydrazides  
To examine in more detail the reason that INH and its analogs have different 
yields of adduct, the reactions between INH, BZH, PNH, and KatG Compound I were 
examined using double-mixing stopped-flow spectrophotometry, respectively. KatG 
Compound I has been demonstrated to be catalytically competent in INH activation 
(117). Reduction of Compound I by the hydrazides restored the Soret peak to its value in 
resting enzyme. Thus, the reaction of hydrazides with Compound I could be monitored 
by the absorbance increase at 407 nm.  As shown in Figure 17, INH, PNH and BZH all 
react with KatG Compound I. Interestingly, the reaction rates for these three substrates 
decrease in the order BZH > > PNH > INH  (Figure 17). This trend is opposite to that of 
their rates of adduct formation. It has been suggested that the product of the oxidation 
step is a radical intermediate; the subsequent reaction of this radical species with NAD is 
likely the rate-limiting step in adduct formation. NAD is relatively large compared to the 
main substrate access channel in KatG. Therefore, a radical intermediate must be stable 
for long enough to encounter NAD. The different aromatic structures in INH, PNH, 
BZH would affect the stability of the radicals.    
  
 58
 
 
 
    
 
Figure 17   Reduction of KatG Compound I by INH and Its Analogs. 
Resting enzymes were pre-reacted with peroxyacetic acid (PAA) to form Compound I, 
followed (two seconds delay) by addition of INH. The final concentrations of enzymes 
and PAA were 5 and 50 µM respectively; the final concentrations of INH and analogues 
are 200 µM.  Arrows indicate the time points when KatG Compound I (low absorbance 
at 407nm) was reduced back to resting enzyme by hydrazide  
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DISCUSSION 
Why INH Is the Superior Prodrug against TB among the Hydrazides 
The INH analogs were investigated to probe the activation and inhibition 
mechanism of INH. BZH and PNH were activated by Mn(III) and formed adducts with 
NAD(H) similar to INH. Furthermore, the BZH-NAD and PNH-NAD were as potent as 
INH-NAD against InhA in vitro. The structures of InhA:BZH-NAD and InhA:PNH-
NAD complexes were determined and compared to the InhA:INH-NAD structure. The 
binding modes of BZH-NAD and PNH-NAD were similar to that of INH-NAD, which 
correlates well with their high inhibitory activities against InhA. 
However, despite all the similarities of their activated forms, the MIC values of 
BZH and PNH showed much less antitubercular activity than INH. The MICs of PNH 
and BZH on Mtb H37RV strain are 50 and 5000 fold higher than that of INH, 
respectively. To understand this tremendous difference between the in vivo 
antitubercular activity and in vitro inhibition activity, we have to go back to the 
mechanism of drug action of INH. In the cell, INH is activated by a catalase-peroxidase 
(KatG) and forms an INH-NAD adduct, which inhibits InhA. A Drug with this 
mechanism must fulfill at least two requirements to exert high antitubercular activity. 
First, the active form of the drug must be a potent inhibitor of InhA. Second, the 
formation of adducts catalyzed by KatG must have reasonable yields. Since BZH-NAD 
and PNH-NAD are potent inhibitors of InhA, we hypothesized that the reason for their 
low antitubercular activity is the low yields of formation of adducts with NAD(H) 
catalyzed by KatG. Formation rates of INH-NAD, BZH-NAD, and PNH-NAD obtained 
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in the KatG activation study strongly support this hypothesis. KatG catalyzed reaction 
did not yield sufficient BZH-NAD or PNH-NAD adducts to cause potent inhibition 
against InhA in vitro. The order of oxidation rates of the hydrazides by KatG Compound 
I was opposite to that of the adduct production rates. Therefore, the difference of adduct 
production rate was not caused by different oxidation rates of the hydrazides. Based on 
these results, we believe the most important factor for the adduct production yield is not 
the formation rate of the free radical intermediate but its stability. Since the pyridyl-acyl 
free radicals are more stable than phenyl-acyl free radicals, the production rate of INH-
NAD is much higher than that of BZH-NAD. As the free radicals involved in the 
formation of INH-NAD and PNH-NAD have approximately the same stability, the 
difference in production rate must be attributed to a different mechanism. Based on our 
results, the production rate of PNH-NAD continuously decreases over time while the 
production of INH-NAD remains unchanged. It is likely PNH or its oxidation products 
inhibit KatG catalysis. This leads to the tremendous difference in the final yields of 
adducts between INH and PNH.  
In addition, the oxidation of all three hydrazides tested in the experiments 
releases nitric oxide as one of the products. Since the oxidation rate of INH was the 
lowest compared to other hydrazides, the rate of formation and releasing of its product 
nitric oxide could not at least be faster than other hydrazides if not slower. This indicates 
that the product nitric oxide from oxidation of isoniazid should not be responsible for its 
anti-tubercular activity. 
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In summary, the high antitubercular activity of INH compared to its analogs is 
not due to a structurally unique moiety in the acyl-NAD inhibitor of InhA, but rather the 
high yield of its activated form; this is provided by two important factors: 1) long life 
time of the free radical intermediate; 2) no significant product inhibition to KatG. 
  
Other Putative Targets 
Although genetic and biochemical studies have provided convincing evidence 
that InhA is the primary target of INH, other putative targets of INH have been proposed 
as well (120-122). Recently, an INH-NADP adduct was shown to strongly inhibit Mtb 
dihydrofolate reductase (DHFR) in vitro (Kiapp = 1 nM) (123). This INH-NADP adduct 
was synthesized by incubating INH and NADP+ in the presence of Mn(III) catalyst. In 
the Mn catalyzed reaction, the product is a mixture of six adducts (two of them are 
acyclic and the other four are cyclic) (114). Unlike INH-NAD adduct, which can be 
synthesized by the KatG mediated reaction, the formation of INH-NADP adduct 
catalyzed by KatG in vitro has not been demonstrated (103). This INH-NADP adduct 
was found to compete with both substrates for DFHR dihydrofolate and NADPH, which 
is similar to the inhibition mechanism of INH-NAD against InhA. Recombinant DHFR 
was co-crystallized with synthesized INH-NADP adduct mixtures to find out which form 
of INH-NADP adduct has the highest binding affinity to the enzyme. The complex 
structure indicated that an acyclic 4R INH-NADP adduct was selectively bound in the 
active site of DHFR. The structural modeling study also suggested the 4S enantiomer 
would not fit in the binding pocket. To demonstrate that the inhibition of DHFR by this 
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4R INH-NADP adduct is relevant to the killing of Mtb by INH in vivo, it was further 
tested if overexpression of Mtb dfrA could protect M. smegmatis from INH inhibition. In 
the previous study, over-expression of dfrA in M. smegmatis caused a two fold increase 
of resistance to INH compared to the wild type. Based on these observations, Argyrou, 
et. al. claimed that Mtb DHFR, which is inhibited by an INH-derived 4R acyclic INH-
NADP adduct, is also a target of INH.  
In the previous study, a synthetic INH-NADP adduct derived from INH 
demonstrated strong inhibition and binding to Mtb DHFR in vitro, which is the 
biochemical evidence for Argyrou, et. al. to link DHFR with the anti-tubercular activity 
of INH (123). However, the INH-NADP adduct in the previous study was synthesized 
using inorganic catalysts, Mn(II) chloride. Thus, the yield of adduct generated from such 
approach could not truly reflect an enzyme mediated process inside the cell. To better 
mimic the in vivo activation of INH, a cell-based activation system was designed to 
examine the KatG catalyzed adduct formation and its binding to DHFR. This E. coli-
based activation system is similar to the one used previously to activate the prodrug ETH 
and PTH (21). In this system, katG and dfrA were co-expressed in E. coli in the presence 
of INH to investigate if the activated drug would inhibit DHFR. To construct this 
system, katG and dfrA were co-transformed into the E. coli BL21(DE3) strain and 
selected by 50 µg/ml kanamycin and carbenicillin. The cells that exhibited high level of 
expressions of both KatG and InhA were selected out for further experiments. The cell 
growth was tested at series of concentrations of INH.100 µg/ml of INH was found to be 
the highest concentration that would not cause inhibition of E. coli cell growth. The E. 
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coli strain containing katG and dfrA genes was grown and induced in the presence and 
absence of 100 µg/ml INH, respectively. After the co-expressions of both genes were 
confirmed by SDS-PAGE, recombinant KatG and DHFR proteins were readily purified.  
Mass spectroscopy method was used to investigate if DHFR purified from the 
experiment sample was bound with any inhibitor. Mass spectroscopy is being widely 
used to characterize both small compounds and macromolecules. We have applied this 
method to the identification of INH-NAD, ETH-NAD and PTH-NAD adducts bound to 
InhA (13,21). Before the mass spectroscopy experiment, the purified DHFR was 
concentrated to 5mg/ml. The protein was then denatured by heating at 100 ˚C for 60 
seconds, followed by filtration (cutoff size = 3000 Da) to separate the small molecules 
from the denatured protein. MALDI mass spectrum of the filtrate on the range between 
200 to 1200 Da was carefully analyzed. We were not able to identify any compound that 
has a molecular weight corresponds to the INH-NADP adduct. The peaks shown on the 
spectrum were most likely originated from small molecules in the buffer solution or 
some small fragments of the protein resulted from proteolytic activity.    
An enzyme assay was performed to determine the activity of purified DHFR. 
DHFR isolated from the experimental sample was found to be fully active (specific 
activity of 12 µmol mg-1min-1) and showed no sign of inhibition compared with the 
enzyme purified from expression in the absence of INH. Since the 4R acyclic INH-
NADP adduct is extremely potent against DHFR in vitro, it would tightly bind to DHFR, 
if the adduct is indeed generated by KatG catalysis inside the cell. However, the activity 
assay result and the mass analysis demonstrated that no detectable amount of INH-
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NADP adduct had bound to DHFR. To confirm that the lack of the INH-NADP adduct 
did not result from the absence of KatG activity, the co-expressed KatG from the same 
experimental sample was purified and assayed for its activity in vitro. The specific 
catalase activity of isolated KatG was 17 mol mg-1min-1, which is comparable to the 
published data (activity of 21 mol mg-1min-1) (113). Therefore, it is clear that 4R acyclic 
INH-NADP adduct is not an activated INH product generated by KatG catalysis inside 
the E. coli cell-based system. 
To demonstrate a target of a bactericidal drug, it is necessary to show that 
binding of the drug to the putative target causes inhibition of biological activity, which 
leads to the death of the cell. In the case of INH, it is more complicated to elucidate its 
mechanism of action, since INH is a prodrug. It is necessary to not only demonstrate that 
the putative target is relevant to the bactericidal activity of INH, but also show how the 
active form of INH inhibits the target protein. The previous work postulated that the Mtb 
DHFR is the target of INH mainly based on two independent observations: 1) a 4R INH-
NADP adduct synthesized from INH by non-enzymatic approach showed strong 
inhibition to DHFR in vitro; 2) Overexpression of dfrA in M. smegmatis conferred 
resistance to INH. However, the two observations are not relevant to each other, unless it 
can be demonstrated that the 4R INH-NADP adduct is a product of INH generated inside 
the cell by KatG catalysis, which is absent in the previous study.  By coexpressing katG 
and dfrA genes in the E. coli cells in the presence of INH, we showed that the DHFR 
protein isolated from the experimental sample was not bound with the INH-NADP 
adduct. This demonstrated that the 4R INH-NADP adduct is not generated by KatG 
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catalysis. KatG is so far the only identified activator of INH and it is very unlikely that 
INH could be activated by another unknown protein to form the INH-NADP adduct in 
mycobacteria. Therefore we can further assert that the synthetic INH-NADP adduct is 
not biologically relevant to INH. 
 
  
 66
 
CHAPTER III 
 MECHANISM OF THIOAMIDE AGAINST MYCOBACTERIA  
 
BACKGROUND 
Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clinically 
effective in the treatment of Mycobacteria infections caused by M. tuberculosis, M. 
leprae and M. avium complex (124,125). ETH and PTH are both bacteriocidal and 
interchangeable in a chemotherapy regimen. They are the most frequently used drugs for 
the treatment of drug resistant TB and therefore are becoming increasingly relevant as 
the number of multi-drug resistant (MDR) and extensively drug resistant (XDR) cases is 
increasing worldwide (126). ETH and PTH are also used in a combined chemotherapy 
regimen with either dapsone or rifampin to treat leprosy (127). While we have 
previously speculated about the mechanism of action of ETH in M. tuberculosis based 
on analogy to Isoniazid (INH)’s mode of action, definitive biochemical evidence that 
ETH targets InhA has not been forthcoming. ETH and PTH are structurally similar to the 
front line drug isoniazid (Figure 18), and it is known that all of these drugs inhibit 
mycolic acid biosynthesis. Banerjee et al. first demonstrated that the gene inhA, which 
encodes an essential enzyme for mycolic acid biosynthesis, was the target of INH and 
ETH (107). Indeed, several M. tuberculosis isolates resistant to INH contain mutations in 
the inhA gene and all have been found to be cross-resistant to ETH (106). An 
experimentally induced single amino acid mutation S94A of inhA was sufficient to 
confer resistance to both ethionamide and isoniazid in M. tuberculosis and M. bovis 
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BCG (128). These observations suggested that the primary target of both isoniazid and 
ethionamide was InhA, the enoyl-acyl ACP reductase involved in mycolic acid 
biosynthesis. The same enzyme has been previously identified as the target of INH 
(13,103,116).  
Like INH, ETH is also a prodrug that requires activation to exert antitubercular 
activity. However, KatG mutant strains resistant to INH are still sensitive to ETH, 
demonstrating that ETH must have a different activator (106,129). Later on, it was found 
that mutations of gene Rv3854c (ethA) were repeatedly found in the clinical isolates 
resistant to ethionamide. The overexpression of ethA in M. smegmatis resulted in 
significantly increased ethionamide sensitivity (20). This evidence suggested that ethA is 
critical for the activation of ETH.  
 
N
ONH2
N
ONH
NH2
Ethionamide Isoniazid  
 
Figure 18   Chemical Structures of Ethionamide and Isoniazid 
  
 68
 
METHODS 
Cloning, Expression, and Purification 
The Mtb inhA has been previously cloned (116). Mtb ethA was cloned from 
genomic DNA (C.S.U. N01-AI-75320).  The amplified product was inserted into 
pET28b using the NdeI and NotI restriction sites. M. leprae ethA and inhA were cloned 
from genomic DNA. The amplified product of M. leprae ethA was inserted into pET15b 
using the NdeI and BamHI restriction sites. M. leprae inhA was inserted into pET30b 
using the NdeI and HindIII restriction sites. 
The plasmids of Mtb inhA and ethA were singly and doubly transformed into E. 
coli BL21 (DE3) (EMD Bioscience #69387-3). The strain containing plasmids of inhA 
and ethA was cultured in LB-Miller media containing 50 µg/ml kanamycin and 50 µg/ml 
carbanicillin at 37 °C until OD600 reached 0.8. Expression of both genes was induced for 
20 hours at 16 °C by addition of 1 mM isopropyl β-D-thiogalactopyranoside (IPTG). At 
the same time of induction, 100 µg/ml of ethionamide or prothionamide was also added 
to the culture. The same protocol was used for the strain containing just the inhA 
plasmid. 
Cells were harvested by centrifugation and re-suspended in 50 mM PIPES (PH 
6.8) and 1 mM phenylmethylsulfonyl fluoride (PMSF) prior to lysing with a French 
press. After treatment with DnaseI, the insoluble material was removed by centrifugation 
and the supernatant containing soluble protein was applied to a HiTrap Blue Sepharose 
column (AP Biotech) pre-equilibrated with the same buffer, using a fast protein liquid 
chromatography system, and eluted through a NaCl gradient (0-2 M). Fractions that 
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contain InhA were pooled and applied to an octyl-sepharose column (AP Biotech) pre-
equilibrated with 1 M NaCl and eluted with a NaCl gradient (1-0 M). InhA fractions 
were pooled and a further step of gel filtration in a Superdex 200 column was performed 
to separate the monomeric protein from aggregated material. The protein appeared 
homogeneous by SDS-PAGE and Coomassie Blue staining.  
The co-expression and purification of M. leprae ethA and inhA were conducted 
using a protocol similar to Mtb. 
 
Isolation and Characterization of ETH-NAD and PTH-NAD 
InhA purified from the experimental strain containing both inhA and ethA genes 
was then concentrated and heated for 40 seconds under 100°C. After the heat treatment, 
ETH-NAD or PTH-NAD was separated from denatured enzymes by filtration, using a 
centricon device (cutoff size 30 KDa). The concentration of ETH-NAD and PTH-NAD 
were determined by its absorbance at 260nM and 326nM (103). The molecular weight of 
both adducts was determined by MALDI, carried out on an ABI Voyager-DE STR: for 
ETH-NAD, calculated 797.2 and found 797.3 (negative mode); calculated 799.2 and 
found 799.2 (positive mode); for PTH-NAD calculated 811.2 and found 811.3 (negative 
mode). 
 
InhA Enzymatic Activity Assay 
All assays were carried out on a Cary 100 Bio Spectrophotometer at 25 °C by 
monitoring oxidation of NADH at 340 nm. Reactions were initiated by adding substrate 
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dodecenoyl-CoA (50 µM) to assay mixtures containing InhA (1 nM), NADH (100 µM), 
and adduct inhibitors (3 - 2000 nM). 
The IC50 was determined from the dose-response plot of enzyme fractional 
activity as a function of inhibitor concentration. Ki was obtained by dividing the IC50 
value by 1 + [S1]/Km1 + [S2]/Km2, where  [S1] and [S2] are the concentration of 
dodecenoyl-CoA and NADH and Km1 and Km2 are their Michaelis constants. 
 
Crystallization of InhA in Complex with ETH-NAD Adduct 
Crystallization was accomplished by the hanging drop vapor diffusion method 
(85). Mtb InhA in complex with inhibitors were co-crystallized in hanging droplets 
containing 2 µl of protein solution at 10 mg/ml and 2 µl of buffer (12% MDP, 4% 
DMSO, 0.1M Hepes, 0.025M Sodium Citrate) at 16 °C in Linbro plates against 1 ml of 
the same buffer. Diamond shaped protein crystals formed ~4 days later. 
M. leprae InhA in complex with inhibitors were co-crystallized in a similar manner, and 
the crystal has a cubic shape. 
 
Data Collection and Processing 
Data were collected at 121 K using cryo-protection solution containing reservoir 
solution with additional 30% MPD. Crystals of Mtb InhA:ETH-NAD and M. leprae 
InhA:PTH-NAD diffracted X-rays to 2.2 Å and 1.8 Å using the beam line 23ID at the 
Advanced Photon Source (APS), Argonne National Laboratory. Diffraction data were 
collected from a single crystal with one-degree oscillation widths for a range of 120°. 
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Crystals of Mtb InhA:PTH-NAD diffracted to 2.5 Å using a Raxis image plate detector 
coupled to a Rigaku X-ray generator utilizing a copper rotating anode (CuKα, λ = 1.54 
Å). The data were integrated and reduced using HKL2000 (Table 6) (86). 
 
Structure Determination and Model Refinement 
Crystals produced from InhA in complex with ETH-NAD were isomorphous to 
those of the native enzyme. Initial phases were obtained by molecular replacement using 
the apo-InhA structure (1ENY) and refined with CNS (Table 6) (118). Fo – Fc and 2Fo – 
Fc electron density map were calculated and additional density resembling the inhibitor 
was found. The ligand was fit into the additional density and the whole model was 
rebuilt using XtalView (89). During the final cycles of the refinement, water molecules 
were added into peaks above 3 σ of the Fo − Fc electron density maps that were within 
hydrogen-bonding distances from appropriate protein atoms. The final refinement 
statistics were listed in Table 6.  
 
Control Experiment 
To ensure that over expression of ethA did not interfere with the activity of the 
co-expressed InhA, over expression of both ethA and inhA in the absence of ETH was 
used as one control (designated control 1). Furthermore, over expression of only the 
target protein InhA under the same concentration of ETH was used as control 2 for the 
experiment to verify that EthA is critical for the activation of ethionamide. InhA was 
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isolated from both controls and assayed for the activity. Mass analysis was performed on 
purified InhA to identify any bound adduct inhibitors.    
 
 
Table 6   Data Statistics of Mtb and M. leprae InhA Complexes  
 
  Mtb M. leprae 
  InhA:ETH-NAD InhA:PTH-NAD InhA:PTH-NAD 
Data Collection    
Space group P6222 I212121 I212121 
Cell dimensions    
   a, b, c (Å) 97.9, 97.9, 140.4 91.6, 100.5, 186.5 91.2, 100.0, 186.6 
   α, β, γ (°) 90, 90, 120 90 90 
Resolution (Å) 2.2 (2.28 - 2.2) 2.5 (2.59 - 2.5) 2.1 (2.18 - 2.1) 
Rsym (%) 16.6 (74.3) 14.8 (92.9) 6.8 (56.9) 
I/σI 19.8 (3.0) 8.6 (1.3) 31.5 (2.0) 
Completeness (%) 99.6 (99.9) 99.5 (100) 99.5 (95.6) 
Redundancy 10.4 (9.0) 3.0 (3.0) 7.0 (4.9) 
    
Refinement    
Resolution  (Å) 40.85 - 2.20 19.99 - 2.5 19.99 - 2.1 
No. reflections 19683 28424 47248 
Rwork / Rfree 23.3 / 26.1 21.9 / 26.8 22.0 / 24.4 
No. atoms / ASU    
   Protein 1994 3988 4016 
   Ligand 54 110 110 
   Water 34 83 203 
B-factors (Å2)    
   Protein 49.1 33.8 41.3 
   Ligand 47.8 32.6 35.7 
   Water 42.5 30.3 49.5 
R.m.s deviations    
   Bond length (Å) 0.007 0.015 0.017 
   Bond angles (°) 1.3 2.1 2.1 
 
  
 73
 
RESULTS AND DISCUSSION 
Activation of ETH Using Purified EthA or Chemical Agents in vitro 
ethA encodes a flavin monooxygenase known to catalyze the Baeyer-Villiger 
reaction to detoxify aromatic and long chain ketones (130). EthA is membrane-
associated and has a tendency to form large oligomers after purification, although its 
membrane attachment site has not been identified based on sequence prediction 
(130,131). The monooxygenase activity of the purified EthA is very low (kcat = 0.00045 
s-1), suggesting that the enzyme may require cell membrane to be fully functional. We 
and other groups have tried to use purified recombinant EthA to activate ETH in vitro. It 
has been demonstrated that some polar metabolites were generated by the catalytic 
oxidation of ethionamide by EthA by TLC and HPLC (19). However, none of the 
isolated metabolites of ETH have antitubercular activity, suggesting that the active form 
of the ethionamide is unstable and was not isolated in previous attempts. In our 
experiment, we incubated EthA with ETH, NADPH, and NAD+ in phosphate buffer pH 
7.5 for two hours. After incubation the small molecule was separated from EthA, and 
incubated with purified InhA for one hour. The enzyme assay results indicated that the 
products from a direct activation of ethionamide by purified recombinant EthA did not 
show any measurable inhibition of InhA. All these results suggested that the activation 
of ETH could not be reconstituted in vitro. Non-enzymatic approaches were also tried to 
activate ETH. Since Mn (II) and Mn(III) have been shown to activate INH, these two 
metal complexes were used to activate ETH. ETH and NAD+ were incubated with Mn 
(II) or Mn(III) for 30 minutes. The product mixture was then filtered and incubated with 
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purified InhA. The activity of InhA was assayed and compared with the native enzyme. 
It was found that InhA remained active even after two-hour incubation with the product 
mixture, which indicated that ETH was not activated by the Mn catalysts. Other 
oxidants, such as hydrogen peroxide, were tested using the aforementioned methods. 
None of them could yield any products that showed inhibition to InhA. 
      
Design of a Cell-Based Activation System  
Since in vitro activation of ethionamide has not been possible by either chemical 
or enzymatic approaches, we developed a cell-based activation method. In this system, 
InhA and EthA were co-expressed in E. coli BL21(DE3) in the presence of 100 µg/ml of 
ethionamide. Overexpressed recombinant EthA was used to activate the thioamide drugs 
ETH or PTH and InhA to scavenge the activated species in E. coli. While ETH or PTH 
is a potent drug against M. tuberculosis (MIC = ~ 0.5 µg/ml) (132), it does not affect E. 
coli growth even at very high concentrations (100 µg/ml) primarily due to the absence of 
EthA, the activator of the drug. Co-expression of multiple recombinant proteins in E. 
coli has been used to get protein complexes. However, to our knowledge it is the first 
time that the activator and target genes have been co-expressed to isolate active species 
of a prodrug. 
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Isolation and Characterization of the Active Forms of ETH and PTH  
InhA and EthA were co-expressed in E. coli BL21 (DE3) in the presence of 100 
µg/ml of ETH. The recombinant InhA was rapidly purified, and an in vitro enzyme assay 
was performed. InhA isolated from the experimental sample had less than 1% of the 
specific activity of InhA purified without addition of ETH under the same assay 
condition. Mass analysis of denatured InhA from the experimental sample indicated the 
presence of a small molecule with a molecular weight of 798.2 (Figure 19).  This mass 
corresponds to the exact molecular weight of an ethyl-isonicotinic-acyl-NAD covalent 
adduct. Moreover, purified fractions of this small molecule showed strong inhibition to 
native InhA in vitro (Ki = 7 ± 5 nM), which is as potent as the INH-NAD adduct, the 
active form of isoniazid (Ki = 5 nM). When prothionamide was used in the same co-
expression experiment, a compound was identified with a molecular weight of 812.2 that 
corresponds to the mass of a propyl-isonicotinic-acyl-NAD adduct (Figure 19). This 
compound is also very potent against InhA in vitro (Ki = 2 ± 0.8 nM).  
  
 76
 
  
A. 
 
Figure 19   MALDI Mass Spectra of ETH-NAD and PTH-NAD. 
A. MALDI mass spectra, carried out on an ABI Voyager-DE STR, showing that two 
inhibitors bound to InhA are compounds with apparent mass of 798 and 812, 
respectively. A. The positive mode mass spectra showing a peak at m/z = 799 ([M + 
H]+). Peaks corresponding to [M + Na]+ (m/z = 821), [M - H + 2Na]+ (m/z = 843), and 
[M - 2H+ 3Na]+ (m/z = 865) can be observed as well. 
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B.   
 
Figure 19 continued 
B. The negative mode mass spectra showing a peak at m/z = 797 ([M - H]-). Peaks 
corresponding to [M - 2H + Na]- (m/z = 819), and [M - 3H + Na + K]- (m/z = 859) can be 
observed as well. Therefore, the apparent mass of the compound is 798, which is in 
agreement with the chemical structure of ETH-NAD.  
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C. 
 
 
Figure 19. continued 
C. The negative mode mass spectra showing peaks at m/z = 811 ([M - H]-) and 833 ([M - 
2H + Na]-), indicating an apparent mass of 812 that is in agreement with the chemical 
structure of PTH-NAD. 
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Binding Mode of the ETH-NAD Adduct 
Mtb InhA in complex with both inhibitors was crystallized. Dataset to 2.2 and 2.5 
Å resolution were collected from single crystals of both complexes (Table 6). Unbiased 
electron density maps of each complex clearly indicated the presence of a modified 
NAD with an ethyl-isonicotinic-acyl or propyl-isonicotinic-acyl group at the 4-position 
of the nicotinamide ring in a 4S configuration (Figure 20A).  The chemical structures of 
both inhibitors are consistent with molecular weights obtained by the mass analysis. 
Similar to the structure of InhA bound with the adduct INH-NAD (13), the ethyl-
isonicotinic-acyl, or propyl-isonicotinic-acyl, moiety is found in a hydrophobic pocket 
that was formed by the rearrangement of the side chain of Phe149 (Figure 20B, C, D). 
The ethyl-isonicotinic acyl, or propyl-isonicotinic-acyl, group also forces the side chain 
of Phe149 to rotate ~90° forming an aromatic ring-stacking interaction with the pyridine 
ring (Figure 21A). The pocket is lined predominantly by hydrophobic groups from the 
side-chains of Tyr158, Phe149, Met199, Trp222, Leu218, Met155, Met161, and Pro193, and is 
adjacent and partly overlapped with the fatty acyl substrate-binding site. Indeed, the 
atoms common to ETH-NAD, PTH-NAD, and INH-NAD are in identical positions. The 
only difference is the extra ethyl or propyl group at the 2 position of the pyridine ring of 
ETH or PTH. The ethyl group contributes to the binding of ETH-NAD adduct by 
forming π-stacking interactions with the aromatic side chain of Tyr158 at a distance of 
~3.3 Å. It is also within hydrophobic interaction distances with side chains of Leu218 (3.3 
Å) and Met155 (3.2 Å). The hydrogen-bonding interactions on the nucleotide-binding site 
are well conserved. Therefore, it is very likely that mutations, such as S94A, that 
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decrease the binding of NAD(H) and the INH-NAD adduct would also weaken the 
binding of ETH-NAD and PTH-NAD (Figure 21B). This explains why the S94A mutant 
strain of Mtb is co-resistant to both isoniazid and ethionamide. 
 
 
 
 
Figure 20   Active Sites of Mtb InhA Bound to Inhibitors  
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Figure 21   Active Site of InhA in Complex with ETH-NAD and PTH-NAD. 
A. The stereo view of the superposition of active sites of Mtb InhA:NADH structure and 
InhA:ETH-NAD structure, showing the side chain of Phe149 rotated ~90° once the ETH-
NAD adduct binds to the enzyme. B. The stereo view of the active sites of M. leprae 
InhA:PTH-NAD structure 
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Mechanism of Drug Action of ETH and PTH against Leprosy 
Unlike Isoniazid, the front line anti-TB drug, which is not effective against M. 
leprae, ethionamide and prothionamide are used in the treatment of leprosy.  Genome 
analysis indicated that both M. leprae and M. avium have ethA and inhA homologs with 
high sequence similarity to Mtb. The M. leprae ethA and inhA were cloned, co-
expressed, and purified in the presence of the prothionamide using a cell based 
activation method similar to Mtb. A compound with same molecular weight as PTH-
NAD adduct was identified, which also showed strong inhibition to M. leprae InhA (Ki 
= 11 ± 6 nM) in vitro. 
The crystal structure of M. leprae InhA in complex with PTH-NAD was solved 
to 2.1 Å resolution, in order to compare the binding mode of the inhibitor to the enzyme 
with Mtb InhA. The overall structure of M. leprae InhA is similar to Mtb InhA (r.m.s.d = 
1.3), and the active site residues are conserved. The propyl-isonicotinic-acyl moiety of 
the adduct is observed inside a hydrophobic pocket. The pyridyl ring forms π-stacking 
interaction with the aromatic side chain of Phe149 and the propyl group is π-stacking with 
the aromatic side chain of Tyr158. Residues including Ser94 in nucleotide binding site 
forms hydrogen-bonding interactions with NAD moiety of the adduct in a similar 
manner as Mtb InhA (Figure 21B). These results supported our hypothesis that the active 
form of prothionamide inhibits M. leprae InhA in a similar way to Mtb InhA. Although 
no clinical or experimental mutant of M. leprae InhA has been reported yet, based on the 
binding mode of the PTH-NAD adduct, it is legitimate to predict that those InhA 
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mutations in ETH resistant Mtb mutant strains, such as S94A, would also confer 
resistance of M. leprae to ETH and PTH. 
 
Activation Mechanism of ETH and PTH 
Although ethionamide, prothionamide, and isoniazid NAD adducts are similar, 
their activation mechanisms are very different. Isoniazid, a hydrazid, is activated by the 
heme-utilizing catalase-peroxidase, KatG (15,103). We proposed that isoniazid was 
oxidized to generate an isonicotinic acyl free radical, which subsequently attacked the 
NAD+ to form INH-NAD (13). Ethionamide, a thioamide, has been shown to be 
metabolized by EthA, a FAD enzyme found in Mtb, however, none of the final 
metabolites isolated were active either in vitro or in vivo (19). It has been proposed that a 
free radical metabolite intermediate could be generated through EthA oxidation of ETH, 
in analogy to the activation of INH. There is a possibility that other unknown cell 
component is required for the formation of the adduct by the free radical intermediate. It 
is also possible that the activation of ETH itself may happen inside cell membrane, 
which creates a hydrophobic environment. This is usually critical for a free radical type 
reaction. These may explain why no active species were isolated in vitro. We believe 
those inactive metabolites isolated in previous attempts could result from the side 
reactions and quench of the free radical intermediate in solution. It is still not clear how 
the thioamide is oxidized inside the active site of EthA, although it is common for a 
flavin monooxygenase that a peroxide free radical is generated during oxidation, assisted 
by the cofactor FAD or FMN. Tokuyama et al. demonstrated that a thioamide could be 
used as a precursor of a synthon equivalent to an imidoyl radical in converting 
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thioamides to corresponding indole derivatives (133). The Bu3SnH/Et3B was used as a 
free radical initiator in pure organic solvent. Similarly, we postulate that ETH is 
converted to an imidoyl radical inside the active site of EthA using O2/FAD as a radical 
initiator. The imidoyl radical subsequently forms an adduct with NAD, which is then 
converted to ethyl-isonicotinic-acyl-NAD adduct after hydrolysis to release the amine 
group. It is also possible that the imidoyl anion is the intermediate before forming the 
adduct with NAD (Figure 22). 
 
Other Anti-TB Thioamide Drugs 
Other than ETH and PTH, there are several anti-TB thioamides drugs currently 
used as second line drugs to cure TB. Among them, the best known are thioacetazone 
and isoxyl. These thioamides are cheap and very effective against TB and even some 
drug resistant strains. Thioacetazone and isoxyl are prodrugs that also have to be 
activated by EthA. However, their final targets are still not clear. We grew the E. coli 
cell with both EthA and InhA co-expressed in the presence of 100 µg/ml of 
thioacetazone. However, the isolated InhA are fully active. Mass and crystallographic 
analysis indicated that there is no small molecule tightly bound to InhA, which 
suggested that unlike ETH the final target of thioacetazone is not InhA. Later on, the 
genetic studies indicated that both thioacetazone and isoxyl are more likely targeting the 
mycolic acid modification pathways, not fatty acid biosynthesis, which is consistent with 
our results. 
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Figure 22   Possible Reaction Mechanisms of the Activation of ETH  
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Crystallization Trials of EthA 
Since EthA plays a key role in the activation of several anti-mycobacteria 
thioamides, it is important to understand the reaction mechanism in the active site of 
EthA. The structure of EthA would greatly benefit the studies of the activation 
mechanism. As mentioned previously, EthA is a membrane associated protein, although 
it is still not clear about the lipid attachment site based on sequence analysis. More than 
95% of the recombinant EthA is attached to membrane after overexpression in E. coli. 
Several detergents have been tried to extract the protein from the membrane. Triton X-
100 showed good yield (>90%) of extraction of the recombinant EthA. Interestingly, 
once the EthA is extracted from membrane, it does not require detergent in the 
purification buffer. However, the protein formed large oligomer during purification. 
Several detergents were screened to stabilize the protein monitored by dynamic light 
scattering method. None of the detergents tried could turn the protein into smaller 
oligomer state. The purified protein was tried for crystallization. More than 400 
crystallization conditions were screened, however no protein crystal was observed. 
     
Conclusion   
 These studies describe the molecular mechanism of the drug action of 
ethionamide and prothionamide against M. tuberculosis and M. leprae. This information 
is important for the optimization of drug activity and the understanding of drug 
resistance. As the molecular target of ethionamide, prothionamide, and isoniazid is the 
same, it validates InhA as an outstanding anti-tuberculosis and anti-leprosy drug target. 
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Since most of the clinical strains resistant to ethionamide and prothionamide contain 
mutations in the ethA gene, it is clear that agents that inhibit InhA without the need for 
EthA activation will be effective against resistant bacteria.  
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CHAPTER IV 
 INHIBITOR DESIGN TARGETING MTB INHA 
 
BACKGROUND 
The emergence of strains resistant to INH and other widely used antitubercular 
drugs is a global health problem, making it critical to search for a new generation of 
antitubercular agents (126,134). The activities of INH and ETH are dependent on their 
activation in Mtb by KatG and EthA, respectively (19,106). Mutations in activator genes 
katG and ethA have been found in most of the clinical isolates resistant to these two 
drugs (106). 
Compounds that do not require activation and directly target InhA represent a 
promising approach to circumvent this resistance mechanism. Aiding such an effort are 
several crystal structures, such as those of InhA:NADH, InhA:NAD+:triclosan, 
InhA:NAD:Genz10850, InhA:NAD+:C16-substrate and InhA:INH-NAD. The complex 
structures indicate two hydrophobic cavities capable of being filled, the substrate 
binding site and the pocket where the isonicotinyl group protrudes. There are also 
several possibilities for hydrogen-bonding, aromatic stacking, van der Waal, and 
hydrophobic interactions distributed throughout the active site. The precisely defined 
active site of InhA, by these structures, has facilitated a thorough understanding of the 
ligand-enzyme interactions that render potent enzyme inhibition. The design of novel 
inhibitors also requires the discovery of new lead compounds.  
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METHODS 
Cloning, Expression and Purification 
M. tuberculosis inhA has already been cloned  into E. coli BL21 (DE3) (116). It 
was expressed and purified as described in chapter II. 
  
InhA Enzymatic Activity Assay 
All assays were carried out using a Cary 100 Bio Spectrophotometer at 25 °C by 
monitoring oxidation of NADH at 340 nm. Reactions were initiated by adding substrate, 
dodecenoyl-CoA (50 µM), to assay mixtures containing InhA (5 nM), NADH (100 µM) 
and inhibitors (1 - 10000 nM). 
The IC50 was determined from dose-response plot of enzyme fractional activity 
as a function of inhibitor concentration. Ki was obtained by dividing the IC50 value by 1 
+ [S1]/Km1 + [S2]/Km2, where  [S1] and [S2] are the concentration of dodecenoyl-CoA and 
NADH and Km1 and Km2 are their Michaelis constants. 
InhA in vitro enzyme assay were conducted in the presence of 10 µM inhibitor as 
an initial screen, and those compounds with > 60% inhibition were further subjected to 
IC50 determination, that will be used to compare the inhibition potency quantitatively.  
 
Crystallization of InhA in Complex with Inhibitors 
Crystallization was accomplished by the hanging drop vapor diffusion method 
(85). InhA was incubated with inhibitors and NAD+ at molar ration 1:2:100 for two 
hours and was then co-crystallized in hanging droplets containing 2 µl of protein 
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solution at 10 mg/ml and 2 µl of buffer (20% PEG 3350, 6% DMSO, 0.1M ADA pH 6.8, 
0.08 M ammonium acetate) at 16 °C in Linbro plates against 0.5 ml of the same buffer. 
Protein crystals formed ~4 days later. 
 
Data Collection and Processing 
Data were collected at 121 K using cryo-protection solution containing reservoir 
solution with additional 30% ethylene glycol. Crystal of InhA:JPC5394 diffracted X-
rays to 1.98 Å at beam line 23ID at the Advanced Photon Source (APS), Argonne 
National Laboratory. Crystals of InhA:JPC5274 and InhA:JPC5734 diffracted X-rays to 
2.8 Å and 1.98 Å respectively, using a Raxis detector coupled to a Rigaku X-ray 
generator utilizing a copper rotating anode (CuKα, λ = 1.54 Å). Diffraction data were 
collected from a single crystal with 0.5 degree oscillation widths for a range of 180°. The 
data were integrated and reduced using HKL2000 (Table 7) (86). 
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Table 7   Data Statistics of InhA in Complex with Triclosan Analogs 
 
Data collection       
  InhA:JPC5394 InhA:JPC5274 InhA:JPC5734 
Maximum resolution (Å) 1.98 2.80 1.97 
Space group C2 I4(1)22 I4(1)22 
a (Å) 125.6 90.0 90.0 
b (Å) 92.3 90.0 90.0 
c (Å) 103.0 183.1 183.9 
α (°) 90.0 90.0 90.0 
β (°) 106.4 90.0 90.0 
γ (°) 90.0 90.0 90.0 
Unique reflections 71784 (6260) 9708 (1063) 27204 (2964) 
Rsym (%) 9.9 (70.5) 12.8 (82.3) 6.0 (74.3) 
Completeness (%) 87.3 (65.5) 99.8 (100) 99.8 (100) 
Redundancy 3.7 (2.1) 8.5 (8.6) 10.2 (10.0) 
I/σ 15.7 (1.3) 22.3 (3.7) 42.5 (4.3) 
    
Refinement statistics       
Resolution range (Å) 99.0-1.98 80.9-2.8 80.9-1.97 
Number of reflections 68950 9182 25756 
Number of atoms / subunit    
Protein 7806 1994 1994 
Cofactor (NAD) 176 52 52 
Ligand 88 23 22 
Rcryst (%) 24.4 23.9 25.4 
Rfree (%) 28.5 25.8 28.0 
Average B-factors (Å2) 32.2 52.3 32.4 
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Structure Determination and Model Refinement 
Initial phases of InhA in complex with JPC5394, JPC5274 and JPC5734 were 
obtained by molecular replacement using the apo-InhA structure (1ENY) and refined 
with CCP4 (Table 7). Fo – Fc and 2Fo – Fc electron density maps were calculated and 
additional density resembling the inhibitor was found. The ligand was fit into the 
additional density and the whole model was rebuilt using XtalView (89). During the 
final cycles of the refinement, water molecules were added into peaks above 3-s of the 
Fo − Fc electron density maps that were within hydrogen-bonding distances from 
appropriate protein atoms. 
 
RESULTS AND DISCUSSION 
Structure Activity Relationship (SAR) Study of Triclosan Analogs 
5-chloro-2 (2,4-dichlorophenoxy) phenol, known as triclosan, has been reported 
to potentially inhibit the enoyl acyl reductases (ENR) from several species, such as 
Plasmodium falciparum, Staphylococcus aureus, Escherichia coli, Bacillus subtilis, 
Brassica napus and Pseudomonas aeruginosa. As an antimicrobial agent incorporated 
into many household items, triclosan has been utilized in the United States for over 40 
years.  
The structures of ENR from Escherichia coli (FabI), Plasmodium falciparum 
(PfENR), and Mycobacterium tuberculosis (InhA) bound with triclosan have been 
defined. Although triclosan is a potent inhibitor to all these ENRs, its binding affinities 
to the aforementioned target enzymes are dramatically different (ranging from picomolar 
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to micromolar). Sequence alignment indicated low conservation in substrate binding 
region that is related to the triclosan binding site. Therefore using triclosan as a scaffold, 
it is possible to design triclosan derivatives specific to InhA, the ENR of Mtb to optimize 
potency. A library (JPC) of triclosan derivatives was built to search for inhibitors with 
higher potency to InhA. Those triclosan derivatives were synthesized with a variety of 
substituents at the 1, 5, 6, 2’ and 4’ positions, as well as the linker. InhA in vitro activity 
assay was conducted in the presence of 10 µM inhibitor as an initial screen, and those 
hits with 50% inhibition were further subjected to IC50 determination, that will be used 
to compare the inhibition potency quantitatively.  
 
Triclosan Derivatives with Modification at the Linker 
The ether oxygen which links ring A and ring B plays an important role in the 
triclosan binding. It was found that replacement of the linker oxygen with carbon, sulfur 
or nitrogen led to more than 20 fold decrease in binding affinity. It is possible that the 
linker atom could have some interaction with the adjacent hydroxyl group. Replacing the 
linker oxygen may perturb this interaction and consequently weaken the hydrogen bonds 
of the hydroxyl group.  
Triclosan analogs with several different linkers were synthesized and their 
inhibitory potency was assayed. Some of them were listed in Table 8. A major effort put 
on trials was to use a urea group as a new linker. Similar to the other linkers tested, the 
triclosan derivatives with urea linker did not show any inhibitory potency comparable to 
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triclosan. The urea group may be too flexible to maintain the same geometry of the ring 
A and ring B of triclosan.      
 
 
Table 8   Inhibition of InhA by Triclosan Analogs at 10 µM Concentration 
 
Compound Structure Inhibition 
JPC2118 
 
0.85 
JPC2119 
 
0.93 
JPC2145 
 
0.98 
JPC2295 
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Table 8. Continued 
 
Compound Structure Vi/V0 
JPC2328 
 
1.08 
JPC2357 
 
0.91 
 
JPC2374 
 
 0.87 
JPC2449 
 
0.89 
JPC2576 
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Triclosan Derivatives with Modification at 2’-Position 
The ring B of triclosan, oriented orthogonal to the ring A, was projected along 
the substrate binding site toward the major portal. The chlorine atom at 2’-position was 
located on top of the cofactor NAD+ and within 3.5 Å to its phosphate moiety. The extra 
space between the chlorine and the cofactor made us hypothesize that a hydrophilic 
substituent potentially could increase binding affinity through some new hydrogen 
bonding interactions with NAD+ or residues nearby.  
Triclosan derivatives with 2’ substituent were synthesized and their activities 
were assayed (Table 9). It is quite clear that a polar group such as chlorine increased the 
inhibitory potency. For example, abolishing the chlorine atom of triclosan resulted in a 
dramatic decrease in potency of JPC2274 (23 fold less than triclosan). An amine group 
at the same position somewhat restored the potency of JPC2205 (only 4.0 fold less than 
triclosan). However, a carbon linker between the amine group and the ring B led to more 
than three fold decrease in activities, which suggested that the size of the substituent is 
an important factor for the potency. This is confirmed by the assay results of a series of 
triclosan derivatives with long or bulky substituents at 2’-position (Table 10 and 11). 
The complex structure of InhA:triclosan suggested that there is not enough space 
between the substituent on ring B and cofactor NAD+ to accommodate a bulky group.  
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Table 9   Inhibition of InhA by Triclosan Analogs with Substituents on B Ring 
 
 
 
O
OH
Cl
R1
R2
 
 
 
 
Compound R1 R2 IC50 (µM) % 
Triclosan Cl Cl 1.1   
JPC-2274-A-1 H H 23 0.61 
JPC-2205-A-1 NH2 H 4.2 0.25 
JPC-2210-A-1 CH2NH2 H >10 0.94 
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Table 10  Inhibition of InhA by Triclosan Analogs with NH Group at 2’-Position  
 
 
 
O
OH
Cl
NH
R
 
 
 
Compound R IC50 (µM) Vi/V0 
JPC-2210-A-1 H >10 0.94 
JPC-2239-A-1 CH2Ph >10 0.57 
JPC-2240-A-1 (CH2)3Ph >10 0.55 
JPC-2241-A-1 (CH2)2Ph >10 0.64 
JPC-2242-A-1 1-naphthyl >10 0.69 
JPC-2243-A-1 2-naphthyl >10 0.91 
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Table 11  Inhibition of InhA by Triclosan Analogs with Cyclic NH at 2’-Position  
 
 
 
 
O
OH
Cl
R
Cl
 
Compound R IC50 (µM) 
JPC-2468-A-1 
 
>10 
JPC-2469-A-1 
 
>10 
JPC-2442-A-1 
 
>10 
JPC-2444-A-1 
 
>10 
JPC-2470-A-1 
 
>10 
N
N
N
N
Ph
N
N
Ph
N
N
Ph
Ph
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Triclosan Derivatives with Modification at 4’-Position 
The chlorine atom at 4’-position of triclosan was projected toward the major 
portal of the substrate-binding site. It is surrounded by the backbones of residues Met98, 
Ala198, and Ile202. Since the chlorine atom is pointing toward the major portal of the 
substrate-binding site, there is large space open to the substituent at 4’-position. Two 
strategies were applied on the design of new inhibitors to optimize the potency. First 
approach is to replace the chlorine atom with some other polar groups that potentially 
could form strong hydrogen bonding interactions with those residues surrounded. 
Second approach is to utilize large substituents to fit into the cavity to create 
hydrophobic interactions.  
As showed in Tables 12, 13, 14, most of the triclosan derivatives with polar 
substituents have high inhibitory potency (IC50 < 2 µM), except JPC2197 (IC50 > 10 
µM). It is probably due to its hydrophobic carbon chain at the end of the substituent. All 
compounds with hydrophilic terminals at 4’-position have good activities. When the 
substituents become too large, the inhibitory potency starts to decrease, most likely due 
to steric hindrance. 
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Table 12  Inhibition of InhA by Triclosan Analogs with Substituents at 4’-Position  
 
 
O
OH
Cl
Cl
R
 
 
 
Compound R IC50 (nM) Vi/V0 
Triclosan Cl 1100  
JPC-2136-A-1 NH2 662 0.12 
JPC-2137-A-1 NO2 805 0.12 
JPC-2149-A-1 CN 599 0.08 
JPC-2150-A-1 tetrazol 2390 0.30 
JPC-2153-A-1 COOH 2503 0.26 
JPC-2181-A-1 OH 972 0.16 
JPC-2197-A-1 CH(OH)CH2CH3 >10000 0.67 
JPC-2211-A-1 C(O)NHOH 7833 0.40 
JPC-2212-A-1 C(O)NH2 851 0.15 
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Table 13  Inhibition of InhA by Triclosan Analogs with (CO)R Group at 4’-Position  
O
OH
Cl
Cl
O
R
 
 
 
Compound R IC50 (nM) Vi/V0 
JPC-2212-A-1 NH2 851 0.15 
JPC-2211-A-1 NHOH 7830 0.40 
JPC-2166-A-1 N(H)Me 6510 0.47 
JPC-2167-A-1 NMe2 7250 0.43 
JPC-2171-A-1 N-pyrrolidine >10000 0.55 
JPC-2168-A-1 N-piperidine 5710 0.31 
JPC-2169-A-1 N-morpholine 5300 0.39 
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Table 14  Inhibition of InhA by Triclosan Analogs with (NH)R Group at 4’-Position  
  
 
 
O
OH
Cl
Cl
N
H
R
 
Compound R IC50 (nM) Vi/V0 
JPC-2136-A-1 H 662 0.12 
JPC-2159-A-1 C(O)NH2 577 0.15 
JPC-2160-A-1 SO2Ph >10000 0.79 
JPC-2162-A-1 C(O)Ph 412 0.02 
JPC-2182-A-1 C(O)CH3 6460 0.44 
JPC-2190-A-1 SO2(1-naphthyl) >10000 0.53 
JPC-2191-A-1 SO2(2-naphthyl) 5900 0.31 
JPC-2192-A-1 CH2(2-CNPh) 2730 0.29 
JPC-2193-A-1 C(NH)NHCN 3130 0.27 
JPC-2194-A-1 2-pyridyl 1940 0.21 
JPC-2200-A-1 SO2CF3 >10000 0.50 
JPC-2263-A-B1 (C(NH)NH)2CH(CH3)2 >10000 0.75 
JPC-2556-A-1 CH2Ph 2260 0.19 
JPC-2202-A-1 
 
3190 0.19 
N
N
N
H
N
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Triclosan Derivatives with Modification at 1-Position 
The hydroxyl group at 1-position is critical to the binding affinity and 
antibacterial activity.  The replacement of this hydroxyl group by methoxy or sulfur 
derivatives resulted in a more than 10000-fold reduced affinity for E. coli ENR. The 
hydroxyl group forms hydrogen bonds to the side chain of Tyr158 of InhA and the co-
factor NAD+ at distance of 2.2 Å and 2.8 Å, respectively. These hydrogen-bonding 
interactions are conserved in all complex structures of ENRs bound to triclosan. Despite 
the significant role of the hydroxyl group at 1-position of triclosan in the binding to the 
enzyme, it is rapidly glucuronidated or sulfonated in vivo, which causes the 
ineffectiveness of triclosan. Therefore, it is necessary to remove the hydroxyl group at 
the 1-position or replace it with other functional group that cannot be modified in vivo. 
Meanwhile, the new inhibitors should have comparable inhibitory potency as triclosan. 
36 triclosan derivatives with 1-position substituents were synthesized and subsequently 
assayed for inhibitory potency at 10 µM concentration. The substitution of the hydroxyl 
group at 1-position with all 36 functional groups resulted in a significant loss of 
inhibitory potency (IC50 > 10 µM). Six of these triclosan derivatives were listed in Table 
15. Apparently, all the efforts to search for a substitute of hydroxyl group did not 
successfully maintain the inhibitory potency. Modeling studies indicated that it is 
difficult for the enzyme to accommodate those new substituents larger than hydroxyl 
group without major conformational changes. Slight changes in geometry could perturb 
the hydrogen bonding interaction. That is why some substituents very similar to the 
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hydroxyl group, such as an amine group that is also a hydrogen bond acceptor, still do 
not have a significant inhibitory potency. 
 
Table 15  Inhibition of InhA by Triclosan Analogs with Substituents at 1-Position 
 
 
O
R
Cl
Cl
Cl
 
 
 
Compound R IC50 (µM) 
Triclosan OH 1.1 
JPC-1095-A-1 CONH2 >10 
JPC-2025-A-1 OCH2CN >10 
JPC-2063-A-1 NH2 >10 
JPC-2064-A-1 NO2 >10 
JPC-2548-A-1 CF3 >10 
JPC-2642-A-1 OMe >10 
 
 
 
Triclosan Derivatives with Modification at 6-Position 
There are two rationales behind designing the triclosan derivatives with 
substituents at 6-position. First of all, this design is a new trial to overcome the in vivo 
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modification of the hydroxyl group at 1-position of triclosan indirectly. As mentioned 
before, the trial to replace the hydroxyl group at 1-position with other substituents lead 
to dramatic loss of inhibitory potency. We hypothesized that placing a bulky substituent 
at the 6-position could potentially protect the hydroxyl group at 1-position from enzyme-
catalyzed in vivo modification through steric hindrance. Secondly, superimposition of 
the structures of InhA in complex with triclosan and the substrate showed that the 
substrate-binding site is on top of the ring A of triclosan. Therefore, we proposed to 
utilize a substituent at 6-position of triclosan to project into the substrate-binding site and 
acquire some additional binding affinity. Thus far, three analogs were synthesized. None 
of them showed high inhibitory activity against InhA (Table 16). Based on the structure 
of InhA:triclosan, there is not too much space to contain a large substituent at 6-position 
of the A-ring. It is possible that the aldehyde group used in the inhibitors might caused 
unfavorable clash with side chains of Phe149 and Tyr158, which are only 3.6 Å and 4 Å 
away, respectively.   
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Table 16  Inhibition of InhA by Triclosan Analogs with Substituents at 6-Position  
 
 
Compound Structure Vi/V0 
JPC-2605-A-1 
 
0.73 
JPC-2615-A-2 
 
0.94 
JPC-2616-A-1 
 
0.82 
O
OH
Cl
Cl
Cl
Cl
H
O
OH
H
O
Cl
O
Cl
Cl
O
H
O
O
Cl
Cl
Cl
 
 
 
Triclosan Derivatives with Modification at 5-Position 
In the structure of InhA:INH-NAD, the isonicotinyl moiety of INH-NAD adduct 
is found in a hydrophobic pocket that was formed by the rearrangement of the side chain 
of Phe149. The isonicotinic-acyl group forces the side chain of Phe149 to rotate ~90° 
forming an aromatic ring-stacking interaction with the pyridine ring. The pocket is lined 
predominantly by hydrophobic groups from the side-chains of Tyr158, Phe149, Met199, 
Trp222, Leu218, Met155, Met161, and Pro193, and is adjacent and partly overlapped 
with the fatty acyl substrate-binding site. Among them, Tyr158, Pro193 and Gly192 are 
conserved in other ENR homologues. This pocket also servers as a small portal to the 
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solvent at one side of the active site. The superimposition of the structures of InhA:INH-
NAD and InhA:triclosan indicated that the chlorine atom at the 5-position of triclosan A 
ring is inside the binding pocket of isonicotinoyl moiety of INH-NAD adduct and is in 
van der Waals contact with Pro193, Met199, and  Phe149. While triclosan is extremely 
potent against ecFabI (Ki = 7 pM), it has much lower activity against Mtb InhA (Ki = 
200nM). Based on the structural information, we hypothesized that it is possible to 
utilize this hydrophobic pocket with various hydrophobic substituents at the 5-position 
of triclosan to increase the in vitro activity against Mtb InhA.  
A series of triclosan derivatives with modifications at the 5-position of triclosan 
were evaluated for their inhibition of purified InhA. Inhibitors with hydrophobic 
substituents, such as alkyl (compounds 2 and 7), are much more potent than those with 
hydrophilic substituents (compounds 3, 4 and 5) (Table 17). This result is consistent with 
our proposal that the 5-substituent of triclosan projects into the hydrophobic cavity of the 
enzyme.  
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The hydrophobic substituents at the 5-position can be divided into alkyl and aryl 
subgroups. For the alkyl-substituted inhibitors, potency versus InhA appears to increase 
with the chain length (Table 18). Highest inhibitory potency was observed for 
compounds 10 and 12 with C4 carbon chains. Sullivan et al. observed the same trend 
with 5-alkyl substituted triclosan derivatives where the two chlorines of the B-ring were 
excised.  It was found that the in vitro activity of those inhibitors was optimal at a carbon 
chain length of eight. For those inhibitors with 5-substituents of the same carbon chain 
length, the inhibitors studied in the present report showed better in vitro activity than 
their counterparts in Sullivan’s work (IC50 = 120 versus 2000 nM for derivatives with an 
ethyl substituent and IC50 = 55 nM versus 80 nM for derivatives with a butyl 
substituent), suggesting that the two chlorine atoms on the B-ring contributed to the 
binding of the inhibitor to the enzyme. This contradicts Sullivan’s assertion that the B-
ring chlorines are not essential for enzyme inhibition. Indeed, as indicated in the crystal 
structure of InhA:NAD+:triclosan, the 4' chlorine atom engages the backbone amide 
nitrogen N-H of Met98 at a distance of 3.2 Å.  
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Table 17  Inhibition of InhA by Triclosan Analogs with Substituents at 5-Position  
 
 
 
O
OH
R
Cl
Cl
 
 
 
 
 
Compound R IC50 (nM) 
Triclosan Cl 1100 
2 Me 799 
3 tetrazol >10000 
4 COOH >10000 
5 C(O)NH2 >10000 
6 Ph >10000 
7 CH2(C6H11) 108 
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Table 18  Inhibition of InhA by Triclosan Analogs with Alkyl Groups at 5-Position  
 
 
O
OH
R
Cl
Cl
 
 
 
 
Compound R IC50 (nM) 
Triclosan Cl 1100 
2 CH3 799 
8 CH2CH3 125 
9 (CH2)2CH3 91 
10 (CH2)3CH3 55 
11 CH2CH(CH3)2 96 
12 (CH2)2CH(CH3)2 63 
13 CH2CH(CH3)CH2CH3 129 
7 CH2(C6H11) 108 
 
 
The alkyl substituents in previous studies were all unbranched. In the present 
report, branched alkyl substituents (compounds 11, 12 and 13) are slightly less potent 
than their straight-chain counterparts (compounds 9 and 10) of the same chain length. 
However, the active site seems to be tolerant of the bulky cyclohexyl moiety in 7, which 
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demonstrated reasonable inhibitory activity against InhA in vitro. The crystal structure 
of InhA bound with Sullivan’s unbranched 5-pentyl triclosan derivative showed the 
pentyl chain occupies nearly the same binding site as the acyl chain of the substrate. The 
2.8 Å crystal structure of InhA in complex with compound 7 was solved to provide a 
structural basis for the activity difference amongst the alkyl substituents. The crystal 
belongs to I4122, a space group for InhA that has not been reported previously. The 
structure was readily superimposed on the structures of InhA in complex with the 5-
pentyl triclosan derivative and the C16 substrate. The 5-cyclohexylmethyl group 
occupied a position similar to that of the 5-pentyl triclosan derivative and formed 
predominantly hydrophobic interactions with the sidechains of Phe149, Leu218, 
Met155, and Met199 (Figure 23). The most obvious difference in overall structure is that 
the substrate binding loop (residues 195-205) is ordered in the structure of InhA bound 
with compound 7, while it is always disordered in the structures of InhA bound with 
substrate, triclosan, and all other triclosan derivatives solved to date. Sulllivan suggested 
that the ordering of the substrate-binding loop is related to the binding of the ligand. The 
bulky 5-cyclohexylmethyl group of 7 may have more extended hydrophobic interactions 
with the substrate-binding pocket, helping to order this flexible loop. Indeed, the 
sidechain of Met199 on the substrate-binding loop flips approximately 100° to form a 
hydrophobic interaction with the cyclohexyl group at a distance of 3.6 Å. Compared to 
the inhibitor 5-pentyl-2-phenoxyphenol, the B-ring of compound 7 also rotates about 30° 
to allow the 4'-chloride to form a weak hydrogen bonding interaction with the amide N-
H of Met98 at distance of 3.2 Å. It is not so obvious from a structural point of view why 
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the branched inhibitors are less potent than the unbranched inhibitors of the same chain 
length. A possible explanation could be steric clashes of the sidechains of Phe149 and 
Met199 with the branched alkyl groups. 
 
 
 
       
Figure 23   Surface Diagram of Structure of InhA in Complex with 7.  
The structure of InhA in complex with compound 7 is superimposed with structures of 
InhA bound to two other triclosan analogs with linear alkyl substituents 
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Given the fact that the inhibitors with bulky alkyl substituent showed enhanced 
in vitro activity against InhA than triclosan, we were interested to determine if aryl and 
heteroaryl groups would also be accommodated in the pocket. A linker varying from 0 to 
3 carbons was designed between aryl/heteroaryl groups and the 5-position carbon on the 
A-ring to control the flexibility and placement of the aryl/heteroaryl moiety (Table 19). 
A relationship between the length of the linker and the inhibitory potency is observed. 
Inhibitors with a phenyl or pyridyl group directly attached at the 5-position of the A-ring 
have very low potency against InhA. In addition, the potency of those inhibitors 
correlated to the position and type of substituents on the phenyl ring. Although the 
crystal structures for InhA bound with 5-phenyl or 5-pyridyl triclosan derivatives have 
not been obtainable to date, most likely due to their respective low binding affinities, the 
inhibitors were readily modeled into the active site based on the structure of 
InhA:triclosan. It is clear that the hydrophobic binding pocket is not directly adjacent to 
the A-ring of triclosan. Instead, the A-ring and the hydrophobic pocket are separated by 
a distance of 2.5 Å. A directly connected bulky group appears to be too close to the 
sidechains of Phe149 (shortest distance is about 1.7 Å between the aryl substituent and 
the phenyl group of Phe149), leading to steric clashes. Within the 5-phenyl series of 
triclosan derivatives, the ortho- substituent on the phenyl ring may “clash” with the 
sidechain of Leu218, while the para-substituent may “bump” into Tyr158. In contrast, 
the meta- methyl on the phenyl ring may be in favorable van der Waals contact with the 
sidechains of Met155 and Tyr158. Indeed, m-tolyl 22 is more potent than the 
corresponding o- and p- derivatives 20, 21, and 23 by 1.5, 12, and 12 fold respectively.  
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Table 19  Inhibition of InhA by Triclosan Analogs with Aryl Groups at 5-Position  
O
OH
R
Cl
Cl
 
Compound R1 R2 IC50 (nM) 
Triclosan Cl Cl 1100 
14 2-pyridyl CN >10000 
15 3-pyridyl Cl >10000 
16 4-pyridyl CN >10000 
17 CH2(2-pyridyl) Cl 29 
18 CH2(3-pyridyl) Cl 42 
19 CH2(4-pyridyl) CN 75 
6 Ph Cl >10000 
20 o-CH3-Ph Cl 1334 
21 o-CH3-Ph CN >10000 
22 m-CH3-Ph Cl 871 
23 p-F-Ph Cl >10000 
24 CH2Ph Cl 51 
25 (CH2)2Ph Cl 21 
26 (CH2)3Ph Cl 50 
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Therefore, instead of a directly connected aryl/heteroaryl group, molecular modeling 
suggests a short carbon linker to better position the hydrophobic aryl group into the 
target pocket. 
Consistent with molecular modeling, an evaluation of 5-position substituents of 
the type (CH2)nAr demonstrates that carbon linkers (C1 to C3) dramatically increased 
the inhibitory potency versus purified enzyme. Among them, compound 25 has the 
highest potency of IC50 = 21 nM, representing a 500-fold increase compared to 6, a 
phenyl derivative. It is the most potent triclosan derivative against purified InhA we 
have studied to date. Compounds 24 and 26, with similar activities against InhA (IC50 
equal to 51 nM and 50 nM, respectively), are also potent inhibitors. The crystal 
structures of InhA bound with 24 and 25 showed that the (CH2)nPh group extended into 
the pocket and formed predominantly hydrophobic interactions with residues Leu218, 
Ile215, Phe149, Met199, and Pro193 (Figure 24). The triclosan backbone atoms of 24 
and 25 are in nearly same positions, although their 5-substituents are clearly different. 
The phenyl group of 24 is positioned in the center of the binding pocket, while the 
phenyl group of 25 protrudes about 2 Å deeper into, and is closer to the end of, the 
binding pocket due to the longer carbon linker. The sidechains of Leu218 and Ile215 
rotate 30° and shift 1.5 Å to accommodate the phenyl ring of 25, which also flips ca. 70° 
from the position of the phenyl group of 24. All of these conformational changes suggest 
that there are more hydrophobic interactions between the active site residues and the 5-
substituent of 25 than that of 24, which may explain why 25 is twice as potent than 24 
against InhA.  
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Figure 24   The Superimposition of Structures of InhA Bound with 24 and 25 
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To further increase the potency of the 5- (CH2)nPh series, derivatives with 5- 
CH2(n-pyridyl) (n=2, 3, 4) substituents (compounds 17 - 19) were synthesized and 
examined for in vitro activity. The compounds were designed in light of our knowledge 
of the structure of InhA:INH-NAD.  In this crystal structure, the pyridyl group of the 
INH-NAD adduct formed a hydrogen bonding interaction with a buried water molecule. 
In addition, some residues with charged sidechains, such as Glu219 and Arg195, are 
observed proximal to the binding site of the triclosan derivatives. Pyridyl analogs 17 - 19 
are all potent inhibitors (IC50 < 80 nM), and their IC50 values are in the order 17 < 18 < 
19. Compared to the benzyl derivative 24, the activity of 17 increases twofold while the 
activity of 18 increases only slightly, and 19 is less potent. Superimposition of the 
structures of InhA:NAD+:17 and InhA: NAD+:24 demonstrates that the pyridyl ring of 
24 extends into the substrate-binding site and forms hydrophobic interactions with the 
sidechains of Tyr158 and Phe149 at a distance of 3.6 Å (Figure 25).  These interactions 
are similar to those of the phenyl group in InhA:NAD+:24. However, the nitrogen atom 
on the 2-position of the pyridyl ring also forms a hydrogen-bonding interaction with the 
sidechain carboxylate oxygen of Glu219 through a water molecule. Modeling studies 
indicate that similar interactions could also exist for 18, but are not likely for 19 based 
on the distance between the pyridyl nitrogen atom and the sidechain oxygen of Glu219. 
The nitrogen atom of 19 potentially points to the hydrophobic sidechains of residues 
Met155 and Leu218, which may not be favored energetically.  
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Figure 25   Structure of InhA in Complex with Compound 17 
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High Throughput Screen Identified a Series of New Inhibitors 
The compounds SB363360, SB643152 and SB346352 were found potent against 
Staphylococcus aureus and Haemophilus influenzae enoyl acyl reductases by high 
throughput screening. Interestingly, those aminopyridine derivatives showed even higher 
inhibitory potency against InhA in vitro. Therefore those compounds were utilized as 
new leads for the design of new inhibitors of InhA. Since it was previously reported that 
the indole moiety was necessary for inhibitory potency, this moiety was retained and 
further modifications were done on the rest of the moiety. A series of compounds with 
similar structures were synthesized and assayed to look for improved potency. Among 
them, SB643152, SB363360 and SB389656 showed high potency (IC50 < 100 nM). The 
crystal structures of InhA in complex with SB643152, SB363360, SB533394 and 
SB389656 were determined to establish the structure-activity relationship. The structural 
basis for the high potency was revealed by the complex structures. The carbonyl oxygen 
of the carbamide group forms hydrogen bonds with Tyr158 of InhA as well as the ribose 
2’-hydroxyl of NAD+. This carbonyl oxygen occupies the same position as the hydroxyl 
group of triclosan and the carbonyl group of fatty acyl substrate. The indol group of the 
inhibitor protrudes into a hydrophobic pocket that accommodates the fatty acyl chain as 
showed in the structure of InhA in complex with the C16 substrate. The superimposition 
of the structures of InhA in complex with the inhibitor and the C16 substrate indicated 
that the rigid indol group of the inhibitor overlaps with the turning point of the flexible 
fatty acyl chain. To accommodate the indol group, the side chain of Tyr158 is forced to 
flip about 90° and in a position where its hydroxyl group can form hydrogen-bonding 
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interaction with the carbonyl group of the inhibitor. The interactions in this region are 
conserved in all four inhibitors, which is believed to be the molecular basis of the high 
potency. Some additional interactions could be found in the rest of the moiety of the 
inhibitor. For example, the backbone oxygen of Met98 forms hydrogen bonds with 
hydroxyl group of the inhibitor SB363360 at distance 2.8 Å. Similarly, the amine groups 
of the SB533394 and SB643152 are also within hydrogen bonding distances to the 
backbone oxygen of Met98. The amine group of SB389656 forms hydrogen bond with 
the oxygen of the phosphate group of NAD+. In addition, the pyridine group of 
SB643152 and the bulky alkyl group of SB363360 are found to stick out of the major 
portal of the substrate-binding site. Since these groups are in the binding interface of 
InhA and acyl carrier protein, they could potentially interact with the acyl carrier protein 
and affect the substrate binding to InhA.  
 
Computer Program Based Virtual Screen of ZINC Chemical Database 
Computer program based virtual screen was conducted using the docking 
program FlexX to search for new leads of InhA from the ZINC 3.3 million compound 
database. The free ZINC database contains commercial available chemicals annotated 
with molecular weight, calculated LogP, and some other physical properties. The crystal 
structure of InhA in complex with SB643152 was used to generate the docking site. The 
docking site was defined as the area that is within 7 Å distance to at least one of the 
atoms of inhibitor SB643152. The inhibitor SB643152 and all water molecules were 
removed from the coordinate file, while the cofactor NAD+ remained intact. Charges 
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were assigned to both protein and ligand atoms as described by Gasteiger and Marsili. 
FlexX programs runs on the GRID system using the default parameters provided in 
SYBYL 7.0. The results were retrieved and analyzed using score functions in five 
separate categories, FlexX, DRUG, PFM, GOLD and CHEM scores. 35 top hits were 
selected out as the intersection of the top 2% of each of the five categories. 11 
compounds of the 35 hits were commercial available and were subsequently evaluated 
by enzyme assay. Only three of them showed decent inhibitory activity (IC50 < 10 µM) 
in vitro (Table 20). The low hit rate of the docking program is possibly caused by the 
following reasons: 1) the inaccuracy of the energy calculation, especially for the 
hydrogen bonding interactions. Hydrogen bonding interactions are usually more 
sensitive to the distance and geometry. 2) The docking site is viewed as a rigid body in 
the energy minimization. 3) The charge assignment of the ligand may not be correct, due 
the unknown chemical environment inside the docking site. 
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Table 20  The Evaluation of the “Hits” Obtained from Virtual Screen 
 
ZINC ID IC50 (µM) 
876044 >10 
987104 7.8 
1059860 >10 
1154675 >10 
1212620 5.5 
1954491 >10 
1954493 >10 
2293938 >10 
2863142 >10 
3620257 9.1 
3672291 >10 
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CHAPTER V 
 STRUCTURE AND ACTIVITY STUDIES OF THE MTB β-
LACTAMASE  
 
BACKGROUND 
For over 40 years, drugs that target cell wall biogenesis and chromosomal 
replication have been utilized as frontline agents in drug mixtures to treat 
Mycobacterium tuberculosis (102). The emergence of multidrug-resistant strains that 
resistant to these widely available and affordable anti-tubercular drugs becomes a 
growing clinical problem. New anti-tubercular drugs are needed to treat infections 
caused by these strains. 
 
Transpeptidase, an Essential Enzyme in Cell Wall Biosynthesis 
DD-transpeptidases, also know as penicillin-binding proteins (PBPs) catalyze the 
cross linking of two peptidoglycan strands, which is an essential step in bacterial cell 
wall biosynthesis. The reaction is initiated by the cleavage of the D-alanyl-D-alanine 
bond of one strand of the peptidoglycan, followed by the linkage of the second strand of 
the peptidoglycan (Figure 26). DD-transpeptidases (PBPs) belong to the group I of the -  
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Figure 26   Cross-Linking of Peptidoglycan Strands by Cell Wall Transpeptidases 
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SxxK acyltransferase family. The PBPs are usually classified based on the molecular 
weight. The low molecular weight PBPs are single catalytic entities possessing DD-
peptidase, esterase and thiol esterase activities. The high molecular mass (HMM) PBPs 
are multi-domain enzymes with a non-penicillin-binding domain at the N-termini and a 
penicillin-binding domain at the C-termini. 
 
Mode of Action of β Lactam Antibiotics   
Penicillin was the first β-lactam antibiotic discovered and it was used extensively 
to treat bacterial infections from 1940’s to 1960’s (135). Over the past three decades, 
many other potent β-lactam antibiotics, such as cephems, monobactams and 
carbapenems have been developed and are currently being utilized to treat a wide range 
of bacterial infections. In fact, the high efficacy, specificity, and low rate of adverse 
reactions make β-lactam antibiotics the most prescribed antimicrobial agents worldwide 
(136). All β-lactam antibiotics show structural similarity to the natural substrates of the 
bacterial DD-transpeptidases. Inhibition of DD-transpeptidases by β-lactam antibiotics 
leads to disruption of the synthesis of the bacteria’s cell wall (Figure 27) (137,138). 
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Figure 27   Mechanism of Action of β-lactam Antibiotics 
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Function of β Lactamase and β Lactam Resistance  
A significant increase in the number of β-lactam resistant strains of pathogenic 
bacterial has been reported over the past few years (139). Resistance to the β -lactams 
primarily occurs through the horizontal transfer of β-lactamase genes contained on 
plasmids (140). β-lactamases inactivate β-lactam antibiotics by efficiently hydrolyzing 
the amide group of the β-lactam ring, which is the prevalent mechanism of bacterial 
resistance to β-lactam antibiotics (141). β-lactamases are grouped into four classes, A, B, 
C, and D based on their amino acid sequence homology and general enzyme catalytic 
properties (Figure 29) (for a review of β-lactamases see (142)). Historically, class A β-
lactamases were found to have much greater penicillinase activity than cephalosporinase 
activity. However, several new class A β-lactamases that are active against new 
generations of cephalosporins and carbapenems have been discovered. They are 
typically grouped as Extended Spectrum β-lactamase (ESBL) to differentiate from the 
non- Extended Spectrum β-lactamase (non-ESBL).  
 
Mtb β Lactamase – a Potential Anti-TB Drug Target  
Although it was found in the early studies that penicillin inhibited the growth of 
Mycobacterium tuberculosis under certain conditions, there have been few studies on the 
antitubercular effect of β-lactam antibiotics, probably due to the early discovery that Mtb 
possesses intrinsic resistance to these antibiotics (143). The production of β-lactamase 
has been proposed to be the most significant reason for mycobacterial resistance 
(144,145). Other factors that were believed to contribute to the ineffectiveness of β-
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lactam in Mtb, include cell envelope permeability and low PBP binding affinity for β-
lactams (146,147). Although Mtb’s outer cell wall, formed by waxy mycolic acid layer, 
was thought to make a virtually impenetrable barrier, recently, β-lactams have been 
shown to readily permeate the Mtb cell wall and bind the penicillin-binding proteins 
(144).  
One approach that holds promise to counter Mtb’s inherent resistance is to utilize 
β-lactamase inhibitors in combination with β-lactam antibiotics to increase their efficacy 
(144). For example, class A β-lactamases are generally sensitive to serine β-lactamase 
inhibitors such as clavulanate and sulbactam (148,149). These mechanism-based 
inhibitors covalently cross link two serines in the active site that are essential to the 
hydrolysis of β-lactams and permanently inactivate β-lactamase. The combinations of β-
lactam antibiotics and β-lactamase inhibitors have been used clinically to treat a wide 
range of bacterial infections (139). While they are not being used clinically, these 
combinations have also been shown to be somewhat effective against most strains of 
mycobacteria, including MDR strains in vitro (150-152). In fact, minimum inhibition 
concentrations (MICs) of β-lactams are less than 0.5 µg/ml to MDR strains of Mtb, when 
used in combination with both β-lactamase inhibitors and anti-tubercular drug 
ethambutol (153). These results offer the possibility for treatment of TB with highly 
potent inhibitors in combination with β-lactam antibiotics.  
blaC (Rv2068c) is the only gene in the Mtb genome that shows any detectable 
homology to any of the known β-lactamases. Recently, the Pavelka lab showed that the 
deletion of the blaC gene resulted in an increase susceptibility of Mtb to β-lactam 
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antibiotics by 8-256 fold (154,155), which confirmed the primary role of blaC in Mtb 
resistance. In previous studies, partially purified Mtb BlaC was classified as class A β-
lactamase type2b based on its relatively high level of penicillinases activity (Figure 28) 
(156,157). 
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Figure 28   Classification of β- lactamase  
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METHODS 
Cloning, Expression and Purification 
E. coli expression plasmids of the wild type and a truncated form (41-307) of 
Mtb blaC were cloned from genomic DNA (C.S.U. N01-AI-75320).  The amplified 
product was inserted into pET28b (EMD Biosciences #69865-3) using the NdeI and 
Hind-III restriction sites.  This plasmid was subsequently transformed into E. coli BL21 
(DE3) (EMD Bioscience #69387-3) and cultured in LB-Miller media containing 50 
µg/ml kanamycin at 37 °C until OD600 reached 0.8. Expression of blaC gene was 
induced for 20 hours at 16 °C by addition of 1 mM isopropyl β-D-thiogalactopyranoside 
(IPTG).  Cells were harvested by centrifugation and re-suspended in 25 mM Tris-HCl 
(pH 8.0), 500 mM NaCl, 2 mM β-mercaptoethanol and were lysed by French Press. 
After treatment with 1mM DNaseI, the insoluble material was removed by 
centrifugation. By SDS PAGE, full-length BlaC goes into the insoluble pellet, while ~ 
90% of truncated BlaC (41-307) remained soluble. Therefore, further purification was 
performed only on truncated BlaC (41-307). The supernatant containing soluble protein 
was applied to a Ni2+-loaded HiTrap chelating column (AP Biotech) using a fast protein 
liquid chromatography system and eluted through an imidazole gradient  (0-0.5M). BlaC 
(41-307) was eluted at imidazole concentration of 120 mM. Fractions that contain the 
BlaC (41-307) were pooled and dialyzed against 25 mM Tris-HCl (pH 8.0), 40 mM 
NaCl, 1 mM DTT. The samples were further purified by gel-filtration on a Superdex 
200 column to separate the monomeric protein from aggregated material using dialysis 
buffer. The protein was concentrated to approximately 10 mg/ml. BlaC (41-307) was 
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obtained at 45 mg/L of E. coli culture and appeared homogeneous by SDS-PAGE and 
Coomassie Blue staining. 
  
Kinetic Assays 
Enzyme kinetic evaluation was completed for the substrates ampicillin (∆ε235 = -
820 M-1 cm-1), cephalothin (∆ε262 = -7660 M-1 cm-1), cefoxitin (∆ε270 = -8380 M-1 cm-1), 
ceftazidime (∆ε260 = -10200 M-1 cm-1) and meropenem (∆ε299 = -2500 M-1 cm-1) (158). 
All assays were repeated in triplicate and carried out on a Cary 100 Bio 
Spectrophotometer at room temperature by monitoring the UV absorbance change of β-
lactams (158). The Mtb BlaC activity assays were performed in 100 mM phosphate 
buffer (pH 7.5) by adding 10 nM enzyme into substrates solution. Km and Vmax were 
determined by analyzing Hanes Plot (159). Inhibition studies of clavulanate were 
performed by adding enzyme into solutions containing the substrate ampicillin and 
inhibitor clavulanate with increasing concentrations (0.1-600 µM). During the 
measurement time, no time-dependent loss of enzyme activity could be detected. Value 
for Ki was determined from x-intercept of a Dixon plot, assuming competitive inhibition.   
 
Crystallization of BlaC (41-307) 
Crystallization of the truncated enzyme, missing the first 40 amino acids, was 
accomplished by the hanging drop vapor diffusion method (85). Initial crystallization 
conditions were discovered by sparse matrix screen using Crystal Screens from Hampton 
Research. Hanging drops containing 2 µl of protein solution at 10 mg/ml and 2 µl of 
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buffer (0.1 M Tris-HCl pH 8.0, 2.0 M NH4H2PO4) were equilibrated at 16 °C in Linbro 
plates against 1 ml of the same buffer. Protein crystals appeared in 4 days as thin plate-
shaped clusters and were improved to larger rod-like clusters by co-crystallization with 
its substrate ampicillin. Macro seeding was then used to obtain high quality single 
crystals.  
 
Data Collection and Processing 
A nearly complete diffraction dataset to 1.7Å resolution was collected from a 
single crystal at 121 K using a cryo-protection solution consisting of reservoir solution 
(0.1 M Tris-HCl pH 8.0, 2.0 M NH4H2PO4) with the addition of 20% glycerol. The beam 
line 14BMC at the Advanced Photon Source (APS), Argonne National Laboratory was 
used to collect the dataset using one-degree oscillation widths over a range of 180°. The 
data were integrated and reduced using HKL2000 (86). The completeness of low-
resolution data is slightly lower, due to the high rejection rate caused ice rings. Crystals 
of BlaC belongs to the orthorhombic space group P212121 with cell dimensions a = 42.74 
Å, b = 71.28 Å, c = 85.17 Å, α = 90°, β = 90°, γ = 90°, with one molecule in each 
asymmetric unit.  
 
Structure Determination and Model Refinement 
Initial phases were obtained by molecular replacement with the computer 
program MolRep, part of the CCP4 package (160), using the related structure of β-
lactamase from Streptomyces albus G (PDB 1BSG) (161) as a search model. The best 
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solution gave a correlation coefficient of 34.2% and a R-factor of 50.9% using data 
between 25 and 3 Å resolution. The structure from the molecular replacement solution 
was refined with REFMAC, again in the CCP4 suite (160). The first step in the 
refinement was to use rigid body optimization, and this resulted in a slightly improved 
model (Rfactor, 49.9%; Rfree, 51.8%; 54.6-1.7 Å). Electron density maps were produced 
and manual rebuilding was carried out, using XtalView (89). The model was further 
refined with cycles of model building and REFMAC restrained refinement (160). During 
the final cycles of the refinement, water molecules were added based on peaks above 3-σ 
in the Fo−Fc electron density maps that were within hydrogen-bonding distances from 
appropriate protein atom. The resulting structure had good geometry (88% of the non-
glycine residues were in most favorable conformation and none in disallowed 
conformation) and Rfactor of 17.9% and Rfree, 21.4%. PROCHECK (160) revealed no 
disallowed φ, ψ and the overall structure G factor, a measure of a given stereochemical 
property, was consistently better than expected for this resolution.  
 
Structure Analysis 
DALI (162) was used to search the PDB for proteins having folds similar to Mtb, 
in the order of structural similarity. BlaC and SwissPDB viewer was used to make 
structural alignments (163). The model was evaluated and analyzed using computer 
graphic program SPOCK (90). 
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RESULTS AND DISCUSSION 
Sequence Analysis of BlaC 
Mtb BlaC is a 307 amino acid protein that is predicted to have a signal peptide 
for translocation into the periplasm and a lipid attachment site (residue 14-24), using the 
computer program ScanProsite (164).  This analysis suggests that the mature BlaC is 
linked via the covalently attached lipid to the outer leaflet of the inner membrane, after 
translocation to the periplasmic space. β-lactamase lipoproteins have been reported for 
several Gram-positive bacteria (165,166). However, the enzyme was also predicted, 
using SignalP program (167), to have a signal peptidase II cleavage site at residues 28, 
which would eliminate the lipid attachment site in the mature protein. It is therefore, not 
clear if BlaC exists free or as membrane bound protein in the periplasm. 
  Mtb BlaC shares approximately 40% amino acid sequence identity with other 
known class A β-lactamases. Interestingly, it has the highest sequence identity to the 
class A β-lactamase of Streptomyces clavuligerus (54%), the bacteria that produces the 
antibiotic cephamycin and the β-lactamase inhibitor clavulanate.  
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Three highly conserved regions of the active site, designated as motif I, II, and 
III, have been identified by multiple sequence alignment of class A β-lactamases from 
different bacteria. Motif I has a consensus sequence of Arg61-(Xaa)2-Glu-Xaa-Phe-
(Xaa)3-Ser-Xaa-Xaa-Lys73 that extends from the end of the β-strand B2 through a 
segment of the α-helix H2. Motif II corresponds to sequence Ser130-Asp-Asn132 and is 
located between α-helix H6 and H7. Motif III, located on β-strand B3 and has consensus 
sequence of Asp233-Lys-Thr-Gly236.  Additionally, all class A β-lactamases have a Ω 
loop that in BlaC contains residues Val159 – Thr180. While these regions are highly 
conserved, BlaC from Mtb has several notable amino acid substitutions. The substitution 
of a Gly for Asn at residue 132 only occurs in class A β-lactamase from Mtb and its 
closest homolog S. clavuligerus (Figure 29). The substitutions of R244A and R169A in 
Mtb are also rare in class A β-lactamases.  Another important difference identified from 
amino acid sequence alignment is a four-residue insertion Gly145A to Ala150 and a two-
residue insertion Gly271 to Tyr272 in Mtb BlaC sequence.  
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Figure 29   Sequence Alignment of Class A β-lactamases of Different Organisms 
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Expression, Purification and Characterization of Mtb BlaC 
Initial attempts to express the full-length protein were unsuccessful, primarily 
due to the N-terminal signal peptide. By truncating the codons for the first 40 amino 
acids in our expression construct, we could produce large quantities of active enzyme. 
The truncation and the N-terminal His-tag were not predicted to interfere with the 
enzymes catalytic function based on what was known about homologous enzymes. The 
molecular weight of the truncated protein was confirmed by MALDI (Actual mass 
30629, calculated mass 30666). 
  
Enzyme Activity of Mtb BlaC  
Kinetic measurements of the hydrolysis of the substrates ampicillin, cephalothin, 
cefoxitin, ceftazidime, meropenem as well as the inhibition of the enzyme activity with 
clavulanate were carried out in order to compare the enzyme activity to other class A β-
lactamases (Table 21). Overall, the results show that Mtb BlaC has a broad-spectrum 
substrate profile compared to other class A β-lactamases. While the penicillinase activity 
of BlaC (kcat/Km = 293 µM-1s-1) is about 10-fold lower than most class A β-lactamases, 
the enzyme showed relatively good activity against cephalothin (kcat/Km = 103 µM-1 s-1), 
in contrast to previous studies where Mtb was shown to possess only minor cephalothin 
activity (168). Indeed, we found that the cephalosporinase activity of Mtb BlaC is 
comparable to its penicillinase activity. Furthermore, BlaC shows modest activity 
(kcat/Km ~ 10 mM-1 s-1) against cefoxitin, ceftazidime and meropenem. Inhibition studies 
indicated that clavulanate, a very potent inhibitor of most of class A β-lactamases (Ki < 
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0.1 µM), is a relatively poor inhibitor to Mtb BlaC (Ki = 2.4 µM). The substrate profile 
of BlaC is quite similar to that of M. fortuitum β-lactamase, which also has relatively 
high cephalosporinase activity (169).  
 
 
 
 
Table 21  Kinetic Parameters of Mtb BlaC with Different Antibiotics as Substrates 
 
Class Antibiotics kcat (s-1) Km (µM)
kcat/Km 
(µM-1s-1) Ki (µM)
penicillin Ampicillin  18.5 63 293.65  
cephalosporin Cephalothin  12.1 117 103.42  
 Cefoxitin  1.1 195 5.64  
 Ceftazidime  0.2 593 0.37  
carbapenem Meropenem 0.9 279 3.19  
inhibitor Clavulanate       2.4 
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Overall Structure of BlaC 
The crystal structure of BlaC was solved using molecular replacement and 
refined to 1.7 Å resolution. The final Rfactor and Rfree values for all reflections were 0.18 
and 0.21, respectively (Table 22). BlaC crystals are orthorhombic, belonging to space 
group P212121, with one molecule in the asymmetric unit. The refined structure of BlaC 
includes 265 of the 267 residues in the truncated form of BlaC (41-307) and 248 ordered 
water molecules. The structure of the N-terminal six histidine tag along with the first two 
residues Gly-Ala were not defined due to disorder of this region in the electron density 
map.  Like other class A β-lactamases, the BlaC monomer contains an α domain and an 
α/β domain. The α domain consists of six long α helices (H2, H5, H6, H7, H9 and H10) 
and three short α helices (H3, H4 and H8). The α/β domain includes five anti-parallel β-
strands (B1-B5), the N- and C- termini α helices (H1 and H12) and one short α helix 
H11. The overall structure of BlaC is very similar to other class A β-lactamase 
structures. The root mean square difference (RMSD) of the Cα atoms of several class A 
β-lactamases range between 0.95 – 3.66 Å and are listed in Table 23. The Cα alignments 
of BlaC with other class A β-lactamases of known structure indicates Mtb BlaC is more 
similar to K1 (rmsd  = 0.95 Å) and NMC-A (rmsd  = 1 Å) (enzymes from P. vulgaris 
and E. cloacae, respectively) compared to SHV-1 and TEM-1 (rmsd > 2.5 Å) (enzymes 
from K. pneumoniae and E. coli). ALBS (PDBID 1BSG) was used as search model 
because it showed significant sequence homology to BlaC. Surprisingly, it showed a 
fairly large rmsd value (3.66 Å) compared to BlaC. Indeed, several other class A β-
lactamases with lower sequence homology are structurally more similar to BlaC. 
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Table 22  Data Collection, Processing and Refinement Statistics of Mtb BlaC 
Data collection   
  BlaC 
Maximum resolution (Å) 1.72 
Space group P212121 
a (Å) 42.7 
b (Å) 71.3 
c (Å) 85.2 
Unique reflections 25908 (2808)
Rsym (%) 11.4 (30.6) 
Completeness (%) 91.1 (100) 
Redundancy 6.8 (6.9) 
I/σ 23.2 (6.8) 
    
Refinement statistics   
Resolution range (Å) 54.64-1.72 
Number of reflections 24570 
Number of atoms / subunit   
Protein 2230 
Solvent 248 
Rcryst (%) 17.9 
Rfree (%) 21.4 
Average B-factors (Å2)   
Protein 20.7 
Solvent 32.8 
rmsd from ideal values   
bonds (Å) 0.011 
angles (deg) 1.44 
 
Rsym = hkl i|Ii (hkl)  I(hkl) |/ hkl iIi (hkl), where Ii is the intensity of observation and 
I  is the mean intensity of reflection. 
 
The numbers given in parentheses denote the respective values of the highest resolution 
shell. 
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Table 23  Structure Comparison of Class A β-lactamases from Different Species 
 
 
Enzyme Source PDB_ID Sequence identity (%) 
Rmsd 
(Å) 
BlaC M. tuberculosis    
BS3 B. licheniformis 1I2S 47.3 1.57 
ALBS S. albus 1BSG 45.0 3.66 
Toho-1 E. coli 1IYS 46.5 1.87 
SME-1 S. marcescens 1DY6 42.5 0.97 
NMC-A E. cloacae 1BUE 41.1 1.00 
K1 P. vulgaris 1HZO 42.9 0.95 
MYC M. fortuitum 1MFO 40.7 1.54 
SHV-1 K. pneumoniae 1SHV 40.0 2.74 
TEM-1 E. coli 1BT5 38.0 2.85 
 
 
  
 143
 
Enzyme Active Site 
In all class A β-lactamases, the hydrolysis of the β-lactam substrates is 
accomplished by a nucleophilic attack initiated by an active site serine residue Ser70.  It 
has been proposed that Glu166, a general base in the active site is the serine70-activating 
residue, based on the ultrahigh resolution crystal structure (0.91 Å SHV-2 and 0.85 Å 
TEM-1) studies (170,171). However, others believe that Lys73 is involved in the 
activation (172). Although the mechanism of Ser70 activation is contentious (173), the 
deacylation mechanism has been established. Glu166 has been demonstrated to be critical 
for the deacylation of the acyl-enzyme intermediate based on site-directed mutagenesis 
studies (Figure 30) (174). The enzyme active site is located at the interface between the 
α and the α/β domains (Figure 31). Ser70 and Lys73, located on α-helix H2 in the center 
of active site (Figure 32), are completely conserved in all class A β-lactamases and are 
surrounded by other key residues on β-strand B3 (Lys234, Thr235, Thr237), and the loop 
region between H5 and H6 (Ser130, Gly132) as well as the Ω loop (Glu166). These eight 
residues are all involved in direct hydrogen bonding interactions with β-lactam 
substrates. Two bound water molecules, WAT36 and WAT65, are also highly conserved 
in the structures of all class A β-lactamases, determined to date. WAT65 is part of a 
hydrogen-bond network with the side chain oxygen of Ser70, as well as the side chain 
oxygen of Glu166 at distances of 2.5 Å and 2.5 Å, respectively. This hydrolytic water 
functions to deacylate Ser70 from the product after hydrolysis of β-lactam substrates 
(175-177). WAT36 is in the oxyanion hole, forming hydrogen bonds with the backbone 
nitrogen of Ser70 and the backbone nitrogen of Thr237 at distance of 2.6 Å and 2.7 Å, 
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respectively. Although ampicillin improved the diffraction quality of the crystals, neither 
the substrate nor any products could be identified in the active site. 
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Figure 30   Mechanism of Class A β-lactamase 
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Figure 31   Overall Structure of Mtb BlaC 
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Figure 32   Stereo View of Active Site of Mtb BlaC 
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Although the overall structure of Mtb BlaC is similar to other class A β-
lactamases, some differences are clear, the most obvious difference being the size of the 
active site. The active site of Mtb BlaC is significantly larger than the other class A β-
lactamases with known structures. Three factors that contribute to the greater size of the 
active site are: 1) amino acid substitution of several key residues, 2) rearrangement of 
conserved side chains, and 3) a four residue long insertion in the active site region. The 
β-lactam-binding motif Ser-Asp-Asn is highly conserved among the class A β-
lactamases. In Mtb BlaC, Glycine occupies the position of asparagine. In the class A β-
lactamase with structures determined thus far, the side chain of this asparagine points 
towards the center of active site, forming a hydrogen bond with the side chain nitrogen 
of Lys73. The carbamide group of the asparagine is in close contact with the ester 
carbonyl group of penicillin and cephems in the complex structures published (178). The 
6α-1R-hydroxyl group of imipenem was also observed to hydrogen bond with the side 
chain oxygen of Asn132 in the structure of E. coli TEM-1 (PDBID: 1BT5) (179) and E. 
cloacae NMC-A (PDBID: 1BUE) (180). It was proposed that extra space at this 
location, created by about a 1 Å shift of Asn132 (equivalent to Gly132 in Mtb BlaC) and its 
side chain pointing away from catalytic center, would accommodate the substituents at 
the R6 position of carbapenem and therefore increase carbapenemnase activity 
(180,181). In fact, this is true for all the carbapenemases of known structures. Having a 
glycine instead of asparagine in this position makes the BlaC substrate-binding pocket 
wider and likely more flexible. Therefore, this substitution in BlaC offers an alternative 
approach to enlarge the active site and could allow Mtb BlaC to specifically bind 
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carbapenems or cephems with large α substituents. Furthermore, on the same side of the 
substrate-binding site as Gly132, the side chain of Ser104 is unusual in that it is extended 
away from the substrate-binding site. In other class A β-lactamases, this position is 
typically an asparagine or an aspartate, and the side chain points into the active site. Like 
the Asn132 to Gly132 substitution, the conformation of the Ser104 side chain creates more 
space in the active site and reduces the potential hydrogen bonding interactions with the 
substrate. On β-strand B3 of BlaC, Thr237 is unusual for class A β-lactamases. This 
location is most often occupied by an alanine, as found in non- Extended Spectrum β-
lactamase (non-ESBL) or a serine in the ESBLs. The hydroxyl group of Thr237 points to 
the same direction as the comparable serine in the ESBLs. Ser237 (equivalent to Thr237 in 
Mtb BlaC) is believed to play a critical role in extended spectrum activity of K1 (P. 
vulgaris) β-lactamase. Superimposition of BlaC structure with substrate bound complex 
forms of Bs3 from B. licheniformis (PDBID: 1I2W) and mutant of the RTEM-1 from E. 
coli (PDBID: 1FQG) (172,182) indicates that Thr237 potentially forms three hydrogen 
bonding interactions with the substrate: backbone oxygen to carbamide nitrogen of α 
substituent of β-lactam (~3.5 Å), backbone nitrogen to ester carbonyl oxygen of β-
lactam (~2.8 Å), and side chain oxygen to carboxyl oxygen of β substituent of β-lactam 
(~3 Å). The side chain of Arg220 extends into the top part of the active site and it forms 
hydrogen bonds with the side chain oxygen of Thr237, the backbone oxygen of Gly236 and 
the ester carboxyl oxygen of bound β-lactam. A similar hydrogen bond is only seen in 
the carbapenemase NCM-A (E. cloacae). The position of Arg220 is usually occupied by a 
serine in ESBL type enzymes. The hydrogen bonding between Thr237 and Arg220 of Mtb 
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BlaC pulls the side chain of Thr237 about 2.5 Å away from the active site. This 
conformation helps to contain the relatively large substituents, such as 6α-1R-hydroxyl 
group of carbapenems, which could be critical for their binding (Figure 33). On the other 
side of the β sheets, Arg243 is unusual for class A β-lactamases. This position is typically 
occupied by a threonine. The two nitrogens of the guanidinyl group of Arg243 form 
hydrogen bonds with the backbone CO group of Asp172 and Asn170 at distance of 2.8 Å 
and 3.1 Å, respectively, and serve to link B4 with Ω loop. Another observed difference 
of potential importance is that Arg171 in Mtb BlaC is usually occupied by either a 
threonine or a serine in other class A β-lactamases. The long side chain of Arg171 
extends toward the side of the entrance to the active site. On the opposite site of the Ω 
loop, the region Ile102-Ile105 of BlaC is quite different from other class A β-lactamases as 
well. While all other class A β-lactamases have either tyrosine or histidine with their 
aromatic side chains covering the entrance, Ile105 at the same position makes BlaC’s 
active site ~3 Å wider than other class A β-lactamases. A four residue insertion, 
consisting of Gly145A to Thr145D at the beginning of α helix H7 makes H7 ~6 Å longer 
than that of other class A β-lactamases.  
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Figure 33   Comparison of Active Site of Mtb BlaC with Homologs in Stereo View 
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Structural Basis for Broad Substrate Recognition  
Mtb BlaC has a broad-spectrum substrate profile. The penicillinase activity of 
BlaC is about 10 fold lower than most of class A β-lactamases. However, the enzyme 
showed moderate activity against cephalothin and some activity against cefoxitin, 
ceftazidime and meropenem. The broad substrate profile is due to the enzyme’s large 
and flexible substrate-binding site that allows it to accommodate different types of 
substrates. While a large active site can provide broader substrate specificity, it can also 
lead to weak enzyme-ligand interactions. This could explain the generally low activity of 
Mtb BlaC in hydrolyzing substrates and inhibitors. The substrate profile of Mtb BlaC is 
quite similar to the β-lactamase of S. clavuligerus, however the Mtb enzyme has better 
activity against all β-lactams we have tested.  
We have tried to crystallize BlaC bound with substrates and inhibitors. However, 
no clear density of substrates or inhibitors could be identified after numerous trials. This 
is primarily due to the high turnover rate of hydrolysis by BlaC. Nevertheless, structure 
alignments suggest that the reason for the low penicillinase activity is in part due to the 
Asn to Gly substitution at position 132. As a conserved residue in other class A β-
lactamase, the nitrogen atom of Asn132 side chain forms a hydrogen bond with the 
carbonyl oxygen of the α substituent of β-lactam substrates. Glycine at this position 
would result in a loss of hydrogen bonding to the substrate as shown by the 
superimposition of Toho-1-benzylpenicillin (178) and Mtb BlaC structures. The 
hydrogen bond is apparently important for stabilizing the substrate in the active site. 
Therefore, the loss of hydrogen bonding interactions could explain the low activity of 
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Mtb BlaC, especially to penicillin type substrates (Figure 34A and 34B). The critical role 
of Asn132 to the activity of class A β-lactamase has been proven by the study of a N132A 
mutant of S. albus G β-lactamase (183), which showed a 100 to 200 fold decrease of 
penicillinase and cephalosporinase activities. Unlike the N132A mutant of S. albus G β-
lactamase, Mtb BlaC has relatively good activity against cephalothin. The notable 
R164A substitution in the neck of Ω loop is likely the reason why BlaC maintain good 
cephalothin activity. In other class A β-lactamases with known structures, this position is 
always occupied by Arg164. Normally, Arg164 hydrogen-bonds to another highly 
conserved residue Asp179 to form a salt bridge in the neck of Ω loop, which holds the Ω 
loop closed and rigid (Figure 35B). Loss of this hydrogen bond could potentially 
destabilize Ω loop (Figure 35A), which has been shown to play an important in the 
expansion of activity against cephalosporines, based on a mutagenesis study (184). 
Indeed, compared to many other class A β-lactamases, part of the Ω loop region Asn170 – 
Pro173 of BlaC is curved away from B4 by ~2 Å.   
Several other residue substitutions could contribute to the boost of 
cephalosporinase activity. Superimposition to structures of ESBLs in complex with 
cephalosporins, indicated that the hydroxyl group of Thr237 (equivalent to Ala237 or 
Ser237 in other class A β-lactamase) of Mtb BlaC occupies the same position as the side 
chain of Ser237 in the ESBLs and the hydroxyl group is within the hydrogen bonding 
distance (2.5 Å) to the carboxyl group of β substituents of cephalosporins. This could 
help to stabilize the acyl-intermediate of cephalosporins and increase the activity. This is 
consistent with the finding that A237T mutation increased the relative cephalosporinase 
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activity in TEM β-lactamase (non-ESBL) (185). Since S. albus G β-lactamase is a non-
ESBL, at the equivalent position, it has alanine not serine or threonine. The loss of the 
hydrogen bonding interactions at both sites could be the reason why the N132A mutant 
totally lost the cephalosporinase activity.  
 
 
 
 
Figure 34   Comparison of Active Sites of BlaC Bound to Inhibitors    
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A. 
 
 
B.  
 
 
Figure 35   Comparison of Ω loops of BlaC  
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Class A β-lactamase Inhibitors   
Clavulanate is a suicide inhibitor specific for class A β-lactamases. This potent 
(Ki < 0.1 µM) inhibitor forms a covalent acyl enzyme complex with class A β-lactamase. 
After acylation, the intermediate can either tautomerize to form a transient inhibitor to 
the enzyme or acylate another active site serine, Ser130 to form a cross-linked, 
irreversibly inactivated enzyme (186). Our inhibition studies show that clavulanate is a 
relatively poor inhibitor of Mtb BlaC (Ki = 2.4 µM) with a 24 fold higher Ki compared to 
TEM-1. Class A β-lactamases with amino acid substitutions at Arg244, Asn276, Arg275, 
Met69, Met182 and Trp165 have been reported to be resistant to clavulanate and other 
mechanism-based inhibitors (187). Among these residues, the substitutions of R244A, 
N278E, M69C and M182T are all found in BlaC. It is interesting to note that clavulanate 
is produced by S. clavuligerus whose β-lactamase is the closest homolog of Mtb BlaC. 
Not surprisingly, S. clavuligerus β-lactamase is resistant to clavulanate (Ki = 12 µM) 
(188). The superimposition of a E166A variant of SHV-1 with tazobactam bound (189) 
and Mtb BlaC structures reveals that the N132G substitution would also cause the loss of 
a hydrogen bond between side chain of Asn132 and 3-β-carboxyl group of the inhibitor 
(Figure 34C and 34D). In the complex structure of wild type SHV-1 with tazobactam 
bound, Asn132 was also observed hydrogen-bonding with the sulfinic acid group of the 
trans-enamine intermediate (190). Based on structure and activity relationship, it is quite 
clear that Mtb and S. clavuligerus share a very similar strategy in the resistance of 
general class A β-lactamase inhibitors. That is, to weaken the binding of enzyme to 
  
 156
 
those inhibitors mainly through a single amino acid substitution N132G, even though 
this will also sacrifice enzyme activity to other β-lactam substrates.  
BlaC has Ala244 on β strand B4. This position is usually occupied by arginine in 
non-ESBL enzyme and threonine in ESBL enzyme. Interestingly, in Mtb BlaC, the side 
chain of Arg220 is almost in the same position usually occupied by side chain of Arg244 in 
other class A β-lactamases. This Arg220 - Ala244 residue pair only exists in Mtb BlaC, 
carbapenemase NMC-A (E. cloacae) and SCLA (S. clavuligerus). Mutation of Arg244 to 
Serine in the TEM-1 β-lactamase has been shown to produce resistance to inactivation 
by clavulanate in the mutant enzyme and resistance to ampicillin plus clavulanate in a 
strain of E coli producing this enzyme (191). The modeling studies indicated that the 
guanidinyl group of Arg244 and an ordered water molecule stabilize the carboxyl group 
of clavulanate and its acylated intermediate through hydrogen bonding (191). In the 
R244S mutant, these hydrogen bonds would be lost, which could potentially cause 
resistance to clavulanate. It is tempting to speculate that the R244A substitution in BlaC 
would have the similar mechanism of resistance to clavulanate. However, the position of 
the Arg244 side chain in the TEM-1 is occupied by the guanidinyl group of Arg220 in 
BlaC that does not exist in TEM-1 (Figure 36), which complicates the situation. Even 
though the water molecule in the TEM-1 structure that is believed to be important to 
clavulanate inhibition, is not observed in the BlaC structure and the guanidinyl group of 
Arg220 in BlaC does not have the same orientation as that of Arg244 in TEM-1, it is 
possible that the presence of the guanidinyl group of Arg220 could to some degree restore 
sensitivity of BlaC to clavulanate. Indeed the resistance of BlaC to clavulanate (Ki = 2.4 
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µM) is about 10 fold less than the R244S mutant of TEM-1 (Ki = 33 µM) (192). 
However, the clavulanate inhibition is biphasic and Ki only reflects the first phase. 
Arg244 in TEM-1 has been shown to be important to both the binding of clavulanate and 
the chemistry of inactivation (191). Arg220 in BlaC may be able to help the binding of 
clavulanate by hydrogen bonding interaction in the first phase, but not likely to facilitate 
the chemistry of inactivation in the second phase.        
Although clavulanate is not an optimal inhibitor to Mtb BlaC, it has been 
demonstrated that the combinations of β-lactam antibiotics and mechanism-based 
inhibitors such as clavulanate are effective in the treatment of Mtb, even MDR strains. 
This makes Mtb BlaC a promising target for the design of new inhibitors that are specific 
and potent to Mtb BlaC. Based on the structure of Mtb BlaC, it is now possible to either 
modify current inhibitors to increase inhibitory potency or design novel inhibitors that 
are specific to the enzyme. In combination to the highly potent Mtb BlaC inhibitors, β-
lactam antibiotics could become a new regimen to treat tuberculosis.  
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B. 
 
 
Figure 36   The Critical Role of Arg220 in Inhibitor Binding  
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CHAPTER VI 
 IDENTIFICATION OF A MTB VIRULENCE FACTOR  
 
BACKGROUND 
A Putative Operon Rv0096-Rv0101 Is Essential for the Virulence of Mtb  
Mtb Rv0098, unique to actinomycetes, encodes a hypothetical protein that shares 
no homology with any protein with a defined function. Rv0098 is found on an operon 
containing five other genes, Rv0096, a member of the PPE family, Rv0097, an 
oxidoreductase, Rv0099, a fatty acid AMP ligase, Rv0100, which encodes an acyl carrier 
protein, and Rv0101, a non-ribosomal peptide synthase. They were found to be strongly 
co-induced (193). While these genes are not essential for Mtb growth in media, Rv0098 
– Rv0101 are required for its survival in macrophages (Figure 37) (41,42). Furthermore, 
the whole operon is conserved in other pathogenic mycobacteria. It was demonstrated 
that in M. bovis, this operon was involved in the biosynthesis of PDIMs, the virulence-
enhancing lipids produced by Mtb and closely related species. The disruption of gene 
Mb0100 (equivalent to Mtb Rv0097) caused a loss of virulence and an alteration of 
colony morphology. Besides, the mutations of Mb0100 had a polar effect on the 
expression of the downstream genes Mb0101 (equivalent to Mtb Rv0098) – Mb0104 
(equivalent to Mtb Rv0101), which clearly indicated that these genes are in the same 
operon and functionally related (194). Recently, Joshi, et al, found that the virulence of 
Rv0098 is dependent on the functional interaction with the mce loci that was proposed to 
encode an ABC-like transport system (195).  
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 is a long chain acyl-CoA thioesterase.  Acyl-CoA thioesterases, 
l-CoA to fatty acid and coenzyme A, are found in archaean, 
ryotic organisms. Although the thioesterase activity was 
o, the precise physiological function of many of these enzymes 
hioesterases are involved in polyketide, fatty acid, and non-
thesis (197-199). Some thioesterases also play an essential role 
y removing lipids from post-translationally modified proteins 
ioesterases have been identified, thioesterase I and thioesterase 
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II, based on their distinct protein folds, amino acid sequence, and different catalytic 
mechanisms (Figure 38). Enzyme in the thioesterase I family usually exists as a fatty 
acid product-releasing domain of multi-domain proteins, such as polyketide synthase, 
FASI, and non-ribosomal peptide synthase. Thioesterase I enzymes all have an α/β fold 
and use serine or cysteine as the catalytic residue, which upon activation, initiates a 
nucleophilic attack on the carbonyl carbon of the thioester substrate (28). Thioesterase II 
enzymes are discrete proteins that have been found to catalyze the hydrolysis of short or 
medium chain acyl-CoAs (63,196,201,202). Thioesterase II enzymes exist either as a 
homodimer in a single “hot dog” fold or as a monomer in a double “hot dog” fold.  The 
active sites of thioesterase II enzymes invariably contain either an aspartate or glutamate 
that acts as a general base for the reaction (203). While the precise catalytic mechanism 
remains controversial, structural and functional studies reported for several of these 
enzymes have all shown that a general base is required for catalysis (196,202,204). In 
Mtb, FcoT is the only thioesterase identified thus far that is not part of a large multi-
domain enzyme. 
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Figure 38   Catalytic Mechanisms of Thioesterases 
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METHODS 
Cloning, Expression, and Purification 
E. coli expression plasmids of Mtb fcoT were cloned from genomic DNA (C.S.U. 
N01-AI-75320).  The amplified product was inserted into pET28b (EMD Biosciences 
#69865-3) using the NdeI and Hind-III restriction sites.  This plasmid was subsequently 
transformed into E. coli BL21 (DE3) (EMD Bioscience #69387-3) and cultured in LB-
Miller media containing 50 µg/ml kanamycin at 37 °C until OD600 reached 0.8. 
Expression of the fcoT gene was induced for 20 hours at 16 °C by addition of 1 mM 
isopropyl β-D-thiogalactopyranoside (IPTG).  Cells harvested by centrifugation were re-
suspended in 25 mM Tris-HCl (pH 8.0), 500 mM NaCl, and 2 mM β-mercaptoethanol, 
and lysed by a French press.  After treatment with 1mM DNaseI, the insoluble material 
was removed by centrifugation. By SDS PAGE, ~ 15% of FcoT remained soluble. The 
supernatant, which contains soluble protein, was applied to an Ni2+-loaded HiTrap 
chelating column (AP Biotech) using a fast protein liquid chromatography system, and 
was eluted through an imidazole gradient  (0-0.5M). FcoT was eluted out at an imidazole 
concentration of 180 mM.  Fractions that contain the FcoT were pooled and dialyzed 
against 25 mM Tris-HCl (pH 8.0), 60 mM NaCl, and 1 mM DTT.  Using the dialysis 
buffer, the samples were further purified by gel-filtration on a Superdex 200 column to 
separate the monomeric protein from aggregated material.  The protein was concentrated 
to approximately10 mg/ml.  FcoT was obtained at 6 mg/L of E. coli culture, and 
appeared homogeneous by SDS-PAGE and Coommassie Blue staining.  
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In order to perform a multiwavelength anomalous diffraction (MAD) experiment, 
Se-Met substituted protein was overexpressed in the B834 (DE3) E. coli strain and 
purified using the same method as native FcoT.  
 
Mutagenesis, Expression, and Purification 
FcoT mutants N83A, Y66F, Y33F, N74A, Y87F, E77Q, and H72A were 
constructed using the QuickChange site-directed mutagenesis kit (Stratagene) and 
confirmed by DNA sequencing. All mutant proteins were expressed and purified using 
the same protocol as the wild-type FcoT.   
 
Acyl-CoA Thioesterase Activity Assay 
Acyl-CoA thioesterase activity assays were completed for the substrates 
hexanoyl-CoA (C6:0), lauroyl-CoA (C12:0), palmitoyl-CoA (C16:0), stearoyl-CoA 
(C18:0), dodecenoyl-CoA (C12:1 trans), crotonoyl-CoA (C4:1 trans), and benzyl-CoA. 
All assays were repeated in triplicate and carried out on a Cary 100 Bio 
Spectrophotometer at room temperature by monitoring the UV absorbance increase at 
412 nm using 5, 5’ dithiobis (2-nitrobenzoic acid) (DTNB), as previously described 
(205). The Mtb FcoT activity assays were performed in 100 mM phosphate buffer (pH 
7.5) by adding 100 nM enzyme into solutions of acyl-CoA substrate and DTNB (100 
µM). Km and Vmax were determined using software KaleidaGraph (Synergy Software). 
 
  
 165
 
Crystallization of FcoT 
Crystallization of the native and Se-Met substituted FcoT was accomplished by 
the hanging-drop vapor diffusion method (85).  Initial crystallization conditions were 
discovered by sparse matrix screen using Crystal Screens from Hampton Research.  
Hanging drops containing 2 µl of protein solution at 10 mg/ml and 2 µl of buffer (0.1 M 
Hepes pH 7.5, 14-16% isopropanol, 200-300mM NaCl, 10mM MgCl2) were equilibrated 
at 16 °C in Linbro plates against 1 ml of the same buffer in the reservoir. Protein crystals 
appeared in two days and were improved by co-crystallization with dodecenoyl CoA.  
 
Data Collection and Processing 
Diffraction data from a single crystal of protein with dodecoenoyl CoA was 
collected at 121 K using a cryo-protection solution consisting of a reservoir solution (0.1 
M Hepes pH 7.5, 14-16% isopropanol, 200-300mM NaCl, 10mM MgCl2) with the 
addition of 30% 2-methyl-2, 4-pentanediol (MPD). Crystals diffracted to 2.3 Å at beam 
line 23ID at the Advanced Photon Source (APS), Argonne National Laboratory. The 
selenium absorption edge was determined to be at 12.6618 KeV by fluorescence 
scanning of a Se-Met FcoT crystal. Diffraction data of three wavelengths (peak: 0.9792 
Å; inflection: 0.9794 Å; high-energy remote: 0.9611 Å) were collected from a single 
crystal with one-degree oscillation widths through a range of 360° for each wavelength. 
The data were integrated and reduced using HKL2000. Crystals of FcoT belong to the 
space group I213 with cell dimensions a = 100.18 Å, b = 100.18 Å, c = 100.18 Å, α = 
90°, β = 90°, and γ = 90°, with one molecule in each asymmetric unit.  
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Structure Determination and Model Refinement 
MAD phasing was achieved by running the program Sharp 
(http://www.globalphasing.com). Three wavelengths (peak, inflection, high energy 
remote) of data were included into the calculation within the resolution range 2.3 to 20 
Å. One selenium site in one asymmetric unit was found. The overall figure of merit is 
0.25 (Table 24). The electron density map was further improved by Sharp’s solvent 
flipping and flattening program. A clearly interpretable electron density map was 
calculated using FFT in CCP4 suite (160). The initial model was built by an automatic 
modeling building program, TEXAL (92,206). Once again, in the CCP4 suite the 
structure was refined with REFMAC rigid body refinement program (160), and manual 
rebuilding was performed using XtalView (89). The model was further refined with 
cycles of model building and REFMAC restrained refinement to an Rfactor of 23.9% and 
an Rfree of 29.1%. During the final cycles of the refinement, water molecules were added 
into peaks above 3-σ of the F0−Fc electron density maps that were within hydrogen-
bonding distance from appropriate protein atoms.  
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Table 24  Data Collection, Processing, and Refinement Statistics of FcoT 
 
    SeMet FcoT   
Data collection    
Space group  I213  
a (Å)  100.18  
 Peak Inflection Remote 
Wavelength 0.9795 Å 0.9796 Å 0.9537 Å 
Resolution (Å) 50-2.19 (2.29-2.19) 50-2.29 (2.41-2.29) 50-2.35 (2.49-2.35) 
Rsym (%) 8.1 (85.9) 7.7 (65.5) 7.5 (53.6) 
Completeness (%) 98.4 (96.8) 99.9 (98.6) 99.9 (100) 
Redundancy 12.2 (4.8) 9.2 (5.2) 10.1 (6.7) 
I / σI 35.6 (1.7) 30.3 (2.6) 28.2 (4.2) 
FOM  0.40  
    
Refinement statistics    
Resolution range (Å)  20.0 - 2.3  
Number of reflections  7549  
Number of atoms / subunit    
   Protein  1272  
   Ligand  14  
   Solvent  24  
Rwork / Rfree  23.3 / 27.2  
B-factors (Å2)    
   Protein  54.9  
   Ligand  42.6  
   Solvent  60.8  
rmsd from ideal values    
   bonds (Å)  0.02  
   angles (◦)   1.95   
 
The numbers given in parentheses denote the respective values of the highest resolution 
shell. 
 
FOM. (Figure of merit) is the mean value of the cosine of the error in phase angles: 
‹cos(α - αbest)›. 
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Structure Analysis 
DALI (162) was used to search the PDB for proteins having folds similar to Mtb 
FcoT.  SwissPDB viewer was used to make structural alignments (163). The model was 
evaluated and analyzed using SPOCK (90).  
 
RESULTS AND DISCUSSION 
Sequence Analysis of FcoT 
In Mtb, the Rv0098 gene encodes a 183 amino acid protein of unknown function. 
A protein similarity search of all sequences, using BLAST, did not provide any 
homologs (>20% identity) with defined function.  In fact, only two homologs could be 
clearly identified, ML1993 from Mycobacterium leprae (68% sequence identity) and 
SAV606 from Streptomyces avermitilis (36% sequence identity), and both were 
annotated as hypothetical proteins. Rv0098 was previously predicted to encode a β-
hydroxyl acyl CoA dehydratase (FabZ) based on sequence analysis (46). However, the 
sequence identity between Rv0098 and any FabZ or FabA proteins was low (<20%).  
  
Purification and Characterization of FcoT 
Mtb FcoT was expressed in E. coli BL21(DE3) cells as a fusion protein with an 
N-terminal His-tag. The protein was purified on a Ni-NTA affinity column to 
homogeneity. Purified recombinant protein, encoded by Rv0098, has a monomeric 
molecular weight of 20 kDa. The molecular weight of the native protein was determined 
to be approximately 110 kDa by gel filtration chromatography, suggesting that it is a 
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hexamer in solution (Figure 39). It is interesting to note that some FabZ dehydratases 
were previously reported to exist as a trimer of dimers of identical subunits in solution 
(207), however most type II thioesterases are dimers. 
 
FcoT Is Not a Fatty-acyl CoA Dehydratase 
The purified recombinant enzyme was tested for dehydratase and hydratase 
activity using crotonoyl, β-hydroxyl butyl, and trans-2-dodecenoyl CoAs. The 
conversion of crotonoyl-CoA to β -hydroxybutyryl-CoA or vise versa, was monitored by 
monitoring the increase or decrease in absorbance at 260 nm. This protocol has been 
used to characterize the activity of PfFabZ (208). However, Mtb FcoT did not show any 
detectable activity using any of these substrates. 
 
FcoT Is a Fatty-acyl CoA Thioesterase 
Only after the structure of the protein bound with dodecenoate was solved, as 
described below, was it possible for us to predict that the enzyme was a thioesterase. The 
thioesterase activity of the enzyme was confirmed by in vitro assays using a series of  
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different chain length (C4-C18) fatty acyl CoA substrates (Figure 40). Among them, 
hexanoyl-CoA (C6:0), lauroyl-CoA (C12:0), palmitoyl-CoA (C16:0), and stearoyl-CoA 
(C18:0) contain a saturated fatty acyl chain; dodecenoyl-CoA (C12:1 trans) and 
crotonoyl-CoA (C4:1 trans) have unsaturated fatty acyl chains; and benzyl-CoA has 
only an aryl group. The enzyme actively cleaved the thioester linkage of all of the 
substrates tested, but showed a marked preference for those thioester substrates with 
long chain fatty acyl groups. Of the substrates tested, maximal kcat (0.037 s-1) was 
observed for palmitoyl-CoA (C16:0) and the enzyme activity decreased for substrates 
with either longer or shorter acyl chains. At the same chain length, saturated substrates 
were marginally favored by the enzyme compared to unsaturated substrates, although the 
former are much more soluble for a given hydrocarbon chain length (Figure 41). 
Relative to the fatty acyl CoAs there was low hydrolysis activity (kcat = 0.004 s-1) and a 
large Km value (272 µM) for benzyl-CoA as a substrate. Its kcat/Km value is ~ 0.3% of 
that of palmitoyl-CoA, which suggests that the enzyme does not prefer aryl thioesters. In 
general, the activity of FcoT is 102 – 104 fold less than other thioesterases.  
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Figure 39   The Superose-6 Size-exclusion Chromatography of FcoT. 
The elution profile of FcoT and calibration of the Superose-6 size-exclusion Column. 
Thyroglobulin, bovine gamma-globulin, chicken ovalbumin, equine myoglobin and 
vitamin 12 (from left to right) were used to calibrate the size-exclusion column. The  
logarithm of the molecular weight (MW) and the elution volume were fit with linear  
regression. The resulting equation was used to estimate the molecular weight of FcoT 
from its elution volume
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Figure 40   The Substrate Profile of Mtb FcoT 
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Figure 41   Substrate Specificity of Mtb FcoT 
 
 
 
The rate of hydrolysis of the acyl CoA substrate by FcoT is pH dependent. In fact 
below pH 7, there was no detectable activity; while in the range of 7 – 8.5, the activity 
showed a linear phase and reached a plateau at pH 8.5 (Figure 42). These results suggest 
that the catalytic rate depends on the concentration of hydroxide anions. Although the 
pH dependence for a thioesterase reaction has not been reported before, several 
esterolytic antibodies showed a similar pH profile to Mtb FcoT (209). 
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Figure 42   The Activity of FcoT for Substrate Palmitoyl CoA in the pH Range 7-9.5 
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Overall Structure of FcoT 
The crystal structure of FcoT was solved using MAD methods and refined to 2.3 
Å resolution. The final Rfactor and Rfree values for all reflections were 0.23 and 0.27, 
respectively (Table 24). FcoT crystals, produced in the presence of the substrate 
dodecenoyl CoA, are cubic belonging to space group I213, with one molecule in the 
asymmetric unit. The refined model of FcoT includes 160 of the 183 total residues of the 
wild-type FcoT, the product dodecenoic acid, and 24 ordered water molecules. The 
structures of the N-terminal six-histidine tag, the first 19 residues Met1-Val19, and the 
four residues Glu149, Arg150, Thr151, and Glu166 were not defined due to disorder of these 
regions in electron density maps. A “trimer of dimers” quaternary structure was 
identified after applying crystallographic symmetry, which is consistent with the gel 
filtration chromatography result that showed that the protein is a hexamer in solution 
(Figure 43A). The dimer is composed of two identical protomers and has overall 
dimensions of 32 Å x 44 Å x 67 Å (Figure 43B). Three identical dimers join together 
“head to tail” to form an equilateral triangle (approximately 105 Å each side) with its 3-
fold rotation axis coincident to a crystallographic triad. This quaternary arrangement has 
not been observed in other type II thioesterases, which are usually packed as dimers or 
tetramers; however, a similar quaternary structure was found in FabZ with a ring-shaped 
packing (207). 
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Figure 43   The Overall Architecture of FcoT. 
(A) Ribbon and surface diagrams showing a “trimer of dimers” quaternary structure of 
Mtb FcoT. (B) Ribbon diagrams of a dimer showing the “hot dog” fold. C) Subunit of 
FcoT. The α helices are represented as H1-H4 and the strands as B1-B6  
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The Mtb FcoT protomer has an α/β “hot dog” fold, in which a six-antiparallel β-
sheet (B1-B6), referred to in the literature as the “bun”, wraps around a six-turn α helix 
(H3) typically called the “sausage”, with both ends sealed, and three short α helices (H1, 
H2 and H4) that cover the open side (Figure 43C). This “hot dog” topology is common 
for dehydratases and thioesterases (210).  
The interface of the dimer is quite extensive. The solvent-accessible buried 
surface area is about 3012 Å2 (18% of the surface area of one subunit), suggesting a 
strong interaction between the two protomers. Three major groups of interactions 
contribute to the dimerization of two subunits: the hydrogen bonding interaction between 
the anti-parallel β strand B3 (Arg121 – Phe127) from each subunit, extensive hydrophobic 
interactions between side chains of residues on the two central α helices (H3) (Val76 – 
Ile79), and the hydrophobic and hydrophilic interactions between the loop region (Ala65 – 
Phe73) of one subunit and two α helices (H2, H4) from the other subunit. Specifically, 
most of the residues of B3 are hydrophilic, with their side chains pointing out towards 
the solvent, and the backbone atoms forming hydrogen bonds with their counterparts 
from the other subunit. This anti-parallel β strand interaction is conserved in all known 
“hot-dog” fold proteins. In the center of the dimer interface, the ends of the two 
“sausage” α helices bundle with each other in an anti-parallel manner. A notable salt 
bridge, formed by side chains of Arg51 and Glu14, links the loop region from one subunit 
to the short α helix H2 from the other. 
An unusual intramolecular disulfide bridge is observed between Cys142 and 
Cys159 that links B4 and B5 (Figure 44). In Mtb FcoT, the Cys142 and Cys159 disulfide 
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bridge is buried between the β sheet and the central α helix, which is a probable reason 
why this disulfide bond remains oxidized despite the presence of the reducing agent, 
DTT, in the buffer.  
 
 
 
 
 
 
Figure 44   The Electron Density Indicating the Disulfide Bond in Mtb FcoT 
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A structure similarity search of the protomer found several proteins with 
modestly similar folds, most of which were dehydratases (FabZ or FabA) and 
thioesterases, however none of them had an RMSD less than 2.5 Å, suggesting that they 
were significantly different. Unlike other hotdog fold proteins, the two protomers of Mtb 
FcoT interact in such a manner that two “sausage” α helices are anti-parallel to each 
other and on the same plane, that is perpendicular to the 2-fold rotation axis of the dimer. 
This unique arrangement makes the dimer of Mtb FcoT longer and straighter in one 
dimension than other proteins with a “hot dog” fold. 
  
Structural Basis of Substrate Recognition 
FcoT has a long, narrow, hydrophobic substrate binding site. This “L” shaped 
substrate-binding tunnel is composed of two branches. The longer branch, buried inside 
one subunit, is formed by hydrophobic residues from two bundled α helices, H3 and H4, 
and the β-sheet (B1-B6). It is approximately 24 Å deep and has a cross-sectional 
diameter of about 5 Å. This part of the tunnel is generally straight, extending along the 
“sausage” α helix, H3. The bottom of the tunnel is at one end of the subunit, sealed by 
residues Ile99 – Ile107 from the loop region between H3 and H4. The other end opens to 
the dimer interface. The shorter branch of the tunnel is about 9 Å long and is formed by 
residues on the dimer interface from both subunits. It has a narrow opening (about 5 Å) 
to the solvent and is surrounded by residues Leu119 and Pro130. Although one of the 
products, coenzyme A, is absent in the structure, the superimposition of the structure of 
FcoT and the 4-hydroxylbenzoyl-CoA thioesterase with bound products clearly indicates 
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that FcoT can bind co-enzyme A in a similar manner, when CoA was modeled into 
FcoT. The pantetheine moiety of CoA fits inside the short branch of the substrate-
binding tunnel of FcoT surrounded by residues His72, Arg121, Asn74, Met118, and Tyr87. 
The adenine ring and the phosphate group are outside of the tunnel and within hydrogen 
bonding distance to the residues on the surface of the protein, such as Ser116, Ser117, and 
Trp152.  
The product of FcoT reaction, dodecenoic acid, is located inside the longer 
branch of the substrate tunnel (Figure 45) along with four ordered water molecules. The 
acyl chain portion of the product extends along the central α helix, H3, into the tunnel, 
stabilized by van der Waals interactions with the hydrophobic residues Ala86, Tyr87, 
Phe90, Leu102, Tyr110, Met118, and Ile120.  Its carboxyl group is located in a hydrophilic 
cavity created by the residues Asn83 (subunit A), Asn74, and His72 (subunit B) on the 
dimer interface (Figure 46). There is a 6 Å gap between the end of the acyl chain and the 
bottom of the tunnel, suggesting that acyl substrates longer than C12 could easily be 
accommodated. This observation correlates well with our results that FcoT has a 
preference for long chain fatty-acyl-CoA substrates. Although the tunnel appears to be of  
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optimal length for C16-18 to bind, it is possible that more space can be created to 
accommodate even longer substrates through conformation rearrangements of flexible 
residues on the bottom of the tunnel. 
The narrow substrate-binding tunnel suggests that FcoT would not efficiently 
bind any substrates with bulky aryl groups. The superimposition of structures of Mtb 
FcoT and the Arthrobacter 4-hydroxylbenzoyl-CoA thioesterase with bound products 
indicates that while the overall shape of the CoA binding site is well conserved, the 
binding pocket for the product, 4-hydroxylbenoate, is blocked by the side chain of Tyr70 
in Mtb FcoT (Figure 45).  Indeed, only negligible thioesterase activity (0.3% of 
palmitoyl-CoA) could be detected when benzyl-CoA was used as a substrate.  
FcoT does not seem to have much selectivity between saturated and unsaturated 
fatty acyl substrates. With the same length of the carbon chain, the enzyme favors 
dodecenoyl CoA (kcat/Km = 0.52 µM-1s-1) slightly more than lauroyl CoA (kcat/Km = 
0.39 µM-1s-1). This is probably because the hydrophobic tunnel is able to bind both 
saturated and unsaturated fatty acyl chains in a similar manner.  
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Figure 45   The Substrate-binding Tunnel of Mtb FcoT with Bound Ligand. 
Cross section through the surface of the aligned FcoT active site with bound product 
dodecoenoyl acid shown to illustrate the “L” shaped substrate-binding tunnel of FcoT.  
Carbon atoms of 4-hydroxylbenzoic acid and CoA in the structure of Arthrobacter 4-
hydroxylbenzoyl-CoA thioesterase are colored in green and cyan, respectively. The 
carbon atoms of dodecoenoyl acid in the structure of M. tuberculosis FcoT are colored in 
white
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Figure 46   The Active Site of Mtb FcoT with Bound Dodecoenoate. 
The dodecoenoyl acid is colored cyan and water is red. The residues in the active site are 
colored according to the atom type as following: carbon atoms are gold in subunit A and 
green in subunit B, oxygen atoms are red, nitrogen atoms are blue, sulfur atoms are 
yellow, and phosphor atoms are orange 
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Catalytic Site and Mechanism 
With the help of the bound product dodecoenoic acid, two symmetrically related 
active sites were identified at the interface of subunit A and B, ~20 Å apart. Each 
catalytic site is located at the intersection of the two branches of the “L” shaped 
substrate-binding tunnel.  Upon the acyl-CoA substrate binding to the enzyme, the acyl 
chain portion fits into the longer hydrophobic branch of the tunnel while the pantetheine 
moiety extends out along the shorter hydrophilic portion (Figure 46). The thioester group 
is positioned in a cavity formed by Asn83, Tyr87, Tyr33, Met118 (subunit A), and Tyr66, 
Thr70, His72, Asn74 (subunit B).   
The active site of FcoT is very different from any other type II thioesterases 
characterized to date. In all type II thioesterases with defined structures, a residue with a 
carboxyl group side chain (either aspartate or glutamate) is observed in the active site 
and acts as general base to deprotonate the water molecule, assisted usually by either a 
threonine or serine. None of these residues are in the catalytic site of Mtb FcoT, 
suggesting a different catalytic mechanism. Seven FcoT mutants, N83A, Y66F, Y33F, 
N74A, Y87F, E77Q, and H72A were constructed to identify the residues critical to the 
catalysis. Mutations of Y66F, Y33F, and N74A abolished the activity of the enzyme, 
while Y87F, E77Q, H72A, and N83A decreased the enzyme activity to less than ten 
fold. Although no atom of the protein directly forms hydrogen bonds with the product, 
the carboxyl group of the product interacts with Tyr87 and Tyr33 (subunit A), as well as 
Tyr66 (subunit B) through two ordered water molecules (Figure 46). WAT185 forms 
hydrogen bonds with the oxygen of dodecenoic acid (2.6 Å) and the side chain of Tyr66 
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(3.0 Å). WAT208 is in the center of a hydrogen-bonding network with the oxygen of 
dodecenoic acid, the side chain hydroxyl group of Tyr33, and Tyr87 at distances of 2.3 Å, 
2.6 Å, and 3.0 Å, respectively. Interestingly, WAT208 forms a low energy barrier 
hydrogen bond (211) to the oxygen of the fatty acid. The electron density and the B 
factor of WAT208 are comparable to the average of the protein, which suggests that it is 
not a coordinated metal. Although Tyr33 (subunit A), and Tyr66 (subunit B) of FcoT are 
critical to catalysis, they do not seem to function as general bases in the active site, 
because the pH profile indicated the pKa of the reaction is only 8.1, much less than 
tyrosine’s pKa, 10.4. Moreover, there is no ionizable group within 7 Å of the tyrosine 
residues, so it is not likely that the environment of the tyrosines could dramatically 
decrease the pKa to 8.1. While the residues in the catalytic site have never been observed 
in any other thioesterase, either type I or type II, the catalytic site of FcoT is similar to 
that of hydrolytic antibody D2.3. The catalytic site of D2.3 is located in the antibody-
combining site at the interface between the heavy and light chain variable regions (212). 
By comparing the catalytic sites of FcoT and D2.3, the residues critical for the D2.3 
activity, such as TyrH100, TyrL27, TyrL96, AsnL34, and HisH35, can be observed in 
the catalytic site of FcoT in a similar arrangement (Figure 47). Furthermore, the activity 
of D2.3 is also pH dependent and was maximal at pH 9. The catalytic mechanism of 
D2.3 is believed to be a direct hydroxide attack on the ester, in which the catalytic rate 
depends on the concentration of the hydroxide anions. It is likely that FcoT adopts a 
similar catalytic mechanism that activates the thioester substrate and stabilizes the 
negatively charged oxyanion intermediate resulting from a hydroxide attack on the 
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substrate, by the side chains of three residues, Tyr33, Asn74, and Tyr66 (Table 25). The 
catalytic activity of this mechanism is 102 –104 times lower than those of type I and type 
II thioesterases or esterases, which is seldom observed in natural enzymes. Because of 
the distinct active site and catalytic mechanism, FcoT should be classified as a type III 
thioesterase (Figure 48). 
 
 
Table 25  Kinetic Parameters of Mtb FcoT Mutants Using Palmitoyl-CoA  
 
  kcat (s-1) Km (µM) 
Y87F 1.10E-03 29.31 
N83A 9.30E-04 17.50 
E77Q 2.60E-02 12.19 
H72A 1.70E-02 35.14 
Y66F n/a n/a 
Y33F n/a n/a 
N74A n/a n/a 
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Figure 47   Comparison of the Catalytic Sites of FcoT and D2.3. 
A. Catalytic site of FcoT bound to dodecoenoic acid. Carbon atoms of residues from 
subunit A and B are colored in gold and green, respectively. B. Catalytic site of D2.3 
bound to acetic acid. Carbon atoms of residues from heavy chain and light chain are 
colored in gold and green, respectively 
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Figure 48   A Catalytic Mechanism Without a General Base 
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Physiological Function of FcoT  
Rv0098 – Rv0101 are critical for Mtb survival in the macrophage (41,42). 
Moreover, mouse infection studies have indicated that a knockout of any of the four 
genes leads to the attenuation of pathogenicity. Recently, it is found that the 
pathogenicity of Rv0098 is highly dependent on the mce loci that encodes an ABC-like 
transport system (195). This newly identified transport system is believed to be 
responsible for both the export of a variety of complex lipid virulence factors and import 
of fatty acids as a source of nutritional carbons during in vivo growth. Based on 
sequence alignment, Rv0099 (fadD10) is tentatively predicted to be a fatty acid AMP 
ligase, Rv0100 encodes an acyl carrier protein, and Rv0101 is a non-ribosomal peptide 
synthase (NRPS) (213). There are only two NRPS genes (or gene clusters) identified in 
the Mtb genome. The product of the other NRPS complex is known to be mycobactin 
(Figure 49). In other organisms, type II thioesterase genes have been found to be 
associated with the NRPS gene in surfactin, tyrocidine, and bacitracin biosynthesis 
pathways (201). Unlike the thioesterase I domain in NRPS, type II thioesterases are not 
involved in the termination of the synthesis. It was previously reported that the carrier 
domain of a NRPS might become misprimed by an acylated phosphopantetheine (PPT) 
instead of being the holo-enzyme. Type II thioesterases could hydrolyze acylated PPT to 
correct the misprimed NRPS (201); they have also been shown to catalyze 
deaminoacylation in order to edit the misloaded NRPS module (214). However, Mtb 
FcoT prefers long chain substrates, while the thioesterase II that functioned to regenerate 
  
 190
 
misprimed NRPS only showed activity to very short chain (up to C3) substrates (201). 
Furthermore, no deaminoacylation activity was detected in Mtb FcoT.  
We hypothesize that Mtb FcoT hydrolyzes fatty-acyl-CoA substrates to generate 
free fatty acids with specific lengths (C16-C18) and the protein encoded by fadD10 
subsequently catalyzes the ligation of the fatty acid with the “specialized” acyl carrier 
protein encoded by Rv0100 to produce acyl-ACP, a precursor for the non-ribosomal 
peptide synthase to generate a lipopeptide. Unlike the mycobactin NRPS, it is believed 
that the gene product of Rv0101 does not have a cyclization domain, based on sequence 
analysis (213). Therefore, unlike mycobactin, the product of this pathway could be 
linear. No linear lipopeptide has been identified in Mtb, but a linear lipopeptide product, 
fortuitin, has been found in M. fortuitum (Figure 50) (215). Lipopeptides are major 
constituents of the cell envelopes of mycobacteria. They alter colony morphology and 
usually relate to virulence. In M. bovis, the product of this PPE - nrp operon is essential 
in the biosynthesis of PDIMs. In Mtb, this operon is likely related to PDIM synthesis, 
although it was found that fadd26-mmpL7 gene cluster played a major role in the 
synthesis of PDIMs. Nevertheless, the identification of Mtb FcoT provides new insights 
into this heretofore uncharacterized operon that is crucial for Mtb pathogenicity. 
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Figure 50   Chemical Structure of Fortuitin 
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CHAPTER VII 
 CONCLUSION 
 
 
As the world’s most successful pathogen, Mtb has infected more than one third 
of the human population. The emergence of MDR and XDR TB strains and the co-
infection of Mtb with HIV make it more deadly than ever. It is urgent to develop a new 
generation of TB drugs to counter resistance.  
As Sir James Black said, “the most fruitful basis to develop a new drug is an old 
drug”. INH and ETH (and PTH) have been widely used to treat TB for more than 40 
years. Knowledge of their mechanism of action is crucial to the design of new drugs that 
can overcome drug-resistant TB cases. INH has been demonstrated to be activated by 
KatG, a catalase-peroxidase, to form the INH-NAD adduct that inhibits InhA to block 
mycolic acid biosynthesis. Mtb strains harboring the inhA(S94A) mutation have been 
shown to confer resistance to INH. We purified the InhA(S94A) recombinant protein. 
The mutant protein showed much higher IC50 (17 fold) and Ki (30 fold) values, 
compared to the wild type InhA, in the inhibition studies of the INH-NAD adduct. The 
crystal structure of InhA(S94A) in complex with INH-NAD adduct clearly showed the 
structural basis for the resistance. The substitution of Ser94 to alanine disrupted a 
hydrogen-bonding network, which weakens the binding of INH-NAD adduct. These 
results helped to elucidate the mode of action of INH and confirmed that InhA is the 
target of INH. In order to find out the basis for the extremely high activity of INH, we 
used three hydrazides as probes to study their difference in the activation and inhibition 
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steps. All three hydrazides were activated and formed adducts with NAD cofactor. The 
INH-NAD, PNH-NAD, and BZH-NAD adducts are potent inhibitors against InhA. 
However, the yield of these adducts are dramatically different. Therefore, the high 
antitubercular activity of INH compared to its analogs is not due to its structurally 
unique moiety in the INH-NAD adduct, but rather the high yield of its activated form; 
this is provided by two important factors: 1) high stability of the isonicotinoyl 
intermediate; 2) no significant product inhibition to KatG during activation.  
The mechanism of action of ETH and PTH was demonstrated in a cell-based 
activation system. In this experiment, Mtb ethA and inhA were co-expressed inside E. 
coli cells in the presence of ETH or PTH. The ETH-NAD and PTH-NAD adducts were 
identified by solving the crystal structures of InhA bound with the inhibitors and 
confirmed by mass analysis. Similar to the INH-NAD adduct, the ETH-NAD and PTH-
NAD adducts are extremely potent against purified InhA in vitro (Ki = 7 nM and 2 nM 
respectively), which elucidated the mode of action of ETH and PTH against both Mtb 
and M. leprae.  
Since INH, ETH and PTH all target InhA, this validates the enzyme as a good 
drug target. Using a structure-based drug design approach with triclosan as the scaffold, 
a series of 5-substituted derivatives of triclosan was developed targeting InhA. Two 
groups of triclosan derivatives with alkyl and aryl substituents, respectively, were 
identified with dramatically increased potency against purified InhA. Crystal structures 
of InhA in complex with these compounds demonstrated the structural basis for their 
activities. Moreover, the correlation of the activities of these triclosan derivatives against 
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purified enzyme and Mtb strains supported the proposal that InhA is the biological 
target.  
Other than the known target InhA, we also tried to search for new potential 
therapeutic targets in Mtb. Two important Mtb proteins were structurally and 
functionally characterized. Mtb Class A β-lactamase has been proposed to be the most 
significant reason for mycobacterial resistance to β-lactam antibiotics. The determination 
of a high resolution structure of BlaC not only demonstrates the mechanism of drug 
resistance but also provides a solid base for the design of new β-lactamase inhibitors that 
could be used with β-lactam antibiotics as a new regimen to treat TB. Mtb FcoT, 
encoded by Rv0098, is functionally characterized by a combination of biochemical and 
structural approaches. The previously hypothetical protein is now annotated as a long 
chain fatty acyl CoA thioesterase. Since it lacks a general base or nucleophile in the 
active site, which always exists in type II and type I thioesterases, respectively, FcoT 
adopts a new type of catalytic mechanism. The characterization of FcoT revealed an 
important pathway that is critical for Mtb’s survival in host macrophages.  
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